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ABSTRACT 
 
The development of acquired resistance to chemotherapeutic drugs is often a limiting factor in the 
treatment of cancer. In this study, I investigated alterations in MAP kinase signalling and metabolism in a 
doxorubicin/epirubicin-resistant breast cancer cell line. Doxorubicin, also known as adriamycin, is one of 
the most important drugs in the treatment of breast cancer. The MAP kinases ERK, JNK, and p38 have all 
been linked to drug response and tumorigenesis, as well as apoptosis, in different cell types. I found that 
ERK activity was downregulated in the resistant cell line, while transcripts of the ERK phosphatases 
DUSP5 and DUSP6 were enriched. The resistant cells also contain less FOXO3a, a broadly pro-apoptotic 
transcription factor that regulates many aspects of cellular activity. I also used NMR-based 
metabonomics to generate a metabolic profile of the parental and doxorubicin-resistant cell lines. Many 
metabolic changes are seen during tumorigenesis, with further changes seen after the development of 
drug resistance. An increase in glycolysis is the best known, but alterations in choline metabolism and 
glutamine usage are also commonly seen in cancer. My results confirmed an increase in glycolysis in the 
resistant cells, as well as altered glutamine metabolism, and also provided novel findings for future 
work. The reduction in intracellular glutamine in the resistant cells was correlated with a loss of 
expression of the metabolic enzyme glutamine synthetase. My results show that the doxorubicin-
sensitive parental cell line expresses glutamine synthetase, which was required for maximal proliferation 
rate. Conversely, the lack of glutamine synthetase in the doxorubicin-resistant cells caused them to be 
dependent on the provision of extracellular glutamine for growth. This may have implications for the 
treatment of drug resistant breast cancers.  
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1.1 CANCER 
 
Cancer is the name for a collection of similar diseases based on cumulative genetic mutations that lead 
to increased cellular proliferation. Several “hallmarks” of cancer have been determined, including 
upregulation of proliferative signalling, unlimited replicative potential, induction of angiogenesis, 
avoidance of the immune system, alterations in metabolism, and resistance to cell death (Hanahan and 
Weinberg, 2011). 
 
Worldwide, the most common cancers overall are of the lung, breast, colorectal, stomach and prostate 
(Ferlay et al., 2010). Lung cancer is also associated with the highest mortality rate, partly due to its high 
incidence and often late stage of disease at the time of diagnosis. The lung cancer mortality 
rate:incidence rate ratio is 0.85. Liver and pancreatic cancers have the highest mortality:incidence ratios, 
of 0.95-1.00 (Kamangar et al., 2006). 
 
1.1.1 Breast cancer 
 
Breast cancer is the most commonly diagnosed cancer in women, with over one million cases diagnosed 
per year worldwide. It accounts for 23% of all female cancers, and 10% of diagnosed cancers overall 
(Kamangar et al., 2006; Ferlay et al., 2010). The mortality is relatively low as breast cancer responds well 
to treatment, with about 400 000 deaths annually worldwide, a mortality:incidence rate of 
approximately 0.33 (Ferlay et al., 2010). Breast cancer can also occur in males, but this is rare and 
accounts for less than 1% of all breast cancers (Gómez-Raposo et al., 2010). 
 
Risk factors for (female) breast cancer include age (particularly pre-menopause), obesity, and family 
history, including inherited genetic predisposition due to mutations in particular genes (Mcpherson et 
al., 2000). Two of the most well known genes causing hereditary breast cancer are BRCA1 and BRCA2. 
 
Breast cancer is a heterogeneous disease, and is clinically divided into subtypes depending on cellular 
origin and expression profile of certain proteins (Anderson and Matsuno, 2006). The different 
classifications include luminal A and B, HER2-overexpressing and basal-like (Berrada et al., 2010). There 
is considerable overlap between the basal-like type and “triple negative” breast cancers, lacking the 
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proteins oestrogen receptor alpha (ERα), the progesterone receptor (PR) and the human epidermal 
growth factor receptor 2 (HER2 aka ErbB2). Together these account for 15% of all breast cancers 
(Cleator et al., 2007). 
 
ERα and PR are part of the nuclear receptor family of transcription factors. Both can bind a number of 
hormone ligands that modulate their activity. Activation of ERα via ligand binding causes a 
conformational change promoting receptor phosphorylation, that inhibits sequestration by proteins 
such as HSP90 (heat shock protein 90), and recruits coactivators (Osborne and Schiff, 2005). ERα can 
then bind to estrogen response elements (EREs) in the promoters of its target genes, and alter their 
transcription. ERα target genes are associated with cell proliferation and survival (Madureira et al., 
2006). However, ERα expression correlates with better survival in breast cancers (Ali and Coombes, 
2000). PR is regulated in a similar manner to ER (Rubel et al., 2010). Both receptors can respond to 
oestrogen. 
 
HER2 is a cell surface receptor tyrosine kinase that is overexpressed in 20-30% of breast cancer, due to 
gene amplification (Moasser, 2007). On ligand binding it dimerises with itself and related receptors such 
as HER3 and EGFR (epidermal growth factor receptor), and causes activation of pro-growth, pro-
invasion, pro-survival signalling pathways via phosphoinositide-3-kinase signalling (Chapter 1.3). 
 
1.1.1.1 Breast cancer treatment 
 
Breast cancer is treated by surgery, generally in conjunction with hormone, chemo-, radiation or 
targeted therapy. 
 
Hormone or endocrine therapy can be used for patients with hormone receptor (ER and PR)-positive 
tumours (Ali et al., 2011). Such cancers are usually dependent on oestrogens for growth signalling and 
proliferation. Therefore inhibition of oestrogen/ERα activity can reduce cell growth. One of the drugs 
used for this is tamoxifen, a selective ER modulator (SERM). Drugs in this class, which also includes 
raloxifene, are tissue-specific and act as ER agonist or antagonist in different tissues. Binding of 
tamoxifen to the ERα in breast cells causes recruitment of corepressors and suppresses ER-responsive 
gene transcription (Dutertre and Smith, 2000). ERα degradation is upregulated by the drug fulvestrant 
(ICI 182, 780). Of ER-positive breast cancers, a third will not respond to tamoxifen treatment (de 
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novo/intrinsic resistance). Some cancers respond initially but become resistant (acquired resistance), 
most of which retain ERα expression (Ali et al., 2011). Other endocrine therapies include aromatase 
inhibitors, which act against ER-dependent tumours not by inhibiting ER but by suppressing oestrogen 
synthesis (Smith and Dowsett, 2003). 
 
HER2 overexpression is a negative prognostic factor in breast cancer (Moasser, 2007). Several specific 
inhibitors, known as targeted therapies have been developed against it. Trastuzumab is a monoclonal 
antibody that recognises HER2 and promotes its degradation (Nahta and Esteva, 2003). HER2 is also 
targeted by tyrosine kinase inhibitors (TKIs) such as lapatinib, which has been used in patients with 
trastuzumab-resistant HER2-overexpressing breast cancer (Moreira and Kaklamani, 2010). 
 
Traditional chemotherapeutic drugs are still used to treat most breast cancer patients. These are non-
targeted compounds that mainly induce cell death or growth arrest. Chemotherapeutic drugs to treat 
breast cancer are usually given in combination. The main drugs used fall into two classes, namely the 
anthracyclines and taxanes, although others such as 5-fluorouracil (capecitabine) or etoposide are also 
used. The taxanes used in breast cancer treatment are paclitaxel and docetaxel. These drugs stabilise 
microtubules, notably inhibiting mitosis and causing cell arrest and subsequent death (McGrogan et al., 
2008). Anthracycline treatment involves the use of drugs such as doxorubicin and epirubicin (Decatris et 
al., 2004; Gianni et al., 2009). These compounds induce DNA damage (Chapter 1.5). Epirubicin is an 
analogue of doxorubicin, although the only structural difference is the spatial orientation of the 4’ 
hydroxyl group on the sugar rings (Minotti et al., 2004). This alteration does affect the pharmacological 
properties of epirubicin, but the two drugs are thought to be equally effective in treating cancer, and 
unfortunately both are associated with similar levels of cardiotoxicity, a problem of anthracyclines (van 
Dalen et al., 2010). Anthracyclines cause DNA damage directly, and by inhibiting topoisomerase II. 
 
1.2 ONCOGENES AND TUMOUR SUPPRESSORS 
 
Many proteins involved in promoting growth or cell cycle progression are known as proto-oncogene 
products/oncoproteins. Mutations in proto-oncogenes, or in other members of their pathways, can lead 
to inappropriate expression or activity. Such deregulation promotes transformation and cancer 
progression. These genes become known as oncogenes. HER2 is one such gene. Oncogenes can also be 
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generated by chromosomal translocation events. One of the most famous oncogenic fusion proteins is 
BCR-ABL in chronic myeloid leukemia, inhibited using the targeted therapy drug imatinib (Helgason et 
al., 2011). Conversely, genes encoding proteins with the opposite effects, those that for example 
negatively regulate proliferation, are often lost in cancer. These are called tumour suppressors. The 
most well studied of these is p53, product of the gene TP53. 
 
1.2.1  p53 
 
A transcription factor linked to many cellular processes, including cell cycle regulation, apoptosis and 
metabolism, p53 is constitutively present in normal cells at low levels. It is regulated chiefly by post-
translational modifications, and is activated by stressors such as DNA damage or hypoxia (Dai and Gu, 
2010). It can then bring about cell cycle arrest, senescence or apoptosis (Chapter 1.6). In breast cancer, 
over 20% of tumours harbour p53 mutations (Forbes et al., 2011). Aside from somatic mutations, the 
rare Li-Fraumeni syndrome is usually caused by hereditary p53 mutation. Women with this syndrome 
have a 90% lifetime risk of developing breast cancer (Hemel and Domchek, 2010). Basal-like breast 
cancers also have altered p53 (Berrada et al., 2010). 
 
1.2.2 BRCA1 and BRCA2 
 
The hereditary breast and ovarian cancer syndrome is the result of germline mutations in either BRCA1 
or BRCA2 (breast cancer susceptibility protein 1 and 2 respectively). These proteins are involved in the 
DNA repair pathway homologous recombination (HR). Mutations in BRCA1 give a poorer prognosis, with 
a lifetime breast cancer risk of 40-80% vs 30-60% for those with altered BRCA2 (Hemel and Domchek, 
2010). Although problematic for those with this syndrome, fewer than 5% of breast cancer tumours 
have been found to have mutations in the BRCA genes (Forbes et al., 2011). 
 
 
1.3 PI3K/AKT SIGNALLING PATHWAY 
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While p53 mutations in cancer result in loss of function, the oncogenic pathways become overactive. 
One of the most important such pathways in breast cancer is the phosphoinositide-3-kinase (PI3K) 
signalling pathway (Castaneda et al., 2010) (Figure 1.1). Mutation of the p110α PI3K subunit is actually 
more common than p53 mutation in breast cancer (found in around 25% of samples). Overall, it is 
thought that activation of PI3K/Akt signalling exists in up to 70% of breast cancers and is associated with 
a poor prognosis. 
 
There are three types of PI3K enzyme, class I to III (Vanhaesebroeck et al., 2010). Those in different 
classes have different substrates, though all phosphorylate the 3-position on the inositol ring of a 
phosphatidylinositol (PtdIns also called PI) compound. PtdIns is a membrane phospholipid. Only one 
class III PI3K has been discovered, a heterodimer of Vps34 and Vps15. It is involved in vesicle trafficking. 
Mammals have three class II PI3Ks (PI3K-C2 alpha, beta and gamma) but these enzymes are less well 
understood than PI3Ks of the other classes. 
 
The best understood PI3Ks are those in class I (Hawkins et al., 2006). It is these that have been shown to 
be heavily involved in tumorigenesis. The catalytic subunits are p110α (PIK3CA), p110β (PIK3CB), p110δ 
(PIK3CD), and p110γ (PIK2CG). The α, β and δ proteins are also known as class IA; they bind to a p85 
regulatory subunit. There are five known p85 family members in mammals (p85α, p85β, p55α, p55γ, 
and p50α), allowing several combinations of p110 and p85 heterodimers to form. The p110γ subunit 
does not bind p85, instead forming class IB complexes with either p101 (PIK3R5) or p84 (aka p87; 
PIK3R6). All class I PI3Ks create PtdIns(3,4,5)P3 (aka PIP3) from plasma membrane PtdIns(4,5)P2 
phospholipids. The important difference between the p85 subunits and those of p110γ is that the 
former contain two SH2 (Src homology 2) domains. These recognise and bind to their recognition 
sequences containing a phosphorylated tyrosine residue. This is relevant as many cell surface receptors 
are, or associate with, receptor tyrosine kinases (RTKs) (Chapter 1.3.2). Class IB PI3Ks are not able to 
complex with these receptors. Instead, they are chiefly involved with GPCRs (G-protein coupled 
receptors), as well as Ras signalling. Class IA PI3K receptors also integrate signals arising from GPCRs and 
Ras, as well as from tyrosine kinases (Vanhaesebroeck et al., 2010).  
 
1.3.1 Ras 
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The G-proteins activated by GPCRs are heterotrimers consisting of alpha (Gα), beta (Gβ) and gamma (Gγ) 
subunits; the whole trimer is known as Gαβγ (Goldsmith and Dhanasekaran, 2007). The Gα subunit has 
GTPase activity. These Gαβγ complexes are also called large G-proteins, to distinguish them from so-
called small G-proteins: Ras superfamily members. This superfamily of small, monomeric GTPases is 
named after Ras, now part of the Ras subfamily. Some also consider Gα subunits to be a subfamily within 
the Ras superfamily. In general, “Ras” refers to the three canonical mammalian Ras family members: H-
Ras, N-Ras, and K-Ras. These proteins are very closely related (sharing around 80% identity overall) and 
expressed ubiquitously (Castellano and Santos, 2011). Due to their similarity, until quite recently it was 
thought that they were functionally redundant; it is now known that there is functional specificity 
between the isoforms, but for simplicity they are still often considered together as just Ras. Ras is 
membrane bound due to post-translational modifications (Berthiaume, 2002). 
 
All Ras superfamily and Gα subunit GTPases have similar mechanisms of action (Rajalingam et al., 2007). 
Their G-domain enables them to bind guanosine nucleotides. When bound to GTP, the GTPase is active, 
and can recruit its effectors; conversely, hydrolysis of GTP into GDP results in a conformational change 
that inactivates the protein. Although intrinsically able to hydrolyse the GTP, this is regulated by a 
GTPase activating protein (GAP). The GDP nucleotide can be exchanged for another molecule of GTP as 
long as an appropriate GEF (guanine nucleotide exchange factor) protein is bound. Interaction with the 
GEF causes conformational change that allows GDP to escape the binding pocket (Vigil et al., 2010). In 
the case of G-proteins, binding of GTP by the Gα subunit allows it to dissociate from Gβγ. Both Gα and Gβγ 
are able to then bind and modulate their effectors. After hydrolysis of GTP, perhaps with the help of a 
RGS (regulator of G-protein signalling; these are GAPs for G-proteins) protein, the Gα subunit is able to 
reassociate with Gβγ. On binding the appropriate ligand, GPCRs activate their G-protein by acting as a 
GEF (Huang and Tesmer, 2011). 
 
In PI3K signalling, Gβγ dimers are thought to be able to activate p110γ and p110β PI3K (Vanhaesebroeck 
et al., 2010). It is possible that Gα subunits can inhibit p110α signalling. GPCRs can also activate receptor 
tyrosine kinases, and both can activate Ras (by activating a RasGEF). Ras-GTP in turn binds and activates 
p110α or p110γ. For p110α-containing PI3K heterodimers, recruitment by a receptor tyrosine kinase 
may be a prerequisite for further activation by Ras. Ras is an oncogene and has been found activated in 
many cancer types (Roberts and Der, 2007). 
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1.3.2 Receptor Tyrosine Kinases 
 
There are 58 known receptor tyrosine kinases (RTKs) in humans, classified into 20 subfamilies (Lemmon 
and Schlessinger, 2010). Two of the most important of these in cancer are subfamilies class I and class II, 
representing EGFR family and insulin receptor family respectively. All RTKs have N-terminal ligand-
binding domains, a transmembrane domain, and a C-terminal tyrosine kinase domain(s). Binding of 
ligand results in conformational change that activates the tyrosine kinase domain. This is usually 
associated with receptor dimerization, although some RTKs, such as the insulin receptor, form 
constitutive, disulphide bond-linked dimers. The dimers are not necessarily homodimers, either; the 
insulin receptor is a heterodimer of α and β isoforms, while members of other RTK subfamilies can 
dimerise with related receptors. 
 
Before ligand binding, each receptor is autoinhibited and inactive (Gavi et al., 2006). The mechanism of 
autoinhibition varies across RTK subfamilies. For the insulin receptor, the activation loop blocks access 
to the active site (cis-autoinhibition). The conformational change induced by dimerization allows one 
monomer to phosphorylate the other at several often hierarchical tyrosine residues (trans-
phosphorylation). Adaptor proteins may also be involved which are also phosphorylated at tyrosines. 
SH2-domain containing proteins, or those containing a PTB (phosphotyrosine binding) domain, which 
serves a similar function, can then bind to the RTK. It is at this point that PI3K class IA are recruited. This 
interaction between RTK/adaptor and p85 subunit causes activation of the PI3K, and allows conversion 
of PtdIns(4,5)P2 into PtdIns(3,4,5)P3. In the case of Ras, the best known activation pathway involves the 
RTK EGFR (Lemmon and Schlessinger, 2010). This protein and its family members (as well as Ret, an RTK 
from a different subfamily) does not use trans-phosphorylation for activation. Instead, EGFR dimerizes 
such that an activator lobe of one monomer contacts a receiver lobe on the other. This then causes the 
required conformational change for activation. Once active, it proceeds to trans-phosphorylation itself 
anyway. The adaptor protein Grb2 binds to the phosphorylated tyrosine residues using its SH2 domain. 
Grb2 brings with it SOS (son of sevenless), to which Grb2 is constitutively bound. SOS is a GEF for Ras; 
binding to EGFR brings it close to the membrane, where Ras is tethered, and allows it to act on and 
activate Ras. Other RTKs are also able to recruit Grb2 (McKay and Morrison, 2007). 
 
In PI3K signalling, effectors are recruited to the phosphorylated PtdIns compounds, binding the PtdIns 
via PH domains. The most important of these effectors is Akt (aka PKB) (Hers et al., 2011). Importantly, 
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PtdIns(3,4,5)P3 can be converted to PtdIns(3,4)P2 by the phosphatase SHIP2 (SH2 domain-containing 
inositol 5-phosphatase type 2), or PtdIns(4,5)P2 by PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) (Hawkins et al., 2006). PTEN is a known tumour suppressor (Zhang and Yu, 2010). 
Though the gene is mutated in few breast cancer samples (<5%), protein expression may be lost in 
almost half of all primary breast cancers (Castaneda et al., 2010). The hereditary breast cancer 
predisposition syndrome Cowden Syndrome usually reflects germline PTEN mutations. 
 
1.3.3 Akt 
 
Akt is a ~56 kDa serine/threonine kinase (Manning and Cantley, 2007). It is conserved, and there are 
three isoforms in humans: Akt1, Akt2, and Akt3. The three isoforms are thought to be partially 
redundant but with some specificities (Gonzalez and McGraw, 2009). Mice with only one copy of Akt1 
are viable, but knockout of Akt1 plus Ak2 or Akt3 is lethal. However, individual knockout mice do have 
different phenotypes. 
 
Akt is activated downstream of both class I PI3K and mTOR signalling (Hers et al., 2011). This activation is 
in the form of phosphorylation at Thr308, part of the activation loop, and Ser473 at the C-terminal. The 
latter phosphorylation occurs downstream of mTOR (Chapter 1.3.4). After PI3K activity, Akt is able to 
bind both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 at the cell membrane via its PH domain. The conformational 
change induced by this binding enables Thr308 to be phosphorylated by PDPK1 (3-phosphoinositide 
dependent protein kinase 1). Note that this protein is often called PDK1, but PDPK1 is preferred for 
distinction between it and pyruvate dehydrogenase kinase-1 (PDK1). PDPK1 is constitutively active, but 
contains a PH domain, so it can be recruited to the membrane. It phosphorylates the Thr308 residue in 
Akt’s activation loop. Prior phosphorylation at Ser473 also enhances phosphorylation of Thr308 
(Sarbassov et al., 2005). Once phosphorylated at both sites, Akt is fully active and detaches from the 
membrane; it moves to the cytoplasm or nucleus to interact with and phosphorylate its downstream 
targets. These phosphorylations are mainly inhibitory. Targets include GSK3 (Wnt signalling), p27Kip1 (cell 
cycle), and importantly, FOXO. Overall, Akt promotes cell survival and growth (Manning and Cantley, 
2007). 
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PI3K/Akt signalling is upregulated in cancers by various mechanisms. These include loss of PTEN, 
activating mutations in p110α or p85α, activating mutations in Akt, amplification of PI3K/Akt proteins, 
activating mutations in Ras, and amplication and/or activating mutations in RTKs (Yuan and Cantley, 
2008; Engelman, 2009; Vigil et al., 2010). One such RTK whose amplification results in upregulation of 
PI3K signalling is HER2. The RTK EGFR is also amplified in some cancers, and activating mutations have 
also been discovered. It is targeted clinically by the monoclonal antibodies cetuximab, panitumumab 
and trastuzumab, and the TKIs gefitinib and erlotinib (Wheeler et al., 2010). The HER2-targeting TKI 
lapatinib actually also inhibits EGFR. Inhibitors have also been designed for clinical usage against class IA 
PI3Ks and Akt (Engelman, 2009). One such PI3K inhibitor is the prodrug SF1126, a targeted version of the 
LY294002 inhibitor used in laboratories (Maira et al., 2009). 
 
1.3.4 mTOR 
 
The mammalian target of rapamycin, mTOR, is a conserved serine/threonine kinase in the PI3K-related 
kinase family (Zoncu et al., 2011). It was named after its sensitivity to inhibition by the drug rapamycin. 
However, mTOR signalling in fact comprises two different complexes, mTORC1 and mTORC2. Though 
both have kinase activity through mTOR, these complexes have different sets of targets. It is the 
mTORC2 complex that phosphorylates Akt at Ser473 (Sarbassov et al., 2005). This complex also activates 
other kinases, including the close Akt relative SGK, and PKC (protein kinase C), as well as having 
involvement in regulation of cytoskeletal polarity. 
 
mTORC2 consists of mTOR plus the accessory protein Rictor (rapamycin insensitive companion of 
mTOR), along with PROTOR1 and -2 (protein observed with Rictor), mLST8 (mammalian lethal with 
SEC13 protein 8; GβL), mSIN1 (mammalian stress activated protein kinase interacting protein 1), and 
DEPTOR (DEP-domain containing mTOR-interacting protein). As suggested by Rictor’s name, the 
mTORC2 complex is not affected by rapamycin treatment. However, the upstream activation of mTORC2 
is not well understood. It is thought to be regulated by growth factors, possibly via Ras (Proud, 2011). 
Understanding of the activation of the mTORC1 complex is more complete (Caron et al., 2010). As for 
mTORC2 it is regulated by growth factors, but importantly also by amino acids (particularly leucine), 
energy and stress. These inputs allow mTORC1 activity to be subtly controlled. Aside from mTOR, the 
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mTORC1 complex contains Raptor (regulatory associated protein of mTOR) with PRAS40 (40kDa Pro-rich 
Akt substrate; aka AKT1S1), and DEPTOR and mLST8 are found in mTORC1 as well as mTORC2. 
 
While Akt is activated by mTORC2, in turn it is able to indirectly activate mTORC1. Activation of Akt via, 
for example, growth factor signalling, allows it to phosphorylate the substrate TSC2 (Winter et al., 2011; 
Zoncu et al., 2011). This protein, in complex with TSC1, is a GAP for the small GTPase Rheb (Ras 
homologue enriched in brain). Rheb-GTP enhances mTORC1 kinase activity. Akt’s phosphorylation of 
TSC2 inhibits the TSC1-TSC2 complex’s GAP activity, so Rheb does not hydrolyse its GTP and can 
continue to activate mTORC1. The full name of PRAS40 also gives another clue to Akt involvement in 
mTORC1 regulation. PRAS40 is a negative regulator of mTOR, but it is itself inhibited by Akt-mediated 
phosphorylation (Manning and Cantley, 2007). The MAPK ERK (extracellular regulated kinase), 
downstream of Ras, also inhibits TSC2 by phosphorylation. 
 
Overactivity of PI3K/Akt in cancer results in overactive mTOR (Gibbons et al., 2009), and it is targeted 
with drugs such as rapamycin or derivative compounds known as rapalogs (Carew et al., 2011). These 
have a much lower effect on mTORC2 than mTORC1, although they actually bind to the mTOR-
interacting protein FKBP12 (Abraham and Gibbons, 2007). Upstream inhibitors of RTKs, PI3K or Akt of 
course also reduce mTOR activity, but many PI3K inhibitors, including SF1126, are directly effective 
against mTOR due to the similarities between the proteins (Maira et al., 2009; Engelman, 2009). 
 
The mTORC1 complex promotes growth and proliferation through regulation of protein synthesis. It 
upregulates ribosome biosynthesis, as well as promoting mRNA translation through its substrates S6K 
and 4E-BP1 (Zoncu et al., 2011). Conversely, mTORC1 is the main inhibitor of autophagy (Chapter 1.6.1). 
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Figure 1.1 Class IA PI3K signalling through growth factor receptors. Activation of Akt downstream of a 
growth factor receptor. Activation of Class IB PI3Ks by GPCRs is not shown. Pink P: phosphorylation; 
green pentagon: growth factor. 
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1.4 CELL CYCLE 
 
The cell cycle for mitotic cells is divided into four stages: G1, S, G2, and M (Park and Lee, 2003). The DNA 
is replicated during S (synthesis) phase, while M represents mitosis. Cells are also able to exit the cell 
cycle and enter the resting stage G0; cells in G0 do not divide. They can re-enter G1 if appropriate 
signals are received. Progression through the cell cycle is regulated by cyclins and CDKs (cyclin-
dependent kinases). CDKs are serine/threonine kinases that require binding of specific cyclin proteins for 
activity. Four to six isoforms are thought to be involved in the cell cycle: CDK1 (also known as CDC2), 
CDK2, CDK4, and CDK6, and maybe CDK3 and CDK5 (Malumbres, 2011). They are expressed 
constitutively, but cyclin expression and availability is tightly controlled. 
 
The decision to proceed into S phase and onwards to mitosis is made during the G1 phase, in response 
to mitotic signals (Lukas et al., 2004). Near the end of G1 is the “Restriction point”, after which the cell is 
committed to division. This checkpoint is controlled by the tumour suppressor pRb (Retinoblastoma 
protein). There are three pRb family members, Rb (aka p105), Rb2 (aka p130) and p107. All bind to and 
repress the transcription factor E2F (Giacinti and Giordano, 2006). To pass the restriction point, D-type 
cyclins interact with CDK4 or CDK6. The cyclin D/CDK complex can then phosphorylate and inhibit pRb. 
The loss of repression from pRb allows E2F to upregulate transcription of E-type cyclins. Once translated, 
in late G1 phase, cyclin E is recruited to CDK2. This complex phosphorylates pRb again, further 
repressing it and allowing full activity of E2F. This results in progression into S phase. At the beginning of 
S phase, A-type cyclins are expressed. CDK2 now binds cyclin A instead, and promotes transition into 
and through G2. In late G2, cyclin A associates with CDK1 to start mitosis (M phase). These A-type cyclins 
are degraded after entry into M phase, and CDK1 recruits B-type cyclins to regulate progression through 
mitosis until anaphase (Murray, 2004). Each phase of the cell cycle contains a checkpoint, where cell 
cycle inhibitory proteins can delay and/or arrest the cell cycle (Lukas et al., 2004). These involve 
inhibition of cyclin/CDK complexes by CDK inhibitors (CKIs). In M phase, the spindle assembly checkpoint 
makes sure that chromatids are properly attached to the mitotic spindle. This is regulated by APC/C 
(anaphase-promoting complex/cyclosome) plus cofactors, which degrades proteins such as cyclin B. 
 
In the other cell cycle phases, detection of DNA damage prevents cells passing checkpoints (although 
damage-independent checkpoints also exist) (Niida and Nakanishi, 2006). The G2 checkpoint is often 
called G2/M, as these two phases cannot be resolved using a particular flow cytometry-based method 
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for cell cycle analysis. These checkpoints are effected by the PI3K-related kinases ATM (ataxia 
telangiectasia mutated) and ATR (ATM related), as well as the serine/threonine kinases Chk1 and Chk2 
(checkpoint kinase). DNA damage is detected very quickly by sensor proteins, which send the signal to 
the effector proteins (Bartek and Lukas, 2007). Chk1 and Chk2 phosphorylate targets including the 
phosphatase CDC25, contributing to a delay in cell cycle progression and causing CDC25 inhibition and 
degradation (Niida and Nakanishi, 2006). When active, CDC25 removes inhibitory phosphorylations from 
CDK1 and CDK2 (Karlsson-Rosenthal and Millar, 2006). 
 
Chk1/2 also phosphorylate and activate p53, as do ATM/ATR (Lukas et al., 2004). In addition, ATM/ATR 
promotes p53 protein stability by inhibiting the E3 ubiquitin ligase, MDM2, a regulator that promotes 
p53’s degradation via the proteasome. p53 plays an important part in the DNA damage response partly 
by transcriptionally upregulating the CKI p21Cip1/Waf1. This protein is part of the Cip/Kip CKI family, which 
also includes p27Kip1 (p27) and p57Kip2. The other CKI family is the INK4 proteins: p16Ink4a, p15Ink4b, 
p18Ink4c, p19Ink4d. These specifically inhibit CDK4 and CDK6 during G1. The Cip/Kip proteins on the other 
hand have wider specificities, and can act throughout the cell cycle (Maddika et al., 2007). Active CDK2 
phosphorylates p27 to promote its degradation. Akt can also phosphorylate and downregulate p27 
activity by inhibiting its nuclear import (Denicourt and Dowdy, 2004). 
 
Bypassing of the cell cycle checkpoints results in inappropriate proliferation and genomic and 
chromosomal instability. These are hallmarks of cancer. One oncogene involved in cell cycle regulation is 
cyclin D1, which is known to be overexpressed in some cancers (Alao, 2007). This overexpression is 
thought to contribute to the development of breast cancer (Arnold and Papanikolaou, 2005). 
Conversely, p27 is often found at lower levels in tumours, including breast cancers (Alkarain et al., 
2004). The breast cancer predisposition syndrome Li-Fraumeni may also be caused by certain germline 
mutations in Chk2, not just in p53 (Gasco et al., 2002). This is understandable as p53 is downstream of 
Chk2 in the DNA damage response. 
 
1.5 DNA DAMAGE AND REPAIR 
 
DNA is in constant need of repair (Houtgraaf et al., 2006). It is damaged by endogenous reactive oxygen 
species, as well as by drugs, environmental genotoxins, and radiation. Replication errors can also cause 
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problems. DNA damage takes the form of single or double strand lesions. Damage to one strand only is 
repaired by the base excision repair (BER) or nucleotide excision repair (NER). A further pathway, 
mismatch repair, exists to correct nucleotide mistakes made during DNA replication. For other lesions, 
the type of damage determines whether BER or NER is used. The DNA backbone can also be broken. 
Single strand break repair involves binding of PARP-1 (poly ADP-ribose polymerase 1), which recruits 
repair proteins such as XRCC1 (Polo and Jackson, 2011). The more serious type of damage is a break 
through both strands (double strand break; DSB), caused by reactive oxygen species and genotoxic 
agents such as chemotherapeutic drugs. DNA replication across an unrepaired nick (single strand break) 
also results in DSB formation. 
 
If DNA damage is repaired successfully, the checkpoint is passed and the cell continues cycling (Bartek 
and Lukas, 2007). DNA damage which is not repaired should induce senescence or cell death. Continuing 
through the cell cycle instead leads to mutation and chromosomal and genomic instability, and 
therefore tumorigenesis or further transformation. 
 
1.5.1 Double strand break repair 
 
DSBs are repaired by one of two pathways: non-homologous end joining (NHEJ) or homologous 
recombination (HR) (Houtgraaf et al., 2006). NHEJ is less accurate and may itself give rise to mutations, 
however, HR requires the sister chromatid to copy from and so cannot be used until S phase (Lieber, 
2010). 
 
In NHEJ, the Ku70:Ku80 heterodimer is thought to be one of the first proteins that bind to the DSB 
(Jackson, 2002). Ku then recruits various proteins to process the ends and ligate the DNA. The PI3K-like 
family member DNA-PK is one of those involved. It is activated by binding to DNA, then further activates 
itself by autophosphorylation using its serine/threonine kinase activity. It binds to and stimulates activity 
of other important NHEJ proteins such as DNA ligase IV (Lieber, 2010). Although some proteins are 
involved in both DSB repair pathways, HR mainly requires a different set of enzymes. For HR, the ends 
are recognised and bound by MRN, a complex made of Mre11, Rad50 and Nbs1. Other proteins are also 
recruited, and the DNA ends are resected. The same DNA sequence on the other chromatid is used as a 
template for filling in by DNA polymerase, though pieces of DNA get swapped from one chromatid to 
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the other. One of the most important proteins in HR is Rad51. It is regulated by BRCA1/2 (among 
others), which bind it directly (Gudmundsdottir and Ashworth, 2006). BRCA1/2-deficient cells are 
defective in HR, and in a synthetic lethal interaction are often sensitive to PARP inhibitors as a cancer 
treatment (Helleday et al., 2008).  
 
1.5.2 DNA damage by chemotherapeutic drugs 
 
Many non-targeted chemotherapeutic drugs induce cell death by causing DNA damage (Helleday et al., 
2008). Platinum compounds cause DNA crosslinking, usually in the form of intrastrand covalent 
interactions. Such modifications change the shape of the DNA and mostly prevent transcription or 
replication across them. Platinum-derived DNA damage is repaired by the NER pathway (Jung and 
Lippard, 2007).  
 
Anthracyclines such as epirubicin bind to and inhibit topoisomerase II (see below). More directly, these 
drugs are able to intercalate into DNA, interfering with normal DNA activity and causing damage. 
Anthracyclines are also thought to cause DNA crosslinks or anthracycline-DNA adducts, depending on 
reactions with intracellular formaldehyde and/or redox reactions (Chapter 1.8.1) (Kizek et al., 2011). 
 
1.5.2.1 Topoisomerase II 
 
The topoisomerase II enzyme is conserved, and has two forms in mammalian cells, α and β. It is required 
to correct the positive or negative supercoiling, DNA knotting and catenation that occurs due to DNA 
transcription or replication (Nitiss, 2009). It acts by by introducing transient DNA breaks: topoisomerase 
II produces DSBs. These DNA ends are covalently bound to the topoisomerase protein, and so do not 
cause a DNA repair response. An unbroken DNA strand is brought through the broken one before the 
DSB ends are resealed, allowing the DNA topology to be changed. The ligation reaction is reversibly 
inhibited by anthracyclines as well as etoposide, which are considered topoisomerase II poisons 
(Pommier et al., 2010). The covalently joined topoisomerase now blocks replication and transcription 
across the broken DNA. Processing and removal of the poisoned complex then produces DSBs i.e. DNA 
damage is generated by the anthracycline action. Anthracyclines are thought to have some additional 
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activity towards topoisomerase I, related enzymes that introduce transient single strand breaks (Minotti 
et al., 2004). 
 
1.6 CELL DEATH AND APOPTOSIS 
 
Cell death is important during development and in the adaptive immune system, as well as in tissue 
homeostasis and removal of damaged cells (Elmore, 2007). Several programmed cell death mechanisms 
exist in mammalian cells, mainly apoptosis, necrosis, and autophagy. Unlike apoptosis, necrosis involves 
cell and organelle swelling, and lysis (Van Herreweghe et al., 2010). Release of cellular contents into the 
extracellular matrix is inflammatory and causes damage to surrounding cells. Another form of cell death, 
known as mitotic catastrophe, occurs when cells fail to execute mitosis properly. This is distinct from 
apoptosis but uses many of the same mechanisms (Zhivotovsky and Kroemer, 2004). 
 
Within apoptosis, two main pathways exist (Elmore, 2007). These are the extrinsic pathway, via death 
receptors in the plasma membrane, and the intrinsic pathway that involves the mitochondria. Both are 
mediated by caspases (cysteine-aspartic acid protease). Caspases are translated as inactive pro-
caspases, and must be cleaved to be activated. Both pathways also result in the same downstream 
effects, such as DNA fragmentation, membrane blebbing, and the presence of phosphatydlyserine on 
the outer leaflet of the plasma membrane (Portt et al., 2011). This phospholipid on the surface of the 
cell is recognised by phagocytes which engulf and destroy the apoptotic cell. 
 
The extrinsic pathway is induced by activation of a death receptor. These are TNFR superfamily 
receptors such as TNFR (tumour necrosis factor receptor), Fas, and TRAIL-R (Pereira and Amarante-
Mendes, 2011). Activation allows them to recruit death domain-containing adaptor proteins (TRADD and 
FADD) to their own death domain. Pro-caspase 8 is then recruited and activated through formation of 
the death-inducing signalling complex (DISC). Caspase 8 is known as an initiator caspase. It activates the 
main “executioner” caspase, caspase 3, which induces apoptosis (Elmore, 2007). Caspase 8 activation 
can also induce the intrinsic apoptotic pathway by activating Bid (Pereira and Amarante-Mendes, 2011). 
Intrinsic apoptosis involves permeabilisation of the outer mitochondrial membrane (MOMP), resulting in 
the release of cytochrome c. This is regulated mainly by Bcl-2 family members. Pro-apoptotic family 
members such as Bax, Bak or Bim also help to inhibit the anti-apoptotic Bcl-2 proteins, including Bcl-XL 
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and Bcl-2 itself. Once MOMP has occurred, the cell is committed to die. Cytochrome c forms part of a 
complex, also including pro-caspase 9, known as the apoptosome. The apoptosome activates caspase 9, 
which activates the executioners caspase 3, caspase 6 and caspase 7. The executioner caspases bring 
about apoptosis by cleaving a variety of proteins, including PARP. 
 
Suppression of apoptosis is often seen in cancer. This may be mediated by upregulation of genes such as 
Bcl-2 or downregulation of the pro-apoptotic Bcl-2 family members (Portt et al., 2011). Notably, p53 is 
involved in the intrinsic pathway of apoptosis. It transcriptionally upregulates pro-apoptotic proteins 
including the Bcl-2 family members Bax, Noxa and PUMA (Ozaki and Nakagawara, 2011). Aside from 
functioning as a transcription factor, it has been reported that cytoplasmic p53 can also physically 
interact with and inhibit Bcl-2 and Bcl-XL at the mitochondrial outer membrane (Zhivotovsky and 
Kroemer, 2004). Conversely, PI3K/Akt signalling is pro-survival. Akt is able to phosphorylate and inhibit 
Bad and caspase 9, as well as ASK1, upstream of JNK and p38 MAPKs (Roos and Kaina, 2006). Akt also 
inhibits p53’s transcriptional activity by promoting MDM2 activity. 
 
1.6.1 Autophagy 
 
Macroautophagy (autophagy) is the sequestration and degradation of macromolecules in specialised 
vacuoles known as autophagosomes. These then fuse with lysosomes to form autolysosomes, before 
the contents are degraded. The breakdown products are released back into the cytoplasm for use by the 
cell, providing nutrients and energy (Rabinowitz and White, 2010). Autophagy is required for some 
protein degradation, and promotes survival under conditions such as starvation (Maiuri et al., 2007). 
Formation of the autophagosome requires PtdIns3P, generated by the class III PI3K Vps34. The protein 
LC3 is also involved in autophagosome formation, after conjugation to phosphatydlethanolamine to 
form LC3-II (Rabinowitz and White, 2010). 
 
Autophagy can promote survival, possibly in part by removal of damaged mitochondria before 
cytochrome c can be released to trigger apoptosis. However, prolonged autophagic activation may 
result in autophagic cell death, especially if apoptosis is suppressed (Portt et al., 2011). Likely reflecting 
its role in avoiding apoptosis, increased autophagy is often seen in cancer cells treated with 
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chemotherapeutic drugs (Chen and Debnath, 2010). On the other hand, since autophagy promotes 
cellular health, its suppression may contribute to tumorigenesis (Roy and Debnath, 2010). 
 
Autophagy is induced in response to multiple conditions, including lack of amino acids, lack of energy 
(i.e. ATP), oxidative stress, and hypoxia (Rabinowitz and White, 2010). Conversely, the main inhibitor of 
autophagy is mTORC1. Energy availability is detected by the sensor proteins LKB1 and AMPK (AMP-
activated protein kinase), via the AMP:ATP ratio (Hardie, 2011). LKB1 also phosphorylates and activates 
AMPK. AMPK then phosphorylates various targets, regulating metabolism, cell growth, and autophagy. 
Induction of autophagy is effected by AMPK’s activation of the pro-autophagy kinase ULK, as well as 
attenuation of mTORC1 signalling by AMPK-mediated phosphorylation and inhibition of Raptor plus 
activation of TSC2 (Roy and Debnath, 2010; van Veelen et al., 2011), as described in Chapter 1.3.4. The 
TSC complex inhibits mTORC1 by acting as a GAP for Rheb (a GTPase required for mTORC1 activity). 
AMPK has also been found to phosphorylate and stabilise the cell cycle regulator/CKI p27, which 
promoted survival via autophagy (Liang et al., 2007). AMPK is activated by the drug metformin; this 
compound was initially used in hyperglycemia and type II diabetes, but may be used for cancer 
treatment owing to its ability to downregulate mTOR and Akt activity (Jalving et al., 2010; Dowling et al., 
2011). 
 
p53 also regulates autophagy. It upregulates the transcription of target genes such as AMPK, PTEN (to 
inhibit mTOR via PI3K), and sestrin (Chen and Debnath, 2010). Sestrins activate AMPK and inhibit mTOR 
(Lee et al., 2010 a). Conversely, p53 has also been linked to transcriptional downregulation of LC3 
(Scherz-Shouval et al., 2010). 
 
1.7 CHEMOTHERAPEUTIC DRUG RESISTANCE 
 
Cancers invariably become resistant to treatment, whether targeted therapies/specific inhibitors, 
traditional chemotherapeutic drugs, or endocrine therapy. This is known as acquired resistance, to 
distinguish it from intrinsic or de novo resistance i.e. non-response from the start (Lippert et al., 2011). 
For example, a triple negative breast cancer is intrinsically resistant to HER2-targeted therapies. 
However, the mechanisms contributing to each kind of resistance can be similar. 
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Acquired resistance to tamoxifen treatment sometimes involves loss of ERα or amplification or 
hyperactivation of ERα cofactors (Musgrove and Sutherland, 2009). Amplification of HER2/EGFR and 
PI3K/Akt signalling has also been linked to tamoxifen resistance (Haagenson and Wu, 2010; Ma et al., 
2011). Mutations in tubulin proteins contribute to taxane resistance in breast cancer, but so does 
overexpression of HER2 or loss of p53 (Galmarini et al., 2003; McGrogan et al., 2008). Rapalog 
(mTOR/FKBP-12 inhibitor) resistance has been shown to involve increased Akt and ERK activity, among 
other mechanisms including again, loss of p53, or overexpression of antiapoptotic proteins (Carew et al., 
2011). Acquired resistance to gefitinib often develops due to mutation of EGFR so that it is no longer as 
sensitive (Wong et al., 2010). 
 
For treatment with DNA damaging agents, another method of evading cell death is to upregulate DNA 
repair mechanisms. For example, upregulation of the NER pathway protein ERCC1 is often seen in 
tumours resistant to platinum treatment (Köberle et al., 2010). Similarly, increased levels of RAD51 were 
found in small cell lung cancer cells resistant to etoposide (Helleday, 2010). Etoposide induces DNA 
damage by inhibiting topoisomerase II (Deweese and Osheroff, 2009). 
 
Resistance can also develop to several types of drug simultaneously, known as multidrug resistance. One 
important mechanism behind this is upregulation of membrane ATP-binding cassette (ABC) family 
transporter expression (Szakács et al., 2006). These transporters cause drug efflux. The most studied 
such transporter in multidrug resistance is MDR1, also known as P-glycoprotein or ABCB1. It is able to 
transport a wide range of substrates including anthracyclines, taxanes, etoposide, and the TKI imatinib 
(Fletcher et al., 2010). Other family members have different substrates, with some more specific than 
others. Of course, upregulation of drug efflux by ABC transporters can also mediate resistance to a 
single drug, not just multidrug resistance. Expression of MDR1 has been linked to single drug resistance 
in breast cancer (Coley, 2008). 
 
1.8 REDOX SIGNALLING AND OXIDATIVE STRESS 
 
Reactive oxygen species (ROS) is a collective term for oxygen free radicals, such as superoxide (O2
•-) or 
hydroxyl radical (HO•), and non-radical oxygen derivatives including hydrogen peroxide (H2O2) (Circu and 
Aw, 2010). Cells produce ROS during normal activity, but an abundance of ROS (due to overproduction, 
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downregulation of antioxidants, or drug treatment) causes oxidative stress. This is associated with many 
disease states as well as organismal aging. 
 
ROS are required for normal cell function and signalling, including growth factor signalling (Finkel, 2011). 
In particular, oxidation and reduction of certain cysteine residues contributes to “redox” signalling. This 
is named as it is a balance between oxidation and reduction. Depending on the microenvironment (eg 
the other residues in the protein), some cysteine thiols (carbon-bonded SH group) are more amenable 
to oxidation than others. Oxidation of cysteine to the sulphenic form (R-SOH) may alter the protein’s 
shape or activity. It can also allow disulphide bridges to form between two cysteine residues, one 
oxidised and one in its reduced state. These may be within one protein, or form a covalent bridge 
between two proteins (Berlett and Stadtman, 1997). In this way ROS are able to directly regulate protein 
activity. Reactive nitrogen species can also nitrosylate cysteines. Although they also contain sulphur, 
methionine residues are not able to form disulphide bonds. These residues do participate in redox 
signalling, but it is not as well studied as cysteine-mediated redox regulation (Bigelow and Squier, 2011). 
ROS have different specificities due to their different chemistry. The main ROS oxidising cysteines to 
their sulphenic form is H2O2 (Forman et al., 2010). Conversely, superoxide preferentially oxidises the 
iron-sulphur clusters of metalloproteins (D’Autréaux and Toledano, 2007). H2O2 is actually generated by 
the reduction of superoxide, e.g. by manganese superoxide dismutase (MnSOD; SOD2). 
 
Oxidative stress arises from an imbalance between ROS production, and antioxidant/ROS scavenger 
activity. It results in both damage to macromolecules and disruption to redox signalling. While oxidation 
to the sulphenic form is reversible, further oxidation of the cysteine into the sulphinic (R-SOH2) or 
sulphonic (R-SOH3) forms is irreversible. Such modifications can be thought of as oxidative damage. The 
type of damage depends on the type of ROS. Proteins can also be oxidised on their backbone or other 
side chains, or carbonylated or nitrated. These are modifications which are also generally permanent 
(Kim et al., 2011 a). Lipids are similarly sensitive to oxidative damage (Jones, 2008). In the nucleus, ROS 
damage DNA, causing intra- and interstrand crosslinking, single and double strand breaks, damage to 
nucleotides and addition of bulky adducts (Houtgraaf et al., 2006). It has been estimated that oxidative 
damage causes 104 DNA lesions per cell per day (Klaunig et al., 2010). 
 
Disulphide bridges are removed/reduced by the antioxidants thioredoxin or glutaredoxin, which become 
oxidised themselves. Oxidised, sulphenic cysteines can be reduced by glutathione, although this also 
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requires glutaredoxin (D’Autréaux and Toledano, 2007). Reduction requires NADPH (Circu and Aw, 
2010). Other antioxidants/ROS scavengers include peroxiredoxin and catalase, both of which reduce 
H2O2 (Kirkman and Gaetani, 2007; Cox et al., 2010). MnSOD is also considered an antioxidant. Redox 
regulation affects many aspects of cell signalling and activity. The tumour suppressor p53, for example, 
is redox sensitive through cysteines both on its surface and at its catalytic site (Kim et al., 2011 a).  
 
Cancer cells experience a greater level of oxidative stress than normal cells, and ROS production may be 
upregulated in cancer (Trachootham et al., 2009). Chronic low levels of ROS are thought to contribute to 
tumorigenesis by promotion of genomic instability or activation of oncogenes (Lau et al., 2008). 
Conversely, high levels of ROS can cause apoptosis or senescence (Vurusaner et al., 2011). These 
mechanisms require tumour suppressors such as p53, pRb and p21. Both up- and downregulation of 
ROS scavengers and antioxidants has been recorded for tumour cells, demonstrating the complexity of 
redox signalling and oxidative stress in cancer (Trachootham et al., 2009). Even in these cells, a careful 
balance is struck between death and instability. 
 
1.8.1 Oxidative stress and chemotherapy 
 
Though some chemotherapeutic drugs cause DNA damage directly, many drugs also cause oxidative 
stress, further contributing to apoptosis. Anthracyclines have particularly been linked to ROS 
production. They are part of a group of compounds known as redox cyclers; interaction with NAD(P)H 
oxidoreductases allows the anthracycline to reduce oxygen to superoxide (Minotti et al., 2004). A 
second ROS production mechanism involves the anthracycline-mediated release of iron. The iron then 
binds to the antracycline, resulting in production of hydroxyl radicals (•OH) (Trachootham et al., 2009). 
This ROS increase subsequently produces formaldehyde, which contributes to DNA damage (Kato et al., 
2000). Oxidative DNA lesions have been found in cells from patients treated with doxorubicin, 
confirming that ROS production by anthracyclines is clinically relevant (Minotti et al., 2004). Cisplatin 
treatment has also been linked to oxidative and nitrosative stress that contributes to cell death (Chirino 
and Pedraza-Chaverri, 2009). This may be partially due to activation of NADPH oxidase by cisplatin (Itoh 
et al., 2011). The topoisomerase I inhibitor camptothecin induces cell death by causing DNA nicks, but 
also upregulates ROS to induce intrinsic pathway apoptosis directly (Lau et al., 2008).  
 
42 
 
In drug resistant cells, ROS levels are reduced and antioxidants upregulated (Trachootham et al., 2009; 
Maiti, 2012). Co-treatment with ROS has been shown to restore drug sensitivity. Results such as this 
have led to interest in drugs that increase intracellular ROS levels, including activators of NADPH 
oxidases, or inhibitors of glutathione synthesis (Fruehauf and Meyskens, 2007; Lau et al., 2008; 
Trachootham et al., 2009). Conversely, compounds that act as antioxidants have been investigated as 
possible tumour suppressors, such as genistein or curcumin (Acharya et al., 2010). Oxidative stress has 
been shown to cause resistance to rapamycin in yeast, by reducing mTOR’s ability to bind the yeast 
homologue of FKBP12 (Neklesa and Davis, 2008). 
 
 
 
1.9 MITOGEN ACTIVATED PROTEIN KINASES 
 
Three mitogen activated protein kinase (MAPK) families exist: ERK (extracellular regulated kinase), JNK 
(c-Jun N-terminal kinase), and p38, as well as some atypical MAPKs (Raman et al., 2007). MAPKs are 
serine/threonine kinases with wide-ranging roles in the cell. The three classes are regulated similarly, 
each via a kinase cascade from MAPK kinase kinase (MAPKKK or MAP3K), to MAPK kinase (MKK), then 
the MAPK itself. Several proteins can fulfil these roles for each MAPK. In fact there is extensive overlap 
between the signalling pathways for the MAPKs, particularly for JNK and p38. Broadly, the three MAPKs 
are also activated by the same upstream signals: growth factors (Figure 1.2) and oxidative stress. 
 
1.9.1 ERK 
 
There are two main ERK isoforms, ERK1 and ERK2. ERK1 is 44kDa and ERK2 is 42kDa; they are sometimes 
known respectively as p44 MAPK and p42 MAPK. These isoforms are very closely related, with 
approximately 80% identity, and show some functional redundancy (Lu and Xu, 2006). ERK is chiefly 
activated downstream of Ras, therefore being activated by growth factor signalling (McKay and 
Morrison, 2007). Activated Ras at the plasma membrane recruits Raf, a serine/threonine kinase that acts 
as a MAP3K for ERK. Raf is activated by Ras-mediated phosphorylation, and subsequently 
phosphorylates and activates MEK, an MKK (also actually known as MKK). MEK1/2 activates ERK1/2 by 
phosphorylating two residues within the activation loop. These are Thr202 and Tyr204 in ERK1. 
43 
 
 
ERK is regulated by redox signalling and oxidative stress through several upstream mechanisms. In 
growth factor signalling, the EGFR can actually be activated by H2O2 in the absence of EGF (Khan et al., 
2006). Both of these result in ERK activation. Note that this H2O2-dependent EGFR activation also means 
that Akt is activated by H2O2. Ras activity is affected by ROS, through internal redox-sensitive cysteine 
residues (Runchel et al., 2011). ROS also activate the Src kinases, which are able to increase Ras activity 
(Bromann et al., 2004). Finally, H2O2 has been linked to calcium regulation; it causes an increase in 
intracellular calcium that is known to activate ERK (McCubrey et al., 2006). 
 
Activated ERK moves to the nucleus to phosphorylate its targets. It has a wide range of targets and over 
150 substrate proteins have been identified (Lu and Xu, 2006), including transcription factors such as ER, 
Myc and HIF-1α. ERK activity is generally associated with pro-proliferation and pro-survival signalling, 
and Ras/Raf/MEK/ERK signalling is considered oncogenic (Kohno and Pouyssegur, 2006). In cancer, this 
pathway is often hyperactive due to amplification of RTKs, Ras and Raf expression and activity. To inhibit 
apoptosis, ERK mediates inhibition of molecules such as Bad, Bim and caspase 9, in conjunction with 
activation of anti-apoptotic proteins such as IEX-1. In light of these activities, small molecule inhibitors 
have been developed against Raf and MEK that will hopefully prove clinically useful (Montagut and 
Settleman, 2009). 
 
ERK activity has also been found to promote apoptosis. This differential response is possibly regulated 
by ERK subcellular localisation (Mebratu and Tesfaigzi, 2009; Cagnol and Chambard, 2010). Inhibition of 
ERK signalling has been shown to reduce cell death in response to cisplatin and doxorubicin (Wang et al., 
2000; Yeh et al., 2002; Tang et al., 2002). In some cases ERK-mediated apoptosis is dependent on direct 
phosphorylation of p53 by ERK (Woessmann et al., 2002; Yeh et al., 2004). Akt has also been linked to 
ERK pathway inhibition in several cancer cell types, by causing an increase in inhibitory phosphorylation 
of Raf (Lee et al., 2008 c). 
 
1.9.2 JNK 
 
The JNK (previously known as SAPK, stress activated protein kinase) subfamily consists of JNK1, JNK2 and 
JNK3, all of which have multiple splice forms (Liu and Lin, 2005). JNK1/2 are ubiquitously expressed. A 
44 
 
number of MAP3Ks are known to contribute to JNK activation, including MEKK1-4, TAK1 and ASK1 
(Dhanasekaran and Reddy, 2008). These all phosphorylate and activate the JNK pathway MKKs MKK4 or 
MKK7. MKK4 is unusual as it can bind and phosphorylate both JNK and p38. JNK is activated by 
phosphorylation of Thr183 and Tyr185 in the activation loop. As for ERK, JNK is capable of both pro- and 
anti-apoptotic signalling. It is thought that transient JNK activation promotes survival, but prolonged JNK 
activity results in apoptosis (Liu and Lin, 2005; Wagner and Nebreda, 2009). 
 
JNK is activated by the inflammatory cytokine TNFα (tumour necrosis factor α) (Waterston and Bower, 
2004). TNFα belongs to the TNF superfamily of ligands, which includes TNFβ/lymphotoxin, CD40L, FasL 
and TRAIL. These ligands are bound by members of the TNFR superfamily of receptors. Having bound 
TNFα, TNFR1 binds the adaptor protein TRADD using its death domain. TRADD can promote apoptosis, 
but can also recruit TRAF (TNF receptor associated factor) proteins. TRAF2 activates the MAP3K ASK1 
(Han et al., 2009). However, the resultant JNK activity is transient as the canonical NFκB pathway is also 
activated by TRAFs. Activated IKK complex (IκB Kinase; complex consists of IKKα, IKKβ and IKKγ/NEMO) 
phosphorylates and causes the degradation of the inhibitory protein IκBα, allowing activation of an NFκB 
heterodimer of RelA/p65 and p50 that moves to the nucleus to affect transcription (Hayden and Ghosh, 
2008). NFκB overall is pro-proliferation, pro-survival, and anti-apoptotic (as well as pro-invasion) 
(Naugler and Karin, 2008). NFκB inhibits JNK in multiple ways. For example, NF- B can induce the 
expression of GADD45β, which binds and inactivates MKK7 (Papa et al., 2008). Similarly, the NFκB target 
XIAP causes degradation of TAK1 (Kaur et al., 2005). TAK1 also activates the IKK complex, activating 
canonical NFκB signalling in a negative feedback loop (Adhikari et al., 2007). 
 
One of the growth factors that has been studied in MAPK signalling is TGF-β (transforming growth factor 
β) (Shi and Massagué, 2003). Activation of TGF-β receptors generally results in the activation of SMAD 
family members, which then act as pro-apoptotic transcription factors. In cancer the TGF-β pathway is 
deregulated and instead contributes to angiogenesis and invasion, hence its name (Mori et al., 2004). It 
therefore turns from a tumour suppressor into an oncogene. TGF-β activity also results in activation of 
TAK1 (TGF-β activated kinase 1) (Derynck and Zhang, 2003). This signalling is dependent on TRAF6 
(Yamashita et al., 2008). On the other hand, JNK is known to phosphorylate and activate SMAD3, but the 
JNK substrate c-Jun inhibits SMAD2 (Derynck and Zhang, 2003). JNK also regulates the expression of 
TGF-β (Ventura et al., 2004). 
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Members of the Rho subfamily of Ras GTPases, such as Rac and Cdc45, also induce the activity of JNK 
and p38 (Hall, 2005). These GTPases link GPCR activation with JNK and p38 signalling (Goldsmith and 
Dhanasekaran, 2007).  
 
In oxidative stress, ASK1 becomes active. This protein is redox sensitive: it contains redox-sensitive 
cysteine residues itself and is inhibited by thioredoxin, with which it is in complex (Han et al., 2009; 
Nadeau et al., 2009). Oxidative activation of Ras can also contribute to JNK pathway upregulation 
(McCubrey et al., 2006). 
 
JNK’s substrates include nuclear and cytosolic proteins. Two of the most well studied of these are c-Jun, 
which gave JNK its name, and ATF2. Both are phosphorylated and activated by JNK. ATF and c-Jun, along 
with proteins from the c-Fos, JDP and MAF families, form heterodimers known as the AP-1 transcription 
factor. AP-1 regulates promotes proliferation (Shen et al., 2008) by regulation of genes such as cyclin D1 
or cyclin A (Wisdom et al., 1999; Katabami et al., 2005). c-Jun is considered an oncogene, but it has also 
been linked to upregulation of the tumour suppressor p19ARF (Shaulian, 2010). Other JNK targets are the 
pro-apoptotic Bcl-2 family members Bcl-2, Bcl-xL and Bim, which are activated by JNK, and the 
scaffold/sequestering proteins 14-3-3 that sequester them, which are inhibited. p53 is phosphorylated 
by JNK, promoting its stabilisation and activity (Bogoyevitch and Kobe, 2006). In metabolism, JNK inhibits 
insulin signalling by phosphorylating and inhibiting the adaptor proteins IRS1 and IRS2 (insulin receptor 
substrate) (Lee et al., 2003; Sharfi and Eldar-Finkelman, 2008). Although JNK has been reported to 
activate Akt by direct phosphorylation, this is contentious (Bogoyevitch and Kobe, 2006). Conflicting 
reports may reflect JNK’s dual ability to promote survival and apoptosis. In a possible feedback loop, Akt 
was reported to inhibit JNK activity in PC12 cells (Levresse et al., 2000). 
 
Activation of JNK has been linked to cancer development (Shibata et al., 2008; Das et al., 2011), and a 
lower level of phosphorylated JNK (and phosphorylated p38) was associated with better survival for 
breast cancer patients (Yeh et al., 2006). JNK activity has also been linked to increased cellular invasion 
(Igaki et al., 2006; Wang et al., 2010). These results suggest that in cancer, the pathway is deregulated so 
that prolonged JNK activity actually promotes growth rather than apoptosis. 
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1.9.3 p38 
 
The p38 family is the third typical MAPK family. It contains four genes encoding p38α, β, γ, δ. The alpha 
isoform is most widely expressed and has been most studied (Raman et al., 2007). The p38 and JNK 
pathways share MAP3Ks (and MKK4), and are therefore both activated in response to some signals: like 
JNK, the p38 pathway is activated by stressors such as osmotic shock, UV radiation, inflammatory 
cytokines and oxidative stress, as well as by growth factors such as insulin (Zarubin and Han, 2005). 
However, their downstream targets are different, and in fact p38 and JNK activity may be antagonistic 
(Wagner and Nebreda, 2009). Upstream, MKK3, MKK6 and MKK4 activate p38 by phosphorylation at 
Thr180 and Tyr182 (p38α). MKK3 and MKK6 are the dominant MKKs of this pathway. 
 
JNK and p38 also share some substrates, as p38 is known to phosphorylate proteins such as ATF2 and 
Elk-1. p38 regulates the cell cycle and promotes arrest by phosphorylating and activating p53, and 
inhibiting CDC25 (Thornton and Rincon, 2009). As for the other MAPKs, in some cell types p38 has been 
linked with promotion of apoptosis, and in others its activity is linked to survival (Zarubin and Han, 
2005). p38 has also been implicated in cancer and invasion (Wagner and Nebreda, 2009).  
 
1.9.4 MAPK phosphatases  
 
MAPKs are inhibited by protein tyrosine phosphatases (PTPs) (Patterson et al., 2010). Several classes 
and subclasses of PTP exist. The most important subclass for MAPK signalling is the dual specificity 
phosphatases (DUSPs). These enzymes have both tyrosine phosphatase and Ser/Thr phosphatase 
activity, and can therefore remove both Thr/Tyr activating phosphorylations from MAPKs. The 
mammalian DUSP family has over 60 members. Ten DUSPs form a subclass known specifically as MAPK 
phosphatases (MKPs), although other DUSPs do have the ability to inhibit MAPKs (notably those in the 
“atypical DUSP” subclass). Other non-DUSP PTPs that regulate MAPK activity include SHP, which affects 
Ras (Krautwald et al., 1996; Easton et al., 2006), and HePTP, which dephosphorylates ERK2 (Pettiford 
and Herbst, 2000). 
 
Importantly, the catalytic sites of PTPs are cysteine-dependent (Tonks, 2005). This renders them 
sensitive to redox signalling and oxidative stress: oxidation of the catalytic thiol inactivates the PTP. The 
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inhibition of DUSPs in this way is a further mechanism causing activation of MAPKs in response to 
oxidative stress. The MKPs are DUSP1, DUSP2, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, DUSP10 
and DUSP16 (Owens and Keyse, 2007). The different DUSP/MKPs have different substrate specificities. 
For example, DUSP1 (aka MKP1) preferentially dephosphorylates JNK, but also acts on p38 and ERK 
(Keyse, 2008). This specificity is mediated by differences in the interacting motifs on both the MKP and 
the MAPK (Owens and Keyse, 2007). 
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Figure 1.2 Activation of MAPKs by extracellular ligands. Signalling upstream of ERK, JNK and p38. Grey 
arrows denote a secondary role. Trx: thioredoxin; pink P: phosphorylation. Ras is activated by growth 
factor signalling (Figure 1.1). 
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1.10 METABOLISM OF CANCER CELLS 
 
Cellular metabolism is central to cellular activity. Cancer cells show markedly different cellular 
metabolism from normal cells, known as “metabolic transformation” (Hsu and Sabatini, 2008). One of 
the most consistently observed changes is that glycolysis is generally upregulated in tumour cells. 
Normal cells inhibit glycolysis in favour of oxidative phosphorylation when oxygen is available (the 
Pasteur effect). In contrast, glycolysis when oxygen is available, with excessive lactate production, is 
known as the Warburg effect, or aerobic glycolysis. In cancer, a higher rate of glucose uptake/glycolysis 
is associated with a more aggressive phenotype (Ramanathan et al., 2005). 
 
1.10.1 Glycolysis 
 
Glucose is taken up into cells through plasma membrane glucose transporters (GLUT proteins). It is 
phosphorylated by hexokinase (HK), forming glucose-6-phosphate. Both HK and GLUT1 are 
overexpressed in cancer (Young and Anderson, 2008; Mathupala et al., 2010). GLUT1 expression was 
particularly linked to basal-like breast cancer (Hussein et al., 2011). As well as glycolysis, glucose-6-
phosphate can be used in the pentose phosphate pathway (PPP) to produce ribose-5-phosphate (as well 
as two molecules of NADPH), which can be used to synthesise nucleic acids (Buchakjian and Kornbluth, 
2010) (Figure 1.3). In glycolysis however, glucose-6-phosphate is converted through several steps into 
two molecules of pyruvate. Two molecules of ATP are produced per glucose molecule converted to 
pyruvate. This pyruvate usually feeds into mitochondrial metabolism via the TCA (tricarboxylic acid) 
cycle. However, in anaerobic glycolysis or cancer cells, most of the pyruvate is converted to lactate by 
lactate dehydrogenase (LDH) (Feron, 2009). The lactate is then secreted via the monocarboxylate 
transporter (Hirschhaeuser et al., 2011). LDH seems to be important for aerobic glycolysis: inhibition of 
LDH has been shown to revert the Warburg effect (Hsu and Sabatini, 2008). In fact, a LDH isoform was 
found to be required for mTOR-dependent tumorigenesis in a study using MEF cells (Zha et al., 2011) 
 
The upregulation of glycolysis is partly mediated by known oncogenes and tumour suppressors. p53 is 
an important negative regulator of glycolysis. Its target TIGAR inhibits the glycolytic enzyme 
phosphofructokinase-1, promoting the PPP instead of glycolysis. p53 also inhibits phosphoglycerate 
mutase, another glycolytic enzyme (Maddocks and Vousden, 2011). Therefore loss of p53 in cancer 
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increases glycolytic flux. The oncogenes c-Myc and Akt have also been linked to upregulation of 
glycolysis. Akt somehow promotes GLUT activity, aiding glucose uptake. Akt also stimulates HK activity 
(Young and Anderson, 2008). Overexpression of constitutively active Akt1 in a murine leukaemia model 
cell line has been shown to increase glycolysis (Elstrom et al., 2004). 
 
Myc is a proto-oncogenic transcription factor. It has been estimated that the c-Myc isoform is 
overexpressed to some extent in 70% of human cancers (Gordan et al., 2007). In normal cells it is 
regulated downstream of growth factors (via Ras) and Wnt signalling pathways. c-Myc is phosphorylated 
and activated by ERK (Lee et al., 2010 b). Myc regulates transcription in complex with Max, Mad or Mxi. 
Its targets include a large number of metabolic enzymes, including upregulation of some glycolytic 
enzymes, as well as LDH A (Gordan et al., 2007). Akt also indirectly upregulates Myc (Marampon et al., 
2006). 
 
The oxygen sensitive transcription factor HIF1-α (hypoxia induced factor 1α) is involved in glycolysis 
regulation. In normal cells, it is inactive when oxygen is plentiful. A reduction in oxygen availability, 
called hypoxia, inhibits the oxygen-dependent enzyme that regulates the degradation of HIF-1α. HIF is 
therefore stabilised and translocates to the nucleus to affect transcription of mainly metabolic/oxygen-
related target genes, as well as vascularisation genes such as VEGF (Rocha, 2007; Kaluz et al., 2008). 
Many glycolytic enzymes are HIF targets (Gordan et al., 2007). One such enzyme, Pyruvate 
Dehydrogenase Kinase 1 (PDK1, not PDPK1), phosphorylates pyruvate dehydrogenase to inhibit 
pyruvate entering the TCA cycle. As well as hypoxia, HIF-1 transcription can be activated downstream of 
PI3K/ERK growth factor signalling. HIF-1 overexpression in some cancers has been associated with 
increased patient mortality (Semenza, 2003). Both pyruvate and lactate can also stabilise HIF-1α 
(Hirschhaeuser et al., 2011). It is worth noting that in solid tumours, some cells will likely experience 
hypoxia due to disordered or lacking vasculature (Gatenby and Gillies, 2004). Therefore HIF will be 
activated in those cells. HIF-1α also inhibits c-Myc activity (Gordan et al., 2007). 
 
The choice of lactate production over the TCA cycle and oxidative phosphorylation initially seems 
counter-productive, as oxidative phosphorylation is more efficient for ATP production (it can generate 
30-36 net molecules of ATP per glucose compaired to glycolysis’ two, or four if the TCA cycle is 
included). Firstly, if enough glucose is available and can be taken up, the rate of glycolysis may allow 
sufficient ATP production anyway (Feron, 2009). Secondly, proliferating cells require more molecules 
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than just ATP, such as NADPH or acetyl-CoA, which are not generated by oxidative phosphorylation 
(Vander Heiden et al., 2009). Additionally, various theories exist suggesting possible reasons why 
increased lactate production and reduced oxidative phosphorylation may be beneficial for cancer cell 
growth. 
 
It is possible that this cancer phenotype helps avoid oxidative stress (Hsu and Sabatini, 2008). Oxidative 
phosphorylation particularly produces high quantities of ROS. Pyruvate is itself an antioxidant: it can be 
converted to acetate by combining with H2O2 (Sattler and Mueller-Klieser, 2009). Lactate may also 
scavenge ROS to a lesser extent (Hirschhaeuser et al., 2011). Although tumour suppressors such as p53 
also try to reduce ROS levels, severe oxidative stress can result in death or senescence (Lu and Finkel, 
2008). Inhibition of LDH A has been shown to cause oxidative stress and cell death in lymphoma cells (Le 
et al., 2010). 
 
Secretion of large quantities of lactate seems wasteful of carbon, but the acid environment hypothesis 
suggests that the lactate could acidify the microenvironment, to promotes tumour growth and invasion, 
at the expense of normal cells (Gatenby and Gillies, 2004; Hsu and Sabatini, 2008). Low pH generally 
induces cell death; proton transporters have been found upregulated in cancer cells, which would help 
protect against an acidic microenvironment. Low pH has been shown in vitro to contribute to invasion. It 
also seems that the secreted lactate can be taken up and used as an energy source for other, normoxic, 
cells in the tumour (Feron, 2009). A human cervical carcinoma cell line was found to preferentially use 
lactate over glucose (Sonveaux et al., 2008).  
 
1.10.2 TCA cycle 
 
The TCA cycle occurs in the mitochondrial matrix (Figure 1.3). Metabolites from several pathways feed 
into it, including pyruvate produced by glycolysis. One molecule of ATP can be produced per cycle, as 
well as three molecules of NADH (therefore it is two ATP and six NADH per glucose molecule in 
glycolysis). The NADH can then be oxidised in oxidative phosphorylation to produce ATP. 
 
Pyruvate is first converted to acetyl-coA by pyruvate dehydrogenase, in the mitochondria (Vander 
Heiden et al., 2009). Acetyl-coA is then used in the “first” step of the TCA cycle, converting oxaloacetate 
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to citrate. Some of the citrate produced can be transported out of the mitochondria into the cytoplasm, 
where acetyl-CoA can be resynthesised for fatty acid synthesis. In the TCA cycle, various enzymes are 
employed to regenerate the oxaloacetate via α-ketoglutarate, succinyl-CoA, and malate. Malate can be 
removed from the cycle by export to the cytoplasm and decarboxylated to pyruvate by malic enzyme. 
This pyruvate can also be used to generate lactate (DeBerardinis et al., 2008; Buchakjian and Kornbluth, 
2010). 
 
1.10.3 Oxidative phosphorylation 
 
Oxidative phosphorylation occurs in the inner mitochondrial membrane. Its purpose is to generate ATP 
by transferring electrons and protons to various acceptors, eventually reducing oxygen (O2) to water. 
The system consists of five transmembrane metalloprotein complexes, named Complex I-V, plus the 
electron carriers coenzyme Q and cytochrome c (Smeitink et al., 2001). As NADH brings electrons to the 
system, protons are moved into the intermembrane space so that a proton gradient (the proton motive 
force) is formed across the inner membrane. This pathway, from Complex I to Complex IV, is known as 
the electron transport chain. The protons flow down the gradient through Complex V, ATP synthase. 
This enables synthesis of ATP from ADP and Pi (Fernández-Vizarra et al., 2009). 
 
However, depending on the proton motive force, oxygen may not be reduced fully to water. Instead, 
superoxide (O2
•) leaks out from Complex I and Complex III, mainly into the mitochondrial matrix 
(Bartosz, 2009). Not much of the superoxide leaves the mitochondria, but is dismutated into H2O2 by 
MnSOD in the mitochondrial matrix (Murphy, 2009). H2O2 can then diffuse throughout the cell. This 
oxygen leakage is a major source of ROS in cells. ROS are also produced by the NOX family of NADPH 
oxidases, and others (Bedard and Krause, 2007). As well as inhibiting glycolysis in favour of the PPP, p53 
promotes oxidative phosphorylation by upregulating SCO2, involved in the electron transport chain 
(Maddocks and Vousden, 2011). 
 
1.10.4 Glutamine metabolism 
 
One of the pathways that also feeds into the TCA cycle is glutamine metabolism (Figure 1.3). This amino 
acid is the most abundant in human plasma (Shanware et al., 2011). Glutamine participates in several 
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metabolic pathways, including being required for nucleotide synthesis. Glutamine can be converted to 
glutamate (glutamic acid) and ammonia (NH4
+) by glutaminase enzymes in the mitochondria. The 
reverse reaction is catalysed by glutamine synthetase (GS). The ammonia produced is secreted so that it 
does not build up and damage the cell (DeBerardinis and Cheng, 2010). 
 
Tumour cells consume more glutamine than normal cells. In some cells more glutamine is consumed 
than needed for amino acid or nucleotide synthesis (nitrogen requiring); cancer cells also use glutamine 
for carbon to use in the TCA cycle (DeBerardinis et al., 2007; Meng et al., 2010). Unsurprisingly, 
glutamine metabolism is regulated in part by known oncogenes and tumour suppressors. p53 promotes 
glutamine usage as a metabolic source, as well as encouraging glutathione biosynthesis, by 
transcriptionally upregulating glutaminase 2 (Maddocks and Vousden, 2011). Myc also regulates 
glutamine metabolism, mainly by upregulating transcription and translation of glutaminase 1 (Dang, 
2010). 
 
Some of the glutamate pool enters the TCA cycle after conversion to α-ketoglutarate, essentially using 
glutamine to make NADH, and ATP via oxidative phosphorylation (Buchakjian and Kornbluth, 2010). 
Other glutamate molecules are used to make the antioxidant glutathione, which is a tripeptide of 
glutamate, cysteine and glycine. Much of the glutamine that enters the TCA cycle is in fact only partially 
oxidised, and leaves the mitochondria in the form of malate, eventually being decarboxylated into 
lactate. This process is known as glutaminolysis. Malate’s conversion to pyruvate also produces NADPH. 
This molecule is not only necessary for oxidative stress resistance/redox regulation, but is required for 
fatty acid and nucleotide synthesis (Deberardinis et al., 2008). 
 
Glutamine is also indirectly involved in mTOR regulation. The availability of certain amino acids, notably 
leucine, affects mTORC1 complex activation via Rag family small GTPases, although the mechanism is 
not well understood (Kim and Guan, 2011). Depletion of leucine results in inhibition of mTORC1. This 
essential amino acid is taken up into cells via the SLC7A5/SLC3A2 bidirectional transporter, which 
requires simultaneous export of glutamine (Nicklin et al., 2009). Glutamine availability may be a limiting 
factor for mTORC1 activity. 
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1.10.5 Choline metabolism 
 
Alterations in choline phospholipid metabolism are also a hallmark of cancer. Choline is required for the 
synthesis of phosphatidylcholine, an important membrane phospholipid. It is required for membrane 
stability, and cell proliferation/division (Ramírez de Molina et al., 2008). During phosphatidylcholine 
biosynthesis, choline is converted to phosphocholine (PC) by choline kinase (ChoK). Both choline and PC 
are found at higher levels in tumour cells than normal cells (Glunde et al., 2006). Increased PC is 
associated with increased malignancy. ChoK is upregulated in cancer, including breast cancer (Ramírez 
de Molina et al., 2002 b; Glunde et al., 2004). Inhibition of ChoK in breast cancer xenografts has been 
seen to inhibit growth, while ChoK overexpression induced proliferation of human mammary epithelial 
cells (Ramírez de Molina et al., 2004). 
 
Choline metabolism is heavily linked to growth factor signalling. PC, as well as other choline metabolic 
pathway intermediates and breakdown products, are considered second messengers required for 
growth factor receptor pathway activation. ChoK knockdown has been shown to inhibit Akt and 
Raf1/ERK activity (Chua et al., 2009; Yalcin et al., 2010). ChoK itself is also regulated downstream of PI3K 
(Ramírez de Molina et al., 2002 a; Al-Saffar et al., 2010). 
 
1.10.6 Metabolism and chemotherapy 
 
The glycolytic phenotype of cancer cells is thought to contribute to chemotherapeutic drug resistance. 
Knockdown of PDK isoforms has been shown to sensitise HeLa cells to cisplatin and paclitaxel, while 
upregulation of PDK3 had a protective effect in colon cancer cells (Lu et al., 2008, 2011). The glycolytic 
enzyme HK II, upregulated in cancer, has been shown to directly attenuate intrinsic pathway apoptosis, 
by binding to the VDAC ion channel in the outer mitochondrial membrane to prevent MOMP (Suh et al., 
2011). Knocking down of HK II sensitised colon cancer cells to 5-fluorouracil (5-FU) treatment (Peng et 
al., 2008), and HK II overexpression may be a poor prognostic factor in breast cancer (Palmieri et al., 
2009). Several cancer therapies have been designed against glycolysis, including inhibitors against HK II 
(Suh et al., 2011). The thymidine and purine synthetic pathways are also targeted by several drugs, 
inhibiting DNA synthesis (Vander Heiden, 2011). These drugs are collectively known as antimetabolites, 
and include 5-FU/capecitabine, gemcitabine, and methotrexate (Lind, 2011).  
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Figure 1.3 Glucose and glutamine in metabolism. Generation of macromolecules, NADPH and NADH 
from glucose and glutamine. Yellow H: NADPH; orange H: NADH. Red and purple arrows denote use of 
glutamate and glutamine respectively as a nitrogen donor. Diagram is not comprehensive, and not all 
steps in pathways are shown. G-6-P: glucose-6-phosphate; 3-PG: 3-phosphoglycerate; Ac-CoA: acetyl-
CoA; OAA: oxaloacetate; α-KG: α-ketoglutarate; PPP: pentose phosphate pathway. Standard amino acid 
abbreviations are used. 
56 
 
1.11 FORKHEAD TRANSCRIPTION FACTORS 
 
The first forkhead protein to be characterised was fork head in 1989, named after the mutant 
Drosophila’s “forked” head structure (Jürgens and Weigel, 1988; Weigel et al., 1989). Since then, more 
than 150 forkhead transcription factors have been characterised or identified, including more than 40 in 
humans (Wijchers et al., 2006; Myatt and Lam, 2007). All share a conserved forkhead domain/forkhead 
box containing a “winged helix” type structure, making forkheads a subfamily of helix-turn-helix proteins 
(Gajiwala and Burley, 2000). Initial work on this family provided a diverse set of names, but the number 
of forkhead proteins being discovered necessitated a unified nomenclature to avoid confusion (Kaestner 
et al., 2000). The proteins became known as FOXs (forkhead box). In vertebrates, FOX proteins have 
been classified alphabetically into 19 subgroups, FOXA to FOXP. The agreed nomenclature also 
distinguishes between different systems: for all forkheads, capitalising all letters (such as FOXO1) is 
reserved for human proteins. Mouse proteins have a capital F only (eg Foxo1), while other chordates are 
named with capitals for the group and initial letter (eg FoxO1).  
 
1.11.1 FOXO transcription factors 
 
The FOXO subfamily has always been associated with cancer, from the discovery of what is now FOXO1. 
These proteins are considered tumour suppressors, but have been found to regulate a huge range of 
cellular activities. In mammals, the FOXO family contains four members: FOXO1, FOXO3, FOXO4, FOXO6. 
FOXO1 was discovered as part of a fusion protein resulting from chromosomal translocation in alveolar 
rhabdomyosarcoma (Galili et al., 1993). The DNA binding domain of the transcription factor PAX3 was 
found to be fused to a truncated forkhead family protein. This protein was named fork head in 
rhabdomyosarcoma, FKHR. Around the same time, another laboratory also investigated this 
chromosomal translocation; they named the fused fork head gene ALV (Shapiro et al., 1993), but the 
name didn’t catch on. Fusion proteins between PAX7 and FOXO1 have also been found in that disease 
(Barr, 2001). 
 
The next human FOXO was again identified through investigation of a chromosomal translocation, this 
time from acute leukaemia patients. The AFX1 gene was found to be fused to MLL (Corral et al., 1993), 
now known to encode a histone methyltransferase. AFX was characterised and identified as a novel 
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forkhead protein, homologous to FOXO1 (Parry et al., 1994; Borkhardt et al., 1997). AFX was eventually 
renamed as FOXO4. A third closely related protein was also found as part of an MLL fusion in acute 
leukaemia (Hillion et al., 1997). The gene was named AF6q21 after its chromosomal location. At one 
point this protein became known as FOXO2, but it is currently understood to be the same as FOXO3. 
FOXO3 itself was first characterised in a screen to find novel FKHR and AFX subfamily members, and was 
named FKHRL1 (FKHR-like 1) (Anderson et al., 1998). This research also uncovered a pseudogene for 
both FKHR and FKHRL1, now designated FOXO1b and FOXO3b respectively. The existence of this 
pseudogene has led to FOXO3 being widely and more commonly referred to as FOXO3a, although 
FOXO3 is the official gene symbol. 
 
More recently, a FOXO family member was discovered in fish, and called FOXO5 (Rudd et al., 2003). 
Zebrafish also express homologues of FOXO1 and FOXO3a. This protein has since been decided to be too 
close a homologue to FOXO3a, and has been renamed to FOXO3b (Berry et al., 2008; Peng et al., 2010). 
Finally, FOXO6 was discovered using a screen to find novel Foxo members in mouse brain (Jacobs et al., 
2003). Though the original paper described it as also being expressed in thymus and heart, more 
recently its mRNA was shown to be expressed in other C57/Bl6 mouse tissues, particularly lung and 
muscle (Kim et al., 2011 b). Despite this, very little work has been published on FoxO6. 
 
Mammalian FoxOs have been found in all organs tested throughout the body (Furuyama et al., 2000), 
although significant differential expression is seen between tissue type and developmental stage 
(Maiese et al., 2008). The phenotypes of Foxo knockout mice are also dramatically different from each 
other. Knockout of Foxo1 is embryonic lethal due to incomplete and disordered vascular development. 
Foxo3a-/- mice are viable, albeit with defects in female fertility and the immune system, while Foxo4-null 
mice have no discernable phenotype (Arden, 2008). The three main human FOXOs share about 40% 
identity overall, but over 80% within the forkhead box (Kramer et al., 2003; Pohl et al., 2004). All bind 
the consensus sequence (T/G)GTAAACA (Wilson and Lam, 2011). 
 
1.11.2 Regulation of FOXO  
 
FOXO activity is heavily regulated by post-translational modifications, which affect FOXO stability, 
subcellular localisation, and DNA binding activity. Perhaps the most important FOXO-regulating protein 
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is Akt, although FOXO proteins are also subject to phosphorylation by many other proteins, as well as 
acetylation, methylation, ubiquitination, and glycosylation (Figure 1.4). 
 
1.11.2.1 Akt 
 
Active Akt phosphorylates FOXO at three conserved sites (Tzivion et al., 2011). These are Thr32, Ser253 
and Ser315 in human FOXO3a (Brunet et al., 1999; Kops et al., 1999). This phosphorylation is inhibitory 
and results in exclusion of FOXO from the nucleus (Brownawell et al., 2001), eventually followed by 
degradation. The close Akt relative SGK can also phosphorylate the same sites (Brunet et al., 2001), 
although with different affinities. 
 
Phosphorylation of both Ser253 and Thr32 does not affect FOXO DNA binding, despite that Ser253 is 
located within the DBD and may contact DNA (Tsai et al., 2007; Brent et al., 2008). It does however 
promote binding of 14-3-3 family members (Brunet et al., 1999; Obsil et al., 2003). The 14-3-3 proteins 
are a family of conserved ~30 kDa phospho-serine/threonine binding proteins, with diverse roles in the 
cell (Aitken, 2006). There are seven mammalian family members. Overexpression of the 14-3-3ζ isoform 
has been found to be a poor prognostic factor in cancer, including breast cancer (Neal and Yu, 2010). 
Some 14-3-3 interactions result in activation of the target protein, but in apoptosis 14-3-3 is known 
more for sequestering pro-apoptotic proteins including Bax, Bad, Bim and FOXO (Morrison, 2009). 
Binding of phosphorylated FOXO by 14-3-3 reduces FOXO’s DNA binding ability, by masking the interface 
rather than by causing conformational change (Obsil et al., 2003; Silhan et al., 2009). However, 14-3-3’s 
role here is not clear cut: 14-3-3 binding may stabilize FOXO as well as inhibit. In knockout 14-3-3δ B-
cells, degradation of FOXO protein was increased, but FOXO target mRNAs were upregulated overall (Su 
et al., 2011). It is thought that 14-3-3 promotes nuclear exclusion by interfering with FOXO’s NLS (Zhao 
et al., 2004; Obsilova et al., 2005). 
 
Although it is not required for 14-3-3 binding, the final Akt-modified residue, Ser315, is thought to be 
important for the predominantly cytoplasmic localization of phosphorylated FOXO (van der Heide et al., 
2006). FOXO6 does not contain this final site, and is almost constitutively nuclear (Jacobs et al., 2003), 
although not constitutively active; it responds to Akt via the two existing sites, Thr26 and Ser184 (van 
der Heide et al., 2005). 
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The phosphatase that removes Akt-mediated phosphorylation is thought to be PP2A (Yan et al., 2008). 
Further results published from another laboratory suggested, based on in vitro work, that 14-3-3:FOXO 
interaction may block PP2A from dephosphorylating FOXO (Singh et al., 2010). As well as promoting 14-
3-3 association, Akt’s phosphorylation of FOXO at Ser253 allows Skp2 to bind (Huang et al., 2005). This 
F-box-containing protein is part of the E3 ubiquitin ligase SCFSkp2 complex. Skp2 then polyubiquitinates 
FOXO, resulting in its degradation via the proteasome. Akt may further contribute to FOXO degradation 
by causing upregulation of Skp2 mRNA and increasing its stability (Huang and Tindall, 2011). Likely 
partially because of its role in the degradation of FOXO, overexpression of Skp2 is a poor prognostic 
factor in breast cancer (Davidovich et al., 2008). 
. 
FOXO itself also regulates Akt. The PIK3CA gene that encodes p110 , the catalytic subunit for class 1A 
PI3K (Chapter 1.3), was found to be a FOXO target in K562 cells (Hui et al., 2008 b). FOXO also 
transcriptionally downregulated an Akt inhibitor, tribble 3, in hepatocytes (Matsumoto et al., 2006). 
 
1.11.2.2 MAPKs 
 
All three MAPKs are thought to directly phosphorylate FOXO. ERK binds and directly phosphorylates 
FOXO3a in vivo at at least Ser294, Ser344 and Ser425 (Asada et al., 2007; Yang et al., 2008 b). 
Phosphorylation at these sites is thought to promote recruitment of the E3 ubiquitin ligase MDM2, 
resulting in FOXO’s polyubiquitination and degradation (Yang et al., 2008 a; Brenkman et al., 2008). 
However, MDM2 binding to FOXO may require it to be phosphorylated by Akt as well as ERK (Fu et al., 
2009). Conversely, JNK activity promotes FOXO stabilisation and activation (Kawamori et al., 2006; Shen 
et al., 2010). JNK is thought to phosphorylate all of the FOXOs, but the recognised sites are not known 
(Greer and Brunet, 2005). It phosphorylates FOXO4 at Thr447 and Thr451, but these sites are not 
conserved (Essers et al., 2004). JNK also contributes by inhibiting the substrate 14-3-3, attenuating FOXO 
sequestration (Tsuruta et al., 2004; Sunayama et al., 2005). FOXO3a is phosphorylated by p38 at Ser7, a 
modification associated with FOXO nuclear translocation (Ho et al., 2012). p38 has also been linked to in 
vitro phosphorylation of mouse Foxo1 at several other sites (Asada et al., 2007). On the other hand, 
studies in other cell lines have reported increased FOXO nuclear localisation in response to p38 
inhibition rather than activity (Chiacchiera et al., 2009; Clavel et al., 2010). 
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1.11.2.3 Other modifications 
 
As well as by the kinases mentioned, FOXO is also thought to be phosphorylated by MST1, DYRK1A and 
CK1, although the results of these modifications are not well understood (Rena et al., 2002; Lehtinen et 
al., 2006). 
 
FOXO is acetylated by the histone acetyltransferases CBP and p300 (Nasrin et al., 2000; Mahmud et al., 
2002). Acetylation of FOXO increases its stability by reducing poly-ubiquitination by SCFSkp2 (it requires 
the same lysine residues) (Wang et al., 2011 a). CBP/p300 could also be recruited by FOXO to act as 
coregulators, affecting transcription by remodelling chromatin (Daitoku et al., 2004; Perrot and Rechler, 
2005). However, acetylation of FOXO itself by these proteins is inhibitory (Dansen et al., 2009; Senf et 
al., 2011), probably because acetylated FOXO is associated with increased phosphorylation at Ser253 
(Matsuzaki et al., 2005; Jing et al., 2007; Qiang et al., 2010). FOXO4 has been found to form a disulphide 
bridge with CBP/p300 (Dansen et al., 2009). This redox-sensitive bridge is required for CBP/p300:FOXO4 
binding and CBP/p300-mediated acetylation of FOXO4. As the primary cysteine involved in this 
interaction is conserved, it is likely that this also occurs between CBP/p300 and FOXO1 or FOXO3a.  
 
The sirtuins SIRT1, SIRT2, and possibly SIRT3 are thought to act as deacetylases for FOXO (van der Horst 
et al., 2004; Daitoku et al., 2004; Wang et al., 2007), as well as possibly other histone deacetylases 
(HDACs) (Zhao et al., 2011). Possibly contributing to its deacetylation of FOXO, SIRT2 may also 
deacetylate (inactivate) CBP (Black et al., 2009). SIRT1 may act as a HDAC at the FOXO3a promoter in 
prostate cancer cells (Kikuno et al., 2008). Overall, deacetylation of FOXO protein is thought to increase 
DNA binding and transcription, at the expense of its stability (Wang et al., 2011 a). Sirtuins are NAD+ 
dependent, and are therefore redox sensitive. They are regulated by the NAD+/NADH balance: more of 
the reduced form is associated with SIRT inhibition (Circu and Aw, 2010). SIRT activity is increased by 
oxidative stress (Ma, 2010). This is thought to alter FOXO’s target specificity, moving away from 
apoptotic genes in favour of stress resistance, cell cycle arrest and survival. In Rat1 fibroblasts stably 
expressing inducible FOXO3a(A3), overexpression of SIRT1 in conjunction with FOXO3a(A3) activation 
was associated with increased G1 arrest, but lower apoptosis in response to etoposide (Brunet et al., 
2004). SIRTs also deacetylate p53 (Zhang and Kraus, 2010).  
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FOXO is also methylated by PRMT1 (protein arginine methyltransferase 1), which inhibits Akt 
phosphorylation (Yamagata et al., 2008) by blocking the Ser253 recognition sequence. Lastly, two 
laboratories have reported that FOXO1 is glycosylated. The addition of O-linked GlcNAC was found to 
activate FOXO1/FoxO1 transcriptional activity, but again, perhaps favouring one subset of target genes 
over another (Housley et al., 2009; Kuo et al., 2008). 
 
1.11.2.4 microRNA 
 
FOXO is regulated by microRNA (miRNA) both directly and indirectly. miRNA are short (around 22 
nucleotides long) non-coding single-stranded RNAs that bind to target mRNAs to inhibit their translation 
or promote degradation (Inui et al., 2010). Several miRNAs have been reported to target FOXO mRNA 
directly (Myatt et al., 2010; Kong et al., 2010). Other FOXO regulating proteins are also thought to be 
repressed by miRNAs, for example, SIRT1 is targeted by miR-217 (Menghini et al., 2009). It is possible 
that FOXO contributes to miRNA transcription, as it has been found to bind to the promoter region of 
the miR-106b-25 cluster in neural stem cells (Brett et al., 2011). 
  
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4 Post-translational modifications of FOXO3a. Confirmed post-translational modifications of 
the FOXO3a isoform only. JNK is also believed to phosphorylate FOXO3a but the sites are not known. 
DBD: DNA binding domain; NLS: nuclear localisation signal; NES: nuclear export sequence; TAD: 
transactivation domain (Brent et al., 2008; Wang et al., 2008; Obsil and Obsilova, 2008). Pink P: 
phosphorylation; blue Ac: acetylation; green Me: methylation. 
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1.11.3 Cellular roles of FOXO 
 
FOXO has been linked to many different aspects of cellular activity (Figure 1.5). 
 
1.11.3.1 Cell cycle arrest, apoptosis and DNA repair 
 
The DNA repair protein ATM physically interacts with FOXO, promoting ATM activity (Zou et al., 2008). 
FOXO also contains consensus phosphorylation motifs for ATM and ATR (Matsuoka et al., 2007). The 
Drosophila orthologue of ATR, mei-41, has been linked to dFOXO activity and stability (Mattila et al., 
2008). The NHEJ protein Ku70 has also been found to bind and inhibit FOXO in the absence of oxidative 
stress (Brenkman et al., 2010). 
 
In cell cycle control, both CDK1 and CDK2 are able to phosphorylate FOXO1 at Ser249 (Huang et al., 
2006; Liu et al., 2008 a; Yuan et al., 2008). Although FOXO3a and FOXO4 also contain putative CDK sites, 
this modification is thought to be specific to FOXO1 (Huang et al., 2006). The outcome of this 
phosphorylation may depend on cell type as CDK1 phosphorylation has been reported to both inhibit 
and activate FOXO1. FOXO promotes cell cycle arrest by transcriptionally downregulating the cyclins B1, 
B2, D1 and D2 (Schmidt et al., 2002; Takano et al., 2007), as well as upregulating the atypical cyclin G2, 
which acts as a CKI (Martínez-gac et al., 2004). Other CKIs, including p27, p21Cip1, p15INK4b and p19INK4a, 
are also FOXO targets of upregulation (Dijkers et al., 2000; Seoane et al., 2004; Katayama et al., 2008). 
GADD45α expression is also upregulated by FOXO (Furukawa-Hibi et al., 2002; Tran et al., 2002). This 
protein promotes cell cycle arrest, participates in the BER pathway of DNA repair, and activates p38 and 
JNK (Liebermann and Hoffman, 2008). FOXO can induce apoptosis by upregulating the expression of pro-
apoptotic genes such as Bim, bNIP3, TRAIL, FasL, and PUMA (Brunet et al., 1999; Gilley et al., 2003; Real 
et al., 2005; You et al., 2006 a; Modur et al., 2002). 
 
Extensive crosstalk exists between FOXO and p53 activities. The two transcription factors are activated 
by similar stressors (oxidative stress, DNA damage) and both regulate target genes involved in pathways 
such as apoptosis or cell cycle arrest. For example, p21Cip1 and PUMA are transcriptional targets of both 
proteins (Yu and Zhang, 2005). However, p53 is thought to inhibit FOXO. p53 activation has been shown 
to result in FOXO inhibition and degradation via both upregulation of MDM2 expression (a direct p53 
target gene) and activation of the ERK1/2 signalling pathway (You et al., 2004; Singh et al., 2007; Yang et 
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al., 2008 b; Fu et al., 2009). However, a recent publication reported p53-mediated upregulation of 
FOXO3a mRNA and protein (Renault et al., 2011). FOXO and p53 are known to also physically interact. 
This is thought to promote p53’s translocation to the cytoplasm where it interacts with Bax to mediate 
the intrinsic apoptotic pathway (You et al., 2006 b), but may also reduce FOXO transcription factor 
activity (Miyaguchi et al., 2009). 
 
1.11.3.2 Chemotherapy 
 
In breast cancer cells, the EGFR TKI gefitinib mediates growth arrest by upregulating FOXO3a activity. 
FOXO3a then represses transcription of the pro-proliferation forkhead protein FOXM1 (McGovern et al., 
2009). FOXM1 is important in cell cycle progression and mitotic spindle integrity (Myatt and Lam, 2007), 
and is known to compete with FOXO3a for promoter binding sites (Karadedou et al., 2011). Non-
targeted chemotherapeutic drugs also induce FOXO activity (Wilson et al., 2011), including paclitaxel 
(Sunters et al., 2006), doxorubicin (Lüpertz et al., 2008), and cisplatin (Fernández de Mattos et al., 2008). 
In bladder cancer, FOXO3a knockdown increased resistance to cisplatin (Shiota et al., 2010). 
 
1.11.3.3 Oxidative stress 
 
FOXO upregulates the ROS scavengers MnSOD and catalase, as well as PINK1 (Kops et al., 2002; Nemoto 
and Finkel, 2002; Mei et al., 2009). However, the thioredoxin inhibiting protein Txnip, which increases 
intracellular ROS levels, is also a FOXO target (Li et al., 2009). FOXO activity may also be required for 
ROS-induced cell death in some situations (Nakamura and Sakamoto, 2008). As well as upregulating 
scavengers, FOXO reduces ROS production by inhibiting mitochondrial activity: it inhibits Myc activity, 
which normally upregulates expression of mitochondrial genes (Jensen et al., 2011; Ferber et al., 2011). 
This inhibition is mediated by upregulation of Myc inhibitors such as Mxi1 and decreased Myc stability 
(Delpuech et al., 2007). FOXO3a and Myc may also compete for promoter binding, where Myc inhibits 
FOXO3a-dependent transcription of genes such as p27 and PUMA (Chandramohan et al., 2008; Amente 
et al., 2011). In oxidative stress signalling, the MAPKs are particularly important for FOXO regulation. 
Activation of NFκB signalling also inhibits FOXO, as IKKβ of the IKK complex phosphorylates it and 
promotes its degradation (Hu et al., 2004; Chapuis et al., 2010). Active FOXO may contribute to 
activation of NFκB signalling by transcriptionally upregulating NEMO (Lee et al., 2008 b). 
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1.11.3.4 Autophagy 
 
Autophagy is upregulated by FOXO. Several autophagic proteins, including ATG8 and Beclin1, are FOXO 
target genes (Sengupta et al., 2009; Ferdous et al., 2010; van der Vos et al., 2011). The autophagy 
regulator AMPK directly phosphorylates FOXO, at possibly Ser413 and Ser588 in FOXO3a (Greer et al., 
2007). This is thought to activate FOXO (Sanchez et al., 2011). AMPK may also regulate FOXO mRNA in a 
cell type-dependent manner (Nystrom and Lang, 2008; Williamson et al., 2009). Conversely, FOXO can 
regulate AMPK (and therefore inhibit mTOR) by transcriptionally upregulating the AMPK activator 
sestrin 3 (Nogueira et al., 2008; Lee et al., 2010 a). 
 
Interestingly, it has recently been reported that expression of FOXO1 induced autophagy by a 
transcription-independent mechanism (Zhao et al., 2010). This autophagy required acetylation by SIRT2, 
allowing FOXO to bind Atg7 in the cytosol, and was associated with increased cell death. 
 
1.11.3.5 Metabolism 
 
FOXO is strongly involved in glucose metabolism, particularly through its inhibition by insulin signalling. 
Insulin is a signalling molecule that is used for glucose homeostasis in the blood; it binds to the insulin 
receptor on the surface of liver, fat or muscle cells, and triggers PI3K/Akt and Ras signalling (Taniguchi et 
al., 2006). This results in increased glucose uptake and conversion to glycogen, as well as broader 
metabolic effects such as increased lipid synthesis and inhibition of autophagy (via mTORC1 activation). 
Insulin-like growth factor signalling also activates similar pathways to insulin, but promotes cell survival 
and proliferation (Chitnis et al., 2008). 
 
Inhibition of FOXO in liver cells during insulin signalling serves to reduce activity of the glycogenolysis 
and gluconeogenesis pathways, which increase intracellular glucose levels. The metabolic enzymes 
glucose-6-phosphatase and phosphoenolpyruvate carboxykinase-1 are transcriptionally upregulated by 
FOXO (Onuma et al., 2006; Salih and Brunet, 2008). The glucose transporter GLUT4 is also a FOXO target, 
although it is apparently differentially regulated as FOXO has been linked to both up- and 
downregulation of its transcription (Armoni et al., 2002; Ni et al., 2007; Armoni et al., 2007). Insulin is 
produced by β-cells in the islets of Langerhans in the pancreas, and FOXO (particularly FoxO1) has been 
linked to proper function and development of these cells (Kitamura and Ido Kitamura, 2007). In a 
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negative feedback loop, FOXO regulates transcription of upstream proteins in these pathways, including 
IRS-2 (Tsunekawa et al., 2011) and the insulin receptor itself (Puig and Tjian, 2005). Conversely, FOXO 
may also regulate expression of IGFBP-1 (IGF binding protein 1) in the liver, reducing IGF signalling 
(Gross et al., 2008). 
 
In liver, Foxo1 was found to increase blood triglyceride levels by promoting production of VLDL (very low 
density lipoprotein) via transcriptional upregulation of a protein involved in its synthesis, MTP 
(Kamagate et al., 2012). Mice with triple Foxo knockout in the liver were also found to develop hepatic 
steatosis (fat buildup) when fed a high fat diet (Tao et al., 2011). This was linked to FOXO-dependent 
transcriptional upregulation of nicotinamide phosphoribosyltransferase (NAMPT; aka visfatin, PBEF), an 
enzyme used in the NAD+ salvage synthetic pathway. This reveals a regulatory loop between FOXO and 
SIRTs (Dahl et al., 2010; Wang et al., 2011 b). NAMPT overexpression has been found in various cancer 
cell lines and tumour samples (Shackelford et al., 2010). It has been linked to upregulation of VEGF and 
MMP expression, as well as regulating SIRT and PARP activity via NAD+ (Travelli et al., 2011). NAMPT 
activity has also been shown to promote insulin signalling and inflammation (Zhang et al., 2011 b). It is 
the target of novel cancer drugs already in clinical trial (Holen et al., 2008). Inhibition or knockdown of 
NAMPT has been shown to induce cell death and sensitise cells to chemotherapeutic drugs (Hasmann 
and Schemainda, 2003; Billington et al., 2008). 
 
1.11.3.6 Oncogenic activity 
 
Despite being broadly considered a tumour suppressor, not all FOXO activities are desirable, as 
demonstrated by its upregulation of NAMPT. FOXO has also been shown to transcriptionally upregulate 
MDR1 (Han et al., 2008; Hui et al., 2008 a), and its ability to upregulate PI3K signalling can contribute to 
drug resistance (Hui et al., 2008 b). Perhaps for these reasons, one study actually found nuclear FOXO3a 
to be a poor prognostic factor in breast cancer samples, and found that it was associated with increased 
Akt phosphorylation (Chen et al., 2010). FOXO activity has been linked to increased metastatic potential 
by upregulating the matrix metalloproteases MMP1, MMP3, MMP9 and MMP13, which promote 
invasion (Lee et al., 2008 a; Storz et al., 2009; Feng et al., 2011). 
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  Figure 1.5 FOXO involvement in cellular activities. Purple arrows show FOXO regulation, black arrows 
show links between other conditions or activities. Zigzag-headed arrows denote a non-binary (up- or 
downregulation) relationship. Diagram is not comprehensive. 
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1.12 THESIS AIMS 
 
Chemotherapy is used extensively in breast cancer treatment. However, the development of drug 
resistance remains the major cause of treatment failure. The mechanisms through which cancer cells 
develop resistance are not fully understood. The FOXO transcription factors, particularly FOXO3a, are 
thought to play important roles in drug sensitivity and resistance. To investigate the roles of FOXO3a in 
breast cancer drug resistance, I studied a number of potential FOXO target genes that have a possible 
function in resistance. 
 
Understanding of the mechanisms of MAPK regulation is important to understand their activity in 
different circumstances, and whether their activation will lead to increased survival or cell death, as well 
as resistance to chemotherapeutic drugs. Two MKPs, DUSP5 and DUSP6, have been differentially 
regulated by FOXO3a activity in array data (Ferber et al., 2011). I aim to characterise this potential 
regulation, and investigate whether these MKPs contribute to breast cancer drug resistance. 
 
I would also like to look into the possibility that FOXO3a regulates GS expression in breast cancer, based 
on results from a different array (van der Vos, 2010). More broadly, I intend to investigate metabolic 
changes in drug resistance. Published work has suggested that cellular metabolism is fundamental to 
cancer growth and drug response. I hope that my results will enable biomarker development, or enable 
resensitisation of drug resistant cells based on their metabolism. 
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2.1 CELL CULTURE 
 
The human breast carcinoma cell lines MCF7 (hereafter referred to as MCF7 wt) and BT474, and human 
embryonic kidney HEK293 cells originated from the American Type Culture Collection (Teddington, UK). 
The MCF7 doxR (hereafter referred to as doxR) cells were previously generated in the laboratory by 
growing MCF7 wt in medium supplemented with increasing concentrations of doxorubicin (Imperial 
College Healthcare, UK), up to 0.01 mg/ml doxorubicin. The DL23 cells were a kind gift from PJ Coffer, 
University Medical Centre, Utrecht. These cells are derived from the human colon carcinoma cell line 
DLD-1 and were previously described (Kops et al., 2002). 
 
All cell lines were kept in culture for less than six months, and were maintained in Dulbecco’s Modified 
Eagle medium (DMEM) (Sigma Aldrich, Gillingham, UK) supplemented with 10% foetal calf serum (FCS) 
(First Link (UK) Ltd, Birmingham, UK), 4 mM glutamine (Sigma Aldrich) and 100 U/ml 
penicillin/streptomycin (Sigma Aldrich) in a humidified incubator at 37°C in an atmosphere of 10% CO2. 
The doxR cells were further supplemented with 0.01 mg/ml doxorubicin. 
 
2.1.1 Cell maintenance 
 
Cells were grown and split at ~80% confluency, generally twice a week. Medium was aspirated and cells 
washed once with warm PBS (Oxoid Ltd, Basingstoke, UK). Cells were removed using 1x trypsin in EDTA 
(both Sigma Aldrich) at 37°. After detaching, cells were centrifuged at 1000 rpm for 2 min to remove 
trypsin, then resuspended in the appropriate medium and seeded into a new flask or dish. 
 
For long term cell maintenance, low passage cells were frozen. Cells were trypsinsed and centrifuged as 
above, then resuspended in 10% dimethyl sulphoxide (DMSO) (Sigma Aldrich) in FCS. Aliquots of 1 ml 
were transferred to cryovials then placed into a Mr Frosty (VWR International, Lutterworth, UK) at -80° 
overnight. Frozen vials were then transferred for long term storage in liquid nitrogen. 
 
To defrost cells, cryovials were placed into a 37° waterbath or incubator until melted. Cell suspension 
was mixed with fresh, fully supplemented medium, then centrifuged at 1000 rpm for 2 min. Supernatant 
was discarded and the cells were resuspended in fresh DMEM and seeded into a flask. 
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2.1.2 Generation of pooled stable cell lines 
 
MCF7 wt cells were grown in a 75 cm2 flask to a confluency of 70-80%. They were then transfected with 
5 µg plasmid DNA (Chapter 2.3.1). 48 h post-transfection, cells were selected with 1 mg/ml G418 aka 
Geneticin (Invitrogen, Paisley, UK). Cells were split when necessary, and maintained in medium 
containing 1 mg/ml G418. Medium was changed every other day. Expression of FLAG-GS was confirmed 
using Western blotting after three weeks of selection (Chapter 2.4.2). Cells were maintained in 0.5 
mg/ml G418, which was not included in the media when seeding for an experiment. 
 
2.1.3 Treatment of cells 
 
Doxorubicin and epirubicin were both obtained from Imperial College Healthcare, UK. They were both 
stored at 4 °C and aliquotted via syringe at time of use. Hydrogen peroxide (H2O2), ammonium hydroxide 
(NH4OH) and glutamate were obtained from Sigma Aldrich. H2O2 was stored at 4 °C. NH4OH and 
glutamate were dissolved in water and adjusted to pH 7. NH4OH solutions were stored at 4° and 
glutamate solutions were stored at -20 °C. LY294002, triciribine and 4-hydroxytamoxifen (OHT) were 
obtained from Calbiochem (Merck, Hoddesdon, UK). LY294002 and triciribine were dissolved in DMSO 
and stored at -20 °C. OHT was dissolved in ethanol and stored at -20 °C. 
 
2.1.4 Seeding for experiments 
 
Cells for experiments were trypsinised as for splitting. Once resuspended, the cells were counted using a 
haemocytometer to ensure reliable cell confluencies. Cells were treated, transfected or harvested 24 h 
after seeding. 
 
2.2 PLASMIDS AND CLONING 
 
The pcDNA3-FLAG-FOXO3a (hereafter referred to as FOXO3a wt), pLPC-FOXO3a(A3) (hereafter referred 
to as FOXO3a(A3)), pcDNA3-MKP3 (hereafter referred to as DUSP6), and EGFP-LC3 plasmids were 
previously generated in the laboratory. The pGL3-6xDBE and pXP2-GS reporter constructs were kind 
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gifts from PJ Coffer, and have been previously described (Gaunitz et al., 2001; Zanella et al., 2009). The 
mutated GS promoter constructs were generated by K van der Vos (van der Vos, 2010). The pGL3-p27 
reporter was previously generated in the laboratory. 
 
2.2.1 Plasmid generation 
2.2.1.1 FLAG-GS 
 
The p3xFLAG-CMV-14-GS plasmid (referred to as FLAG-GS) was generated using cDNA extracted from 
MCF7 wt cells. PCR (polymerase chain reaction) was performed using DyNAzyme EXT DNA polymerase 
(Thermo Scientific, UK) with primers 5’-GAATTCATGACCACCTCAGCAAG-3’ and 5’-
GGCTCCATTTTTGTACTGGAAGGG-3’. This polymerase is a mix of proofreading and Taq polymerases. 
These primers excluded the stop codon for subcloning into the p3xFLAG-CMV-14 backbone vector (has a 
C-terminal 3xFLAG tag sequence), and contained restriction sites for EcoRI and BamHI respectively (all 
restriction enzymes obtained from NEB, Hitchin, UK). These restriction enzymes are 0-cutters within the 
GS cDNA sequence. 
 
The PCR mixture was run on a 1% agarose gel made with 1x TAE buffer (40 mM Tris base, 20 mM acetic 
acid, 1 mM EDTA) and ethidium bromide (0.2 µg/ml) for visualisation. 1 kb DNA ladder was used 
(Promega, Southampton, UK). The PCR product was visualized using a UV transilluminator. The band was 
the expected size and was excised and gel purified using the Wizard SV DNA cleanup kit (Promega). The 
clean PCR product was then ligated into pCR-2.1-TOPO following manufacturer’s instructions 
(Invitrogen). TOP10 competent cells were transformed with 2 µl of TOPO ligation mixture following 
manufacturer’s instructions (Invitrogen). The cells were plated onto agar plates containing 50 µg/ml 
ampicillin and left overnight at 37°C. 
 
Once colonies were visible, 6 colonies were picked and placed into 5 ml liquid LB medium containing 50 
µg/ml ampicillin (ampicillin LB), in 15 ml Falcon tubes. These were placed in a shaking incubator 
overnight at 37°C. After 16 h growth, 1 ml of each culture was transferred to an eppendorf tube and 
centrifuged at 6000 rpm for 3 min. Plasmids were extracted using the QIAprep Spin Miniprep kit 
(Qiagen, Crawley, UK). DNA concentration of each purified plasmid was determined using a NanoDrop 
machine (Thermo Scientific, Epsom, UK). To confirm successful ligation, these clones were double-
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digested using EcoRI and BamHI for 2 h at 37°C. Digestion mixtures were separated using 
electrophoresis as before. Clones showing the expected digestion pattern of bands on visualisation were 
sequenced to ensure no mutations had been incorporated during PCR. 
 
One correct, positive clone was chosen for subcloning. 1 ml of the leftover miniprep culture for this 
clone was transferred to a flask containing 200 ml ampicillin LB. This was placed overnight in a shaking 
incubator at 37°C. After 16 h growth, the culture was removed and centrifuged at 6000 rpm for 15 min 
at 4°C. Plasmids were extracted by maxiprep using the HiSpeed Plasmid Maxi kit (Qiagen). After elution 
in 1 ml water, DNA concentration was determined as before. 5 µg of this TOPO plasmid was digested 
using EcoRI and BamHI as before. 3 µg of p3xFLAG-CMV-14 vector was similarly digested. Both were 
then separated using electrophoresis and visualized. The digested insert fragment and vector/backbone 
fragment were excised and gel purified as before. DNA concentration was determined as before. 
 
The insert and vector were ligated using a 3:1 insert:vector ug ratio, with T4 DNA ligase. The reaction 
mixture was left at room temperature for 1 h. 2 µl of reaction mix was transformed into TOP10 cells as 
before. After outgrowing in SOC medium for 1 h, the cells were transferred to warmed ampicillin agar 
dishes and placed at 37°C overnight. Once colonies were visible, 6 were picked and cultures grown for 
miniprep as before. The purified plasmids were digested using EcoRI and BamHI and visualised after 
electrophoresis as before to confirm correct ligation. Clones with the expected digestion pattern were 
sequenced to ensure no mutations were incorporated. 
 
One correct FLAG-GS construct was chosen for future work. All DNA was stored at -20°C. 1 ml of leftover 
miniprep culture was grown for maxiprep as before to provide stock plasmid for experiments. A further 
500 µl of miniprep culture was mixed with 500 µl sterile 50% glycerol and stored at -80°C. 
 
2.2.1.2 FLAG-DUSP5 
 
I initially attempted to clone DUSP5 from MCF7 wt cDNA as for FLAG-GS. The primers used were 5’-
GAATTCATGAAGGTCACGTCGCTCG-3’ and 5’-AGATCTTTGCAGGATGTGGCCGTTGC-3’. These contain 
restriction sites for EcoRI and BglII respectively, and as before do not include the final stop codon. 
However, I was unable to obtain a PCR product using the DyNAzyme EXT polymerase, despite 
optimisation. I was able to obtain a product using Taq polymerase but using sequencing the clones were 
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found to have several mutations. I thought that the MCF7 wt cDNA may have a low level of DUSP5 
mRNA. I therefore bought a pre-made DUSP5 cDNA clone from Open Biosystems (Thermo Scientific). 
The DNA was provided inside competent cells, so 10 µl was plated onto a warmed agar plate containing 
25 µg/ml chloramphenicol. The plate was left overnight at 37°C. The next day, 6 colonies were picked 
and grown for miniprep as before. After extraction, the plasmids were sequenced to confirm the identity 
and fidelity of the cDNA. 
 
The cDNA was provided in the pOTB7 vector, unsuitable for expressing in human cells. I decided to 
subclone into the p3xFLAG-CMV-14 vector, using the pOTB7-DUSP5 clone as a template in the PCR 
reaction. Using this, I was able to obtain a PCR product while using the DyNAzyme EXT polymerase. This 
PCR product was ligated into pCR-2.1-TOPO as for the amplified GS cDNA. I followed the same protocol 
as for FLAG-GS to generate a p3xFLAG-CMV-14-DUSP5 (FLAG-DUSP5) construct. 
 
2.3 TRANSFECTION 
2.3.1 Plasmid DNA 
 
Cells were seeded into 10 cm dishes and transfected at approximately 60 % confluency. Plasmid DNA 
was transfected using FuGENE 6 (Roche, Welwyn, UK). A 3:1 µl FuGENE: µg DNA ratio was used; this was 
recommended by the manufacturer and previously successfully used for MCF7 wt cells in this 
laboratory. 
 
Manufacturer’s instructions were followed. Briefly, FuGENE was added to ~980 µl FCS-free OptiMEM 
medium (Gibco, Paisley, UK). This mixture was incubated for 5 min at room temperature. The DNA was 
then added to a total volume of 1 ml. The mixture was mixed gently and incubated for 20 min at room 
temperature, before dropwise addition to cells. 
 
Cells were harvested no earlier than 24 h after transfection. If the cells were being re-seeded or treated, 
this was performed no earlier than 8 h after transfection, and usually around 16 h. 
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2.3.1.1 Reverse transfection 
 
For some experiments, I wanted to reduce the length of time between initial transfection and 
harvesting. On these occasions I used “reverse transfection”. Transfection complexes were formed as 
before using FuGENE. During the 20 min incubation period, the cells were trypsinised, centrifuged, and 
resuspended. To avoid discrepancies between wells/dishes, the cells were mixed with the transfection 
mixture while in suspension, before seeding into e.g. 96 well plates.  
 
2.3.1.2 Transfection of doxR cells 
 
The doxR cells were known to have a lower transfection efficiency. I attempted to optimise transfection 
of these cells using the FLAG-GS construct, following manufacturer’s instructions. Cells were seeded into 
6 well plates and transfected at 70 % confluent. I first tested increasing FuGENE:DNA ratios, using 1 µg 
DNA. Cells were harvested for Western blotting after 24 h (Figure 7.1). I found that the 6:1, 9:1 and 12:1 
µl FuGENE:µg DNA ratios provided similar expression, using the FLAG antibody for detection. I then 
repeated the experiment with increasing DNA, using a 6:1 ratio. The best expression of FLAG-GS was 
seen when using 1.5-2 µg DNA with this ratio. I therefore chose to use a 6:1 ratio with 1.5 µg 
(equivalent) DNA for future transfection of doxR cells. 1.5 µg DNA in a well of a 6 well plate is equivalent 
to 8.7 µg in a 10 cm2 dish, requiring 52 µl of FuGENE. 
 
2.3.2 RNA interference with siRNA 
 
RNA interference was used to specifically knock down expression of genes, by transfection of siRNA. All 
siRNA used in this work was SMARTpool siRNA that is a mix of four oligos complementary to the target 
(Dharmacon, Epsom, UK). The siRNA was resuspended in 1x siRNA buffer to 20 µM. 
 
I used oligofectamine (Invitrogen) as the transfection reagent. Cells were seeded into 6 well plates and 
transfected at 70 % confluency. For each well, 5 µl oligofectamine was mixed into 70 μl of OptiMEM 
(FCS-free) and incubated at room temperature for 10 min. A further 250 µl OptiMEM was added along 
with 7.5 µl siRNA for a 50 nM final concentration on cells. This mixture was incubated for 25 min at 
room temperature. OptiMEM was added to final volume 500 µl. Cells were washed once in warm PBS, 
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and the siRNA mixture was added to the well. The cells were returned to the incubator at 37°C for 4 h, at 
which point 2 ml of fully supplemented DMEM was added to each well. The cells were then returned to 
the incubator until harvesting or further treatment. 
 
2.3.3 Reverse transfection 
 
As for plasmid DNA transfection, to save time between seeding, transfecting then harvesting/re-
seeding/treating cells, reverse transfection was sometimes used. As before, the transfection mixtures 
were prepared as usual, but mixed with cells in suspension in OptiMEM before seeding. Full DMEM was 
added after 4 h. 
 
2.4 PROTEIN ANALYSIS BY WESTERN BLOTTING 
2.4.1 Preparation of whole cell extracts 
 
Cells were harvested by trypsinisation or scraping in PBS. After trypsinisation and centrifugation, cells 
were washed in 1 ml PBS and transferred to an eppendorf, before centrifugation at 1000 rpm for 2 min. 
Scraped cells were also transferred to an eppendorf for centrifugation. The supernatant was discarded 
and the cell pellet was stored at -80°C prior to lysis. 
 
RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS) including inhibitors was used to lyse cell pellets. Inhibitors used were 1x 
Complete protease inhibitor cocktail (Roche), 10 mM sodium fluoride and 1 mM sodium orthovanadate, 
both phosphatase inhibitors (Sigma Aldrich). Cell pellets were defrosted on ice, then resuspended in the 
RIPA buffer. Lysates were incubated on ice for 15 min before centrifugation at 14 000 rpm for 10 min to 
remove insoluble material. The supernatant was transferred to a new eppendorf tube and protein 
concentration was determined using the BCA assay kit (Thermo Scientific). BSA was used for the 
standard curve. Manufacturer’s instructions were followed. This is a colorimetric 96 well plate-based 
assay. Results were obtained using a Sunrise spectrophotometer (Tecan, Reading, UK). 
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2.4.2 Western blotting (SDS-PAGE) 
 
Western blotting was used to investigate protein expression. Whole cell lysates were separated via SDS-
PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) then transferred to nitrocellulose 
membranes for immunoblotting. 
 
2.4.2.1 SDS-PAGE 
 
SDS-PAGE gels consisted of a lower resolving gel and upper stacking gel. In this study I used 7, 12 and 14 
% resolving gels. Gels were made using Bis-acrylamide with ammonium persulphate and 
tetramethylethylenediamine as catalysts for polymerisation. 
 
To prepare the samples, 15-25 µg of whole cell extract was mixed with an equal volume of 2x SDS 
loading buffer (4 % SDS, 62.5 mM Tris-HCl [pH 6.8], 20 % glycerol, 0.01 % bromophenol blue), then 
boiled for 5 min. Samples were centrifuged after boiling for 30 s at 10 000 rpm, then loaded into the 
wells of the stacking gel. The Bio-Rad Mini-Protean system was used (Bio-Rad, Hemel Hempstead, UK). 
SDS-PAGE gels were run using SDS-PAGE running buffer (25 mM Tris base, 250 mM glycine, 0.1 % SDS) at 
180 V for separation of proteins. 
 
Once the bromophenol blue dye front had run off, the gels were removed from the tank so that the 
proteins could be transferred to the Protran nitrocellulose membrane (GE Healthcare, Chalfont St Giles, 
UK) using the Bio-Rad Mini-Protean wet transfer system. Tanks were filled with transfer buffer (25 mM 
Tris, 190 mM glycine and 20 % ethanol) plus an ice block to prevent over-heating, and were run at 90 V 
for 90 min. 
 
2.4.2.2 Immunoblotting 
 
Membranes were removed from the transfer tank and ponceau S was used to confirm transfer of 
proteins. Membranes were then blocked in 2.5 % BSA dissolved in TBS-T (20 mM Tris pH 7.6, 136 mM 
NaCl, 0.5 % Tween) for 1 h at room temperature. Primary antibodies were also diluted into BSA in TBS-T 
and stored at 4° between uses. After blocking, membranes were incubated with primary antibody 
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overnight at 4°C or at room temperature for 2 h. Membranes were then washed three times with TBS-T 
for 10 min. Secondary horseradish peroxidase-conjugated antibodies were diluted in TBS-T. Membranes 
were incubated in secondary antibody for 30 min at room temperature. Proteins were visualised using 
enhanced chemiluminescence (ECL) solutions (Perkin Elmer, Seer Green, UK), with Amersham Hyperfilm 
ECL (GE Healthcare). 
 
Antibodies used for this work are listed in Table 2.1. The DUSP5 antibody was a kind gift from WJ 
Leonard of National Heart, Lung and Blood Institute, Bethesda, MD, USA. 
 
Quantification of blots was performed by densitometry using ImageJ (NIH, Bethesda, MD, USA). 
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Antibody Catalogue number Company/Source 
FOXO3a 07-702 Millipore 
p-FOXO3a Thr32 9464 Cell Signaling Technology 
Akt1 (B-1) sc-5298 Santa Cruz Biotechnology 
p-Akt Ser473 9271 Cell Signaling Technology 
JNK (D-2) sc-7345 Santa Cruz Biotechnology 
p-JNK Thr183/Tyr185 9251 Cell Signaling Technology 
ERK1/2 (137F5) 4695 Cell Signaling Technology 
p-ERK1/2 Thr202/Tyr204 9101 Cell Signaling Technology 
p38 9212 Cell Signaling Technology 
p-p38 Thr180/Tyr182 (3D7) 9215 Cell Signaling Technology 
FLAG M2 200472 Stratagene 
DUSP5 ab54939 Abcam 
DUSP5 n/a WJ Leonard 
MKP3/DUSP6 (H-130) sc-28902 Santa Cruz Biotechnology 
MKP3/DUSP6 (C-20) sc-8599 Santa Cruz Biotechnology 
p27 (C-19) sc-528 Santa Cruz Biotechnology 
Glutamine Synthetase 610518 BD Bioscience 
ERα (MC-20)  sc-542 Santa Cruz Biotechnology 
catalase (EP1929Y) ab76024 Abcam 
MnSOD 06-984 Millipore 
LC3B 2775 Cell Signaling Technology 
GFP (FL) sc-8334 Santa Cruz Biotechnology 
β-tubulin (H-235) sc-9104 Santa Cruz Biotechnology 
 
  Table 2.1 Antibodies used in this study. Antibodies listed in approximate order of appearance in 
Chapters 3 and 5. 
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2.5 QUANTITATIVE REAL-TIME PCR 
2.5.1 RNA extraction and cDNA synthesis 
 
Cells were harvested by trypsinisation as for Western blotting. Total RNA was extracted using the 
RNeasy Mini kit (Qiagen). Eluted RNA concentration was determined using a NanoDrop. RNA was stored 
at -80°C. 
 
2 µg of total RNA was reverse transcribed into first strand cDNA using Superscript III first strand cDNA 
synthesis (Invitrogen). Briefly, 1 µl 50 µM oligo(dT)20 and 1 µl 10 mM dNTPs mix were added to the RNA 
before the volume was adjusted to 13 µl using RNase-free water. This mixture was incubated at 65°C for 
10 min before being placed on ice for 1 min. The reverse transcriptase Superscript III was then added, 
along with 1 µl 0.1 M DTT, 1 µl RNaseOUT and 1x first stand buffer. The solution was incubated at 50°C 
for 45 min, then 70°C for 15 min. This cDNA-containing mixture was diluted 1:6 with water and used 
directly for quantitative reverse transcription PCR (RTq-PCR). 
 
2.5.2 RTq-PCR 
 
RTq-PCR was performed using Power SybrGreen (Applied Biosystems, Paisley, UK) and the 7900HT Fast 
Real-Time PCR system (Applied Biosystems). The standard curve method was used to quantify 
expression. Results were analysed by normalisation to the L19 housekeeping gene as internal control, 
then normalised to one of the samples (eg 0 h of a timecourse). All measurements were obtained in 
triplicate. 
 
Primers were designed using Primer Express (Applied Biosystems) or had been previously designed and 
optimised in this laboratory. Newly designed primers were tested using a mixture of cDNAs as template; 
a dissociation curve was also performed for each primer set to ensure only one product was produced. 
Primer pairs resulting in Ct values below 25 were deemed acceptable. 
 
A list of primers used for RTq-PCR is given in Table 2.2. 
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Target gene Forward primer Reverse primer 
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 
FOXO3a TCTACGAGTGGATGGTGCGTT CGACTATGCAGTGACAGGTTGTG 
FOXO1 TGGACATGCTCAGCAGACATC TTGGGTCAGGCGGTTCA 
FOXO4 TGCACAGCAAGTTCATCAAGGT CAGCATCCACCAAGAGCTTTT 
p27 AGGAGAGCCAGGATGTCAGC CAGAGTTTGCCTGAGACCCAA 
DUSP5 CCTGAGTGTTGCGTGGATGT TGAGGGCTCTCTCACTCTCAATC 
DUSP6 GCTGCCGGGCGTTCTAC GGGAGAACTCGGCTTGGAA 
GS CCCCTTTTCGGTGACAGAAG CATCGCCGGTTTCATTGAG 
Table 2.2 Primers used for RTq-PCR. Primers are written 5’-3’. 
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2.6 SULFORHODAMINE B (SRB) ASSAY 
 
Cells were grown in 96 well plates. To harvest, 100 µl of 10 % trichloroacetic acid was added to each well 
and the plate was incubated at 4°C for 1 h. Plates were washed three times with water before addition 
of 100 µl of 0.4 % SRB in 1 % acetic acid. All compounds were obtained from Sigma Aldrich. Plates were 
incubated at room temperature for 1 h, then washed fully with 1 % acetic acid and left to air dry. To 
read the plates, 100 µl 10 mM Tris base was added to each well and the plate was placed on a tilt table 
for 30 min until the SRB had dissolved. Plates were read at 510 nm using a Sunrise spectrophotometer 
(Tecan). Tris base was used for blank wells. Results were normalised to 0 h or untreated wells. 
 
Although I used the SRB assay as a growth assay, it does not measure growth directly. The treatment 
with TCA lyses and precipitates proteins from the cells, which remain adhered to the bottom of the 
wells. SRB binds to the proteins. This assay therefore measures protein content, which is assumed to 
represent cell mass. Differences in the amount of SRB in wells is assumed to be equivalent to differences 
in cell number. 
 
2.7 LUCIFERASE REPORTER ASSAY 
 
Cells were seeded into 96 well plates and co-transfected with the transfection efficiency control Renilla 
plasmid and a luciferase reporter plasmid. For some experiments plasmids for protein overexpression 
were also co-transfected. Both renilla and luciferase proteins emit light in the presence of their 
substrates. 
 
Cells were harvested and washed once with PBS. 100 µl Steady lite plus reagent (Perkin Elmer) was 
added to each well. The plate was incubated in the dark at room temperature for 10 min while the cells 
lysed. Lysates were transferred to a white luciferase plate and luminescence from the wells was read 
using a PHERAstar Plus (BMG Labtech, Aylesbury, UK). This reading represented luciferase-derived light. 
25 µl of renilla substrate mix (1 % coelenterazine, 0.04 M EDTA, 0.5 M HEPES pH 7.8) was then added to 
each well and the plate was incubated for 15 min in the dark at room temperature. The presence of 
EDTA inhibited the luciferase enzyme. Luminescence was measured again; this was renilla-derived light. 
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The luciferase readings per well were normalised to the renilla readings. Multiple replicate wells were 
measured per experiment. 
 
2.8 GS ACTIVITY ASSAY 
 
Cells were harvested by trypsinisation as for Western blotting. Cell pellets were lysed via freeze-thaw in 
50 mM imidazole pH 6.8. Protein concentration was determined using BCA assay as before. The GS 
activity assay was performed in 96 well plates. 5 µg lysate was used per well; measurements were 
obtained in at least triplicate. GS converts glutamine into glutamyl-γ-hydroxamate in the presence of 
hydroxylamine and arsenic. A glutamyl-γ-hydroxamate standard curve was used to calculate GS activity, 
in moles of glutamyl-γ-hydroxamate produced over 30 min from 5 µg lysate. This is a modified version of 
a previously described assay (Knorpp et al., 2006). 
 
Briefly, the lysates were diluted so that all were the same volume. A same volume again of assay mix (50 
mM imidazole pH 6.8, 25 mM arsenic acid, 0.16 mM ADP, 50 mM L-glutamine, 25 mM hydroxylamine pH 
6.8, 2 mM MnCl2) was added to each well. The plate was incubated at 37°C for 30 min. Two volumes of 
stop solution (1.82 % HCl, 1.45 % trichloroacetic acid, 2.42 % ferric chloride) were then added to each 
well. Production of glutamyl-γ-hydroxamate was measured by absorbance at 540 nm. All compounds 
were obtained from Sigma Aldrich. 
 
2.9 FLUORESCENCE MICROSCOPY 
 
Cells were seeded into chamber slides (BD Falcon, Oxford, UK) and transfected 24 h after seeding. To 
harvest, cells were washed with PBS and fixed with 4 % formaldehyde in PBS for 15 min in the dark at 
room temperature. Fixed cells were washed three times with PBS then permeabilised with 0.2 % triton 
X-100 in PBS for 10 min in the dark at room temperature. Cells were washed again three times with PBS, 
then blocked with 5 % goat serum in PBS for 30 min in the dark at room temperature. Primary FLAG 
antibody concentration had been previously optimised (1:200) and was diluted in 0.2 % goat serum in 
PBS. Cells were incubated with the primary antibody for 1 h in the dark at room temperature, before 
further washing with PBS. The Alexa Fluor 555 secondary antibody (Invitrogen) was diluted 1:500 in PBS 
and added to the slide before incubation at room temperature in the dark for 45 min. Final PBS washes 
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were performed before the chambers were removed from the slide. A drop of Vectorshield mounting 
medium with DAPI (Vector Laboratories, Peterborough, UK) was added to each section of the slide 
before addition of the coverslip and sealing with nail varnish. Slides were stored at 4 °C after drying. A 
Nikon Eclipse E400 microscope (Nikon, Kingston-upon-Thames, UK) was used to visualise the cells and 
take pictures, using Nikon Plan Fluor 10x and 40x objective lens with Hamamatsu digital camera 
(Hamamatsu, Welwyn, UK), Nikon mercury lamp, and Metavue software (Molecular Devices, Sunnyvale, 
CA, USA). 
  
2.10 1D 1H NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
2.10.1 Harvesting 
 
Cells were seeded into 6 cm or 10 cm dishes and harvested at the appropriate timepoint. Cells were not 
confluent at harvesting and all dishes within a timepoint had the same volume of medium. Dishes were 
harvested one by one. Cells were washed twice in cold PBS before addition of 1 or 2 ml cold 100% 
methanol. The dish was left at room temperature for 2 min then cells were scraped, and the 
methanol/cells suspension transferred into an eppendorf. After all dishes were harvested, the 
eppendorfs were transferred to a speed vac and dried. Dried samples were stored at -80°C. Blank 
samples were also obtained at each timepoint by washing and extracting a fresh (unused) culture dish. 
Cell culture media samples were obtained at the same time as cell harvesting. Before the cells were 
washed, the media was quickly removed into a Falcon tube. This was centrifuged at 1000 rpm for 4 min 
to remove contaminants. Aliquots were transferred to eppendorfs and stored at -20°C. 
 
2.10.2 Preparation of samples 
 
Samples for the experiment described in Chapter 4.2.3 were prepared by C-H Lau. 
 
2.10.2.1 Media 
 
Media samples were prepared by the addition of 50 μl 0.2% (w/v) Trimethylsilyl-2,2,3,3-
tetradeuteropropionic acid (TSP) in deuterium oxide (D2O) (GOSS Scientific Instruments Ltd, Nantwich, 
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UK) to 550 μl of sample. This was vortexed and centrifuged before 550 µl were transferred to 5 mm 
NMR tubes. 
 
2.10.2.2 Cell extracts 
 
Dried cell pellets were prepared using a chloroform/methanol extraction. 300 µl of 2:1 
chloroform/methanol solution was added to each sample, which was then vortexed for 30 s. 300 µl of 
ultrapure water was added and the sample was vortexed again. Samples were then centrifuged at 13000 
rpm for 10 min. The aqueous and organic layers were separated into eppendorfs for the aqueous layer 
and glass tubes for the organic layer. The extraction was repeated on each sample, and the aqueous and 
organic layers were pooled with those already extracted. Samples were left at room temperature 
overnight to allow organic solvents to evaporate. The organic extract was not used in this study and was 
stored at -80ºC. The aqueous extract was freeze-dried then reconstituted in 600 µl phosphate buffer 
(0.2 M Na2HPO4, 0.043 M NaH2PO4, 100 µM TSP, 3 mM NaN3 in 100 % D2O) before centrifugation at 
13000 rpm for 5 min. 550 µl sample was transferred to a 5 mm glass NMR tube for analysis. All buffers 
had been previously checked for contaminants by obtaining a 1D 1H NMR spectrum at 600 MHz. 
 
2.10.3 Spectral acquisition 
 
NMR spectra were acquired using a Bruker DRX600 spectrometer (Bruker, Coventry, UK), working at 
600.13 MHz 1H NMR frequency at 300 K, using a TXI probe. Gradient shimming was performed before 
spectral acquisition. CPMG pulse sequence was used. All scans were acquired into 32K data points using 
a spectral width of 20 ppm. All acquisition times were 2.73 s. The pulse sequence was RD-90-( -180- )n-
acquire. A water presaturation pulse was applied during the RD (3 s).  was 400 s, n was 80. 128 scans 
and 8 dummy scans were acquired. FIDs were multiplied by an exponential line-broadening function of 
0.3 Hz, before importing into Matlab (Mathworks, Cambridge, UK) at full resolution. Data were imported 
and manipulated using in-house software written and compiled by Dr TM Ebbels, Dr HC Keun, Dr JT 
Pearce, and Dr O Cloarec. Spectra were referenced to TSP at δ 0.0. Spectra from aqueous cell extracts 
were normalised to median fold change, while spectra from media samples were normalised to TSP. 
Spectra described in Chapter 4.2.3 were acquired by C-H Lau. 
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2.10.4 Analysis 
 
Peak integrals were used to bin full resolution spectra. Binned spectra were imported into SIMCA-P 
v11.5 (Umetrics, Umeå, Sweden) for multivariate analysis by principal component analysis (PCA). 
Regions corresponding to the water and TSP peaks were excluded. Data were processed by univariance 
scaling. Correlation and covariance analysis was performed on full resolution spectra using an in-house 
MATLAB script written by Dr JT Pearce. 
 
Assignments were made by reference to published literature (Fan, 1996), as well as by Chenomx Profiler 
(Chenomx Inc, Edmonton, AB, Canada) and personal knowledge. C-H Lau contributed to NMR 
assignment. 
 
2.11 STATISTICAL ANALYSIS 
 
For analysis of RTq-PCR, luciferase, and GS activity assay results, and integrated NMR peak data, Prism 
v5.0 (GraphPad, La Jolla, CA, USA) was used. One-way ANOVA with Bonferroni post-test or unpaired 
two-tailed Student’s t test was used as appropriate. Statistical analysis was not performed where n<3. 
Multivariant analysis for NMR data was performed as described above (Chapter 2.10.4). 
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3.1 INTRODUCTION 
 
A number of chemotherapeutic drugs have been linked to cytotoxic effects via activation of FOXO3a, 
including doxorubicin (Wilson et al., 2011). It was therefore unsurprising that this and previous work in 
this laboratory found FOXO3a to be downregulated in the MCF7-derived doxR cell line. I also found that 
these cells appeared to have downregulated ERK activity. This led us to investigate the expression of two 
ERK-specific MKPs, DUSP5 and DUSP6 in doxR. 
 
I was particularly interested in DUSP5 and DUSP6 expression levels as published array data had 
suggested that these genes were upregulated on FOXO3a activation (Delpuech et al., 2007). Activation 
of an inducible FOXO3a construct led to a ~7x increase in DUSP5 mRNA, and a ~2.7x increase in DUSP6 
mRNA. The authors used the DL23 cell line, derived from the colon carcinoma cell line DLD-1 (Kops et al., 
2002). These cells stably express a fusion protein consisting of the hormone binding domain of mouse 
ERα with a “constitutively active” form of FOXO3a, FOXO3a(A3), which has all three Akt sites mutated to 
alanines so that it does not respond to Akt. The fusion construct is activated by the addition of OHT. The 
binding of OHT to the ERα domain causes a conformational change that promotes its rapid translocation 
to the nucleus, allowing FOXO3a(A3) to bind to forkhead binding elements in the promoters of target 
genes, regulating their transcription.  
 
DUSP5 and DUSP6 are both ERK phosphatases. DUSP5 binds specifically to ERK1 and ERK2, but not ERK3 
or ERK5, using its N-terminal kinase interaction motif (KIM) (Mandl et al., 2005). It also contains an NLS, 
causing it to have a nuclear localisation. Interaction with ERK has been found to promote ERK nuclear 
retention, independent of DUSP5 phosphatase activity (Mandl et al., 2005; Caunt et al., 2008). Binding 
of ERK by DUSP5 is thought to stabilise DUSP5 and reduce its degradation via the proteasome 
(Kucharska et al., 2009). DUSP5 is transcriptionally upregulated by p53, which binds to its promoter 
(Ueda et al., 2003). 
  
DUSP6/MKP3 is part of the cytoplasmic MKP subgroup. It binds and dephosphorylates ERK1/2 (again, 
not ERK5) (Owens and Keyse, 2007; Arkell et al., 2008). As for DUSP5, substrate specificity is mediated 
by the N-terminal non-catalytic KIM. The phosphatase activity of DUSP6 is low prior to ERK binding. The 
protein-protein interaction causes a conformational change that brings a key residue, Asp262, into the 
active site (Mandl et al., 2005). The equivalent residue in DUSP5 is thought to be in place constitutively. 
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Regulatory mechanisms between DUSP6 and ERK are complex. Much as DUSP5-ERK interaction 
promotes ERK’s nuclear retention, DUSP6-ERK interaction promotes cytoplasmic retention of ERK 
(Karlsson et al., 2004). DUSP6 is phosphorylated downstream of ERK, possibly by ERK itself, causing its 
degradation via the proteasome (Marchetti et al., 2005). However, DUSP6 expression is known to be 
regulated by Ets transcription factors i.e. downstream ERK targets (Ekerot et al., 2008; Zhang et al., 
2010; Nunes-Xavier et al., 2010). 
 
DUSP6 has been linked to cancer growth and drug resistance both as potential tumour suppressor and 
oncogene. Reduced expression has been found in ovarian, lung and pancreatic tumour samples 
(Furukawa et al., 2003; Chan et al., 2008; Okudela et al., 2009). Overexpression of DUSP6 in ovarian 
cancer cells increased sensitivity to cisplatin, and reduced growth (Chan et al., 2008). DUSP6 expression 
has also been suggested as potential biomarker for sensitivity to the MEK inhibitor GSK1120212 (Jing et 
al., 2011). Conversely, DUSP6 overexpression increased cisplatin resistance in glioblastoma cells, and 
increased tamoxifen resistance in MCF7 cells (Cui et al., 2006; Messina et al., 2011). 
 
Despite its status as a p53 target gene, little is known regarding potential roles for DUSP5 in cancer. As 
another ERK-specific MKP, its expression is often tested along with DUSP6. Both genes are upregulated 
by growth factors, including EGF, FGF and VEGF (Owens and Keyse, 2007; Caunt et al., 2008; Bellou et 
al., 2009). In MCF7 cells, DUSP5 and DUSP6 were induced in response to activation of the oncogene PKC 
(Nunes-Xavier et al., 2010).  
 
Such results suggest that as for DUSP6, DUSP5 may be involved in cancer progression or drug resistance. 
I wanted to investigate possible contributions of these MKPs to drug resistance or sensitivity in MCF7 
breast cancer cells. I also wished to find out whether DUSP5 and/or DUSP6 were FOXO3a target genes in 
breast cancer. 
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3.2 RESULTS 
3.2.1 FOXO3a is downregulated in a epirubicin-resistant MCF-7 derived cell line 
 
I confirmed that MCF7 wt cells were sensitive to epirubicin (Figure 3.1). The EC50 of the parental MCF7 
wt cells is 1.4 µM (with 95% confidence limits 0.8 to 2.6 µM) at 24 h, and 0.5 µM (with 95% confidence 
limits 0.3 to 0.6 µM) at 48 h. Based on the EC50 values and previous work in this laboratory, I chose 1 
µM as a suitable concentration for treatment of cells. 
 
Previous work in this laboratory has determined that FOXO3a transcription is upregulated on addition of 
1 µM epirubicin to MCF7 wt cells (McGovern, 2009). I wished to now look at whether FOXO3a is 
activated by epirubicin in these cells using the 6xDBE luciferase reporter. This is an artificial promoter 
consisting of 6 repeats of a canonical FOXO recognition element in front of a luciferase gene (Zanella et 
al., 2009). A renilla plasmid was co-transfected as as internal control for transfection efficiency for all 
luciferase experiments. To confirm that the 6xDBE reporter responds to FOXO3a in MCF7 wt cells, cells 
were transfected with 6xDBE in conjunction with increasing amounts of both the FOXO3a wt plasmid 
and the FOXO3a(A3) constitutively active form (Figure 3.2). A dose-dependent luciferase response was 
seen, with higher light output for the cells co-transfected with the A3 mutant FOXO3a, as expected. 
Having confirmed that the promoter works as intended in MCF7 wt, cells were transfected with 6xDBE, 
then 24 h post-transfection were treated with 1 µM epirubicin over a timecourse. Control cells were 
treated with fresh medium at the same time, and luciferase readings were normalized first to the Renilla 
reading per well, then to the untreated result for each timepoint. The activity of the 6xDBE reporter 
increased after 24 h of epirubicin treatment (Figure 3.2). This represents an activation of endogenous 
FOXO proteins in response to epirubicin. 
 
The doxorubicin-resistant MCF7-derived cells, doxR, were previously generated in this laboratory by 
exposing MCF7 wt cells to increasing concentrations of doxorubicin. The doxR cells are maintained in 17 
µM doxorubicin (0.01 mg/ml), but were at least equally resistant to epirubicin, if not more so (Figure 
3.3). I chose to use epirubicin rather than doxorubicin for consistency with previous work in this 
laboratory. In SRB assays, doxR cell growth increased over 96 h post-treatment even when the cells 
were exposed to 100 µM epirubicin (Figure 3.3B).  
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To investigate possible mechanisms behind the drug resistance of the doxR cells, Western blotting and 
RTq-PCR were performed to compare those cells to the parental MCF7 wt (Figure 3.4). As expected, a 
downregulation of FOXO3a protein was observed. Quantification by densitometry suggested that doxR 
cells contained >50 % less FOXO3a protein, but this may reflect some background staining as visual 
inspection of the blot did not find a detectable FOXO3a band. FOXO3a mRNA in doxR cells was only 
~0.7x of MCF7 wt (Figure 3.4C). This implies that although FOXO3a is downregulated transcriptionally, 
the majority of the FOXO3a regulation is at the post-translational level. The FOXO3a target and tumour 
suppressor p27 was also reduced at mRNA and protein level. 
 
Despite the low levels of FOXO3a and Akt proteins in the doxR cells compared to the MCF7 wt, there 
appeared to be an increase in p-Akt Ser473 and p-FOXO3a Thr32 signals, perhaps representing a greater 
proportion of those proteins being phosphorylated (Figure 3.4). It should be noted that levels of the 
loading control protein tubulin are also increased for doxR. As the MAPK pathways have been linked to 
FOXO3a stability, the relative protein levels of JNK, ERK and p38 were also checked in the two cell types, 
along with blotting for the activated/phosphorylated forms of each. The doxR cells appeared to have 
similar levels of JNK protein to the wt cells, but increased phosphorylation was observed. There was 
more ERK2 in doxR, but ERK1 levels were reduced. Amounts of p-ERK1 were similar in wt and doxR cells, 
such that overall ERK activity was lower in the doxR cell line. There was no difference in total or 
phosphorylated p38. 
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Figure 3.1 MCF7 wt cells are sensitive to epirubicin. MCF7 wt cells were treated with 0-100 µM 
epirubicin for 48 h (A), or with 1 µM epirubicin over 72 h (B). Cell proliferation was determined using SRB 
assay. Results were normalized to untreated or 0 h, respectively. Results shown are mean and SEM of 
three independent experiments, each with three replicates. For (A), EC50 was determined by fitting a 
Sigmoidal dose-response curve to the data. 
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Figure 3.2 The 6xDBE FOXO reporter construct is activated by epirubicin. MCF7 wt cells were seeded 
into 96 well plates and co-transfected with 20 ng 6xDBE, 5 ng Renilla and 0-20 ng FOXO3a wt or 
FOXO3a(A3). Cells were harvested 24 h post-transfection and reporter activity was determined using 
luciferase assay (A). MCF7 wt cells were transfected with 45 ng 6xDBE and 5 ng Renilla. 16 h post-
transfection, cells were treated with 1 µM epirubicin. Cells were harvested together and reporter 
activity was determined using luciferase assay (B). Results shown are mean and SEM of three 
independent experiments, each with six replicates per condition. Significance testing was performed 
using ANOVA with Bonferroni’s post-test (p<0.01 **, p<0.001 ***). Results in (A) were tested for 
significance against the 0 ng condition for each FOXO3a plasmid, and are expressed as fold change 
compared to that condition. Results in (B) were tested for significance against 0 h, and are expressed as 
fold change of treated versus untreated cells for each timepoint. 
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Figure 3.3 doxR cells are resistant to doxorubicin and epirubicin. doxR cells were treated with 0-100 
µM doxorubicin or epirubicin for 48 h (A), or with 0, 1 and 100 µM epirubicin over 96 h (B). Cell 
proliferation was determined using SRB assay. Results were normalized to untreated or 0 h, 
respectively. Results shown are mean and SEM of three independent experiments, each with three 
replicates. 
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Figure 3.4 FOXO3a is downregulated in doxR cells. MCF7 wt and doxR cells were seeded and harvested 
24 h later, without treatment. Samples were processed for Western blotting (A). FOXO3a blots were 
quantified using densitometry (B). RTq-PCR was also performed using primers for FOXO3a (C) and p27 
(D). Graphs show mean and SEM of data from three independent experiments. Results are expressed as 
fold change compared to MCF7 wt. 
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3.2.2 DUSP5 and DUSP6 are upregulated in doxR cells 
 
I found that p-ERK2 was proportionally downregulated in the doxR cells. This led us to investigate 
expression of the ERK-specific MKP DUSP6, which has been previously linked to cancer drug resistance, 
as well as DUSP5. Firstly, the available antibodies were tested in MCF7 wt. As a positive control, cells 
were transfected with constructs for overexpression of DUSP6 and FLAG-DUSP5. The FLAG-DUSP5 
plasmid was generated as described in Chapter 2.2.1. The FLAG-DUSP5 construct was detected by FLAG 
antibody as a band around 50 kDa (predicted 45 kDa including 3 kDa for 3xFLAG tag) (Figure 3.5). This 
antibody also detected several smaller, weaker bands that were presumably degraded forms. The first 
DUSP5 antibody was a kind gift from WJ Leonard of the National Heart, Lung and Blood Institute, 
Bethesda, MD, USA. Unfortunately, this antibody was not able to detect the overexpressed protein. The 
Abcam antibody did weakly detect a band of the correct size, but also bound non-specifically. For 
DUSP6, both available antibodies detected the overexpressed construct at around 42 kDa (Figure 3.6). 
The DUSP6 construct appeared as two bands. This may represent post-translational modification. For 
future overexpression experiments, I chose to use the C-20 antibody for DUSP6, and FLAG to detect 
FLAG-DUSP5. None of the antibodies were able to detect DUSP5 or DUSP6 in the control transfected 
cells. This may be due to low endogenous expression. Therefore I was unfortunately unable to 
investigate endogenous protein levels of DUSP5 or DUSP6. 
 
RTq-PCR was performed to investigate basal mRNA levels of DUSP5 and DUSP6 in MCF7 wt and doxR 
cells (Figure 3.7). Both mRNA were upregulated ~5x in the doxR cells. The increase was significant for 
DUSP5 (p<0.01). Although it is unknown whether these increases in mRNA level correspond to increases 
in protein level, this finding could explain the proportional decrease in ERK1 activity in doxR cells 
compared to wt. 
 
These results suggest that DUSP5 and DUSP6 may contribute to doxorubicin/epirubicin-resistance in 
MCF7. They also suggest that any potential regulation by FOXO3a has become deregulated. I decided to 
investigate whether DUSP5 and DUSP6 are FOXO3a targets in MCF7 wt cells.   
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Figure 3.5 DUSP5 antibodies don’t detect endogenous DUSP5. MCF7 wt cells were transfected with 5 
µg control or FLAG-DUSP5 vectors, and harvested 24 h post-transfection. Western blotting was used to 
test the two available DUSP5 antibodies. FLAG antibody was used to confirm overexpression of FLAG-
DUSP5. 
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Figure 3.6 DUSP6 antibodies don’t detect endogenous DUSP6. MCF7 wt cells were transfected with 5 
µg control or DUSP6 vectors, and harvested 24 h post-transfection. Western blotting was used to test 
the two available DUSP6 antibodies. 
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Figure 3.7 DUSP5 and DUSP6 mRNA are upregulated in doxR cells. MCF7 wt and doxR cells were 
seeded and harvested 24 h later, without treatment. mRNA levels of DUSP5 and DUSP6 were 
determined using RTq-PCR with primers for DUSP5 (A) and DUSP6 (B). Graphs show mean and SEM of 
data from three independent experiments. Results are expressed as fold change compared to MCF7 wt. 
Significance testing was performed using two-tailed unpaired t test (p<0.01 **). 
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3.2.3 DUSP5 and DUSP6 may be FOXO3a targets in breast cancer 
 
I wished to investigate whether DUSP5 and DUSP6 were FOXO3a targets in MCF7 wt cells. First, I 
confirmed the published assay results by using the same DL23 cells as used for the published work 
(Delpuech et al., 2007) (Figure 3.8). The initial array activated the construct using 100 nM OHT. For 
consistency with previous work in this laboratory, I used 200 nM OHT. Treatment with OHT caused a 
shift in band size of the fusion protein after Western blotting, representing activatory phosphorylation. 
This FOXO3a(A3) activation resulted in apparent growth arrest (Figure 3.8B). Endogenous FOXO3a 
protein level increased slightly by 16 h, but there was no change in mRNA level (Figure 3.9A). Therefore 
FOXO3a is not a target of FOXO3a(A3) in DL23 cells. However, significant (p<0.05) increases in mRNA of 
DUSP5 and DUSP6 were seen after 24 h of OHT exposure, confirming the results from the published 
array (Figure 3.9B-C). The fold increase at 24 h for DUSP5 was ~20x, while just ~5x for DUSP6. This 
reflects both a higher final amount of DUSP5 mRNA as well as lower basal mRNA level (pre-
normalisation DUSP5/L19 value ~0.09 at 0 h to ~2.4 at 24 h of OHT treatment, while DUSP6/L19 values 
were ~0.18 at 0 h and ~1.3 at 24 h). 
 
To investigate possible regulation of DUSP5 and DUSP6 by FOXO3a in MCF7 wt, I used a PI3K family 
inhibitor, LY294002. This compound should activate FOXO indirectly, inhibiting Akt via inhibition of PI3K 
and and to a lesser extent mTOR (Ogita and Lorusso, 2011). Surprisingly, treating MCF7 wt for 24 h with 
increasing concentrations of LY294002 resulted in a dose-dependent increase in p-FOXO3a Thr32 (Figure 
3.10). An increase in phosphorylated Akt (p-Ser473) was also observed. Although the result was 
unexpected, I chose to use these results as a FOXO3a inhibition experiment, and therefore checked the 
expression levels of my targets of interest. No trend was seen in FOXO3a mRNA on LY294002 treatment 
(Figure 3.10B). However, there was a dose-dependent decrease in p27 and DUSP5 mRNA, and an 
increase in DUSP6 mRNA. 
 
I also treated the breast cancer cell line BT474 with LY294002 for 24 h, to investigate whether LY294002 
would also activate Akt in these cells (Figure 3.11). As for the MCF7 wt, these cells showed increased 
inhibitory phosphorylation of FOXO3a in response to 24 h of LY294002 treatment. I also tested the Akt 
inhibitor triciribine in BT474 for 24 h (Figure 3.12). Although there was an increase in p27 protein, there 
was no change in total or phosphorylated FOXO3a. The increase in p27 was therefore presumably due to 
reduction in direct Akt regulation, and not via FOXO activity. 
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Returning to MCF7 wt, I used siRNA against FOXO3a to inhibit its activity directly (Figure 3.13). The 
controls were mock transfection (buffer only without siRNA; mock) and a non-specific pool of scrambled 
siRNA (ns). Cells were harvested 48 h post-transfection (performed as described in Chapter 2.3.2). The 
knockdown of FOXO3a was confirmed by Western blotting and RTq-PCR.  
 
I observed a reduction in p27 protein, but this was apparently not a transcriptional downregulation as 
there was no change in mRNA level (Figure 3.13, Figure 3.14). The DUSP6 mRNA level was lower in 
siFOXO3a transfected cells than ns siRNA control cells, but this difference was not significant. No 
significant difference in DUSP5 mRNA was found (Figure 3.14). I also failed to find any effect of FOXO3a 
knockdown on MAPK total protein level or phosphorylation (Figure 3.13). In case FOXO1 and FOXO4 
were compensating for FOXO3a knockdown, I investigated the effect of FOXO3a knockdown on their 
expression in MCF7 wt (Figure 3.14E-F). No changes in mRNA were seen. I unfortunately was not able to 
assess protein levels. 
 
Finally, the FOXO3a(A3) construct was overexpressed in MCF7 wt (Figure 3.15). Cells were harvested 24 
h post-transfection and overexpression was confirmed by Western blotting and RTq-PCR. In this 
experiment, p27 was downregulated at protein and mRNA level (Figure 3.15, Figure 3.16B). No change 
in DUSP5 expression was observed (Figure 3.16C), but I saw a significant increase in DUSP6 mRNA 
(p<0.01) (Figure 3.16D). However, no change in p-ERK level was seen, so it is not clear whether the 
increase in DUSP6 mRNA did reflect an increase in DUSP6 protein. Of the MAPKs, ERK and p38 total 
protein and phosphorylation levels were unchanged. Total JNK levels also seemed unaffected by 
FOXO3a(A3) overexpression, but a greater proportion was in its phosphorylated, active form (Figure 
3.15). 
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Figure 3.8 The FOXO3a(A3):ERα construct in DL23 cells is activated by OHT. DL23 cells were treated 
with 200 nM OHT over a timecourse. Protein levels were determined using Western blotting (A). The 
fusion construct was detected using an antibody specific for mouse ERα. SRB assay was used to 
investigate the effect of OHT on growth of DL23 cells. Cells were seeded and treated with OHT or 
vehicle control (ethanol) over 72 h (B). Results shown are mean and SEM of two independent 
experiments. Results are normalized to 0 h. 
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Figure 3.9 Treatment of DL23 cells with OHT caused upregulation of DUSP5 and DUSP6 mRNA. DL23 
cells were treated with 200 nM OHT over a timecourse. RTq-PCR was performed using primers specific 
for FOXO3a (A), DUSP5 (B) and DUSP6 (C). Results shown are mean and SEM of two independent 
experiments. Results are normalized to 0 h. 
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Figure 3.10 FOXO3a is inhibited by LY294002 in MCF7 wt. MCF7 wt cells were treated with 0-10 µM 
LY294002 for 24 h. FOXO3a phosphorylation was determined using Western blotting (A). RTq-PCR was 
used to determine mRNA level of FOXO3a (B), p27 (C), DUSP5 (D) and DUSP6 (E). Results shown are 
mean and SEM of two independent experiments. Results are normalized to untreated control cells. 
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Figure 3.11 FOXO3a is inhibited by LY294002 in BT474. BT474 cells were treated with 0-20 µM 
LY294002 for 24 h. Protein levels were determined by Western blotting. 
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Figure 3.12 FOXO3a phosphorylation is not affected by triciribine in BT474. BT474 cells were treated 
with 0-20 µM triciribine for 24 h. Protein levels were determined by Western blotting. 
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Figure 3.13 Knockdown of FOXO3a reduced p27 protein level. MCF7 wt cells were transfected with 
non-specific siRNA (ns) or siFOXO3a. The mock control was cells treated with oligofectamine without 
siRNA. Cells were harvested 48 h post-transfection, and Western blotting performed. 
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Figure 3.14 Knockdown of FOXO3a did not significantly affect DUSP5 or DUSP6 mRNA level. MCF7 wt 
cells were transfected with non-specific siRNA (ns) or siFOXO3a. The mock control was oligofectamine 
without siRNA. Cells were harvested 48 h post-transfection. RTq-PCR was performed with primers 
specific for FOXO3a (A), p27 (B), DUSP5 (C), DUSP6 (D), FOXO1 (E) and FOXO4 (F). Data shown are mean 
and SEM of three independent experiments. Results are normalized to mock. Significance testing was 
perfomed using ANOVA (p>0.05 unless stated, p<0.05 *). 
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Figure 3.15 Overexpression of FOXO3a(A3) affects JNK phosphorylation. MCF7 wt cells were 
transfected with 5 µg control or FOXO3a(A3) construct. Cells were harvested for Western blotting 24 h 
post-transfection (A). The JNK and p-JNK blot panels were quantified using ImageJ and normalised to 
tubulin. Result is expressed as p-JNK/JNK ratio normalised to the control transfection condition. 
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Figure 3.16 Overexpression of FOXO3a(A3) increases DUSP6 mRNA. MCF7 wt cells were transfected 
with 5 µg control or FOXO3a(A3) construct. Cells were harvested 24 h post-transfection. RTq-PCR was 
performed with primers specific for FOXO3a (A), p27 (B), DUSP5 (C), and DUSP6 (D). Data shown are 
mean and SEM of three independent experiments, apart from (B) which is mean and SEM of two 
independent experiments and so was not tested for significance. Results are normalized to control 
transfection. Significance testing was performed for (A), (C) and (D) using two-tailed t test (p<0.05 *, 
p<0.01 **). 
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3.2.4 Cellular stress induces upregulation of DUSP5 and DUSP6 
 
Although I was unable to confirm that DUSP5 and/or DUSP6 are FOXO3a target genes, I wanted to 
investigate the expression of these genes in response to drug treatment as a starting point for 
understanding their upregulation in doxR. Firstly, MCF7 wt cells were treated with 1 µM epirubicin over 
a timecourse (Figure 3.17). Although I knew from the 6xDBE luciferase assay that endogenous FOXO 
activity increased during 24 h epirubicin treatment (Figure 3.2), the overall level of FOXO3a protein is 
reduced (Figure 3.17). This may reflect increased activity of FOXO1 or FOXO4 rather than FOXO3a, but 
unfortunately I was unable to check their protein levels. 
 
Epirubicin treatment did not change total levels of ERK or p38 protein, but total JNK did increase over 
the timecourse (Figure 3.17). All three MAPKs were also activated, with different kinetics. The p-p38 
signal increased gradually over 48 h of epirubicin treatment. ERK showed a peak of activation around 8 
h, which then slowly subsided. Despite the increase in total JNK, the increase in p-JNK was more subtle; 
the signal also peaked at 8 h but remained constant until 48 h. It should be noted that the earliest 
timepoint here is 4 h. I did not choose to investigate shorter timepoints as I was interested in de novo 
transcription of mRNA rather than signal transduction. Surprisingly, I did not see any notable increase in 
protein level of the antioxidants and FOXO3a target genes catalase or MnSOD. Using RTq-PCR, I then 
looked at the mRNA levels of my genes of interest (Figure 3.18). The amount of FOXO3a mRNA was 
reduced after 4 h of 1 µM epirubicin, but then increased until 48 h. In contrast, mRNA level for DUSP5 
increased steadily over the timecourse up to ~10x increase. DUSP6 mRNA levels also increased ~3x by 48 
h, although a reduction in mRNA was seen at 4 h (Figure 3.18C). 
 
It is known that treatment by anthracyclines causes oxidative stress/an increase in ROS (Chapter 1.8.1). 
Therefore I also treated MCF7 wt with H2O2 directly. First, I tested different concentrations of H2O2 using 
SRB assays (Figure 3.19). I did not find the expected Sigmoidal drug titration result. Of the 
concentrations I tested, over a 72 h timecourse, the cells did not die nor arrest up to 500 µM H2O2, but 
the growth rate was decreased. Higher concentrations had a greater effect on growth rate. However, 1 
mM H2O2 killed almost all the cells by 24 h. For further experiments, I chose 150 µM as this 
concentration had a noticeable effect on cell growth (Figure 3.19B). 
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I next checked whether FOXO was activated by 24 h of H2O2 treatment. I used the same 6xDBE luciferase 
assay experiment as for epirubicin (Chapter 3.2.1). There was no increase in FOXO reporter activity over 
the timecourse (Figure 3.20). 
 
A timecourse was then performed using 150 µM H2O2 in MCF7 wt cells (Figure 3.21). By Western 
blotting, I did not see any changes in total FOXO3a, nor Akt activity. Of the MAPKs, p38 was not 
activated by 150 µM H2O2. JNK phosphorylation increased at 4 h and then 24-48 h, while the p-ERK 
signal was strongest at 4 h and 24 h. No increase in catalase protein was seen. This may indicate that 
MCF7 wt have high endogenous catalase levels, making upregulation or stabilization unnecessary. 
Analysis of mRNA levels by RTq-PCR showed that there was no change in FOXO3a or DUSP5 mRNA levels 
throughout the timecourse (Figure 3.22). However, a ~3.5x increase in DUSP6 mRNA was seen after 4 h 
of 150 µM H2O2. The mRNA level then slowly decreased over the rest of the timepoints. As the luciferase 
results showed that FOXO is not activated by 150 µM H2O2, this induction (or stabilization) of DUSP6 
mRNA must be independent of FOXO. 
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Figure 3.17 Epirubicin treatment results in MAPK phosphorylation. MCF wt cells were treated with 1 
µM epirubicin over a timecourse. Results were obtained using Western blotting. 
114 
 
 
  
0 4 8 24 48
0.0
0.5
1.0
1.5
2.0
2.5
Time (h)
F
O
X
O
3
a
/L
1
9
0 4 8 24 48
0
5
10
15
Time (h)
D
U
S
P
5
/L
1
9
0 4 8 24 48
0
1
2
3
4
Time (h)
D
U
S
P
6
/L
1
9
Figure 3.18 Epirubicin treatment causes upregulation of DUSP5 and DUSP6 mRNA. MCF wt cells were 
treated with 1 µM epirubicin over a timecourse. Results were obtained using RTq-PCR with primers 
specific for FOXO3a (A), DUSP5 (B) and DUSP6 (C). Results show mean and SEM of two independent 
experiments. Results are normalized to 0 h. 
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Figure 3.19 Treatment with H2O2 reduces growth rate of MCF7 wt cells. MCF7 wt cells were treated 
with 0-1000 µM H2O2 for 48 h (A). MCF7 wt cells were treated with different amounts of H2O2 over 72 h 
(B). Results were obtained using SRB assay. Results show mean and SEM of three independent 
experiments. Non-linear regression was used for curve fitting in (A). 
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Figure 3.20 Treatment with 150 µM H2O2 does not affect activity of 6xDBE reporter. MCF7 wt cells 
were transfected with 45 ng 6xDBE and 5 ng Renilla. 16 h post-transfection, cells were treated with 150 
µM H2O2. Cells were harvested together and reporter activity was determined using luciferase assay. 
Results shown are mean and SEM of three independent experiments, each with six replicates per 
condition. Significance testing was performed using ANOVA with Bonferroni’s post-test; no significant 
differences between groups were found. Results were normalized first to Renilla then to untreated cells 
for each timepoint. 
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Figure 3.21 Treatment with 150 µM H2O2 has a minimal effect on MAPK phosphorylation. MCF wt 
cells were treated with 150 µM H2O2 over a timecourse. Results were obtained using Western blotting. 
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Figure 3.22 H2O2 treatment results in upregulation of DUSP6 mRNA but not DUSP5. MCF wt cells were 
treated with 150 µM H2O2 over a timecourse. Results were obtained using RTq-PCR with primers specific 
for FOXO3a (A), DUSP5 (B) and DUSP6 (C). Results show mean and SEM of two independent 
experiments. Results are normalized to 0 h. 
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3.2.5 Overexpression of DUSP5 and DUSP6 inhibits MAPKs in MCF7 wt cells 
 
I have shown that DUSP5 and DUSP6 mRNA were upregulated in MCF7 wt on epirubicin treatment. I 
then investigated the effect of modulating DUSP5/DUSP6 activity on the response to epirubicin in these 
cells. 
 
First, I confirmed the activity of FLAG-DUSP5 and DUSP6 overexpression constructs. Cells were 
transfected with increasing amounts of FLAG-DUSP5 or DUSP6 cDNA construct, and harvested 24 h post-
transfection (Figure 3.23, Figure 3.24). The largest amount of FLAG-DUSP5 or DUSP6 transfected was 10 
µg; for both this resulted in a fold increase in mRNA of ~4000x (Figure 3.23, Figure 3.24). This 
demonstrates the low basal mRNA level of these proteins (compare to e.g. transfection of 5 µg 
FOXO3a(A3) construct resulting in 400x mRNA increase (Figure 3.16)). Two bands were seen for FLAG-
DUSP5: one at the expected ~45 kDa, and a band with a weaker signal at ~31 kDa (Figure 3.23). This 
lower band presumably represents degradation of the construct. Overexpression of FLAG-DUSP5 or 
DUSP6 resulted in a reduction in phosphorylated ERK, while not affecting total ERK protein levels (Figure 
3.23, Figure 3.24). DUSP6 appeared to have greater phosphatase activity against ERK than FLAG-DUSP5, 
though it is not clear whether the FLAG tag is affecting activity of the FLAG-DUSP5 construct. Activity of 
the other MAPKs was also affected by the overexpression of either construct. Overexpression of FLAG-
DUSP5 caused a reduction in p-JNK levels, as well as possibly p-p38. In MCF7 wt overexpressing the 
DUSP6 construct, a loss of JNK total protein was seen along with a strong reduction in p-JNK, particularly 
of JNK1 (the lower band, 46 kDa). There was also a possible reduction in p-p38. 
 
As alterations in MAPK activity were seen when FLAG-DUSP5 or DUSP6 were overexpressed, I was 
interested to assess downstream effects on FOXO3a level. No obvious change in FOXO3a mRNA was 
found (Figure 3.25), but a slight decrease in total FOXO3a protein was seen (Figure 3.23, Figure 3.24). I 
also used the 6xDBE luciferase reporter assay to determine whether overexpression of FLAG-DUSP5 or 
DUSP6 affected FOXO activity in MCF7 wt cells. Cells were transfected with 6xDBE and FLAG-
DUSP5/DUSP6 constructs. Again, no significant differences were obtained, although there appears to be 
a downwards trend for both experiments (Figure 3.26).  
  
120 
 
  
Figure 3.23 Overexpression of FLAG-DUSP5 inhibits ERK. MCF7 wt cells were transfected with 0, 2.5, 5, 
10 µg FLAG-DUSP5 plasmid, and harvested after 24 h. Western blotting was performed to determine 
protein changes (A). RTq-PCR was used to confirm increased DUSP5 mRNA (B). Graph shows mean and 
SEM of two independent experiments, normalized to 0 µg. 
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Figure 3.24 Overexpression of DUSP6 inhibits ERK. MCF7 wt cells were transfected with 0, 2.5, 5, 10 µg 
DUSP6 plasmid, and harvested after 24 h. Western blotting was performed to determine protein 
changes (A). RTq-PCR was used to confirm increased DUSP6 mRNA (B). Graph shows mean and SEM of 
two independent experiments, normalized to 0 µg. 
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Figure 3.25 Overexpression of FLAG-DUSP5 or DUSP6 does not affect FOXO3a mRNA. MCF7 wt cells 
were transfected with 0-10 µg FLAG-DUSP5 (A) or DUSP6 constructs (B). Cells were harvested 24 h post-
transfection. RTq-PCR was performed using primers specific for FOXO3a. Results show mean and SEM 
of two independent experiments, normalized to 0 µg. 
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Figure 3.26 Overexpression of FLAG-DUSP5 or DUSP6 may affect 6xDBE reporter activity. MCF7 wt 
cells were transfected with 0-20 ng FLAG-DUSP5 (A) or DUSP6 constructs (B) as well as 5 ng Renilla and 
20 ng 6xDBE. Cells were harvested 24 h post-transfection. Results were obtained using luciferase essay. 
Results show mean and SEM of two independent experiments, normalized to 0 ng. 
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3.2.6 Knockdown of DUSP5 increases ERK phosphorylation and inhibits FOXO3a 
 
I then wanted to use siRNA to knockdown the endogenous DUSP5 and DUSP6. Unfortunately, I was not 
able to perform DUSP6 knockdown, and were only able to obtain one set of siDUSP5 samples for 
Western blotting and RTq-PCR. This DUSP5 knockdown should therefore be analysed with caution, as 
the results have not been confirmed. Cells were transfected with siDUSP5 as described in Chapter 2.3.2, 
and harvested 24 and 48 h post-transfection (Figure 3.27). RTq-PCR was used to confirm the knockdown. 
Western blotting was then performed to investigate effect of the DUSP5 knockdown on ERK activity. 
Despite the suspected low basal levels of DUSP5 mRNA in MCF7 wt cells, siDUSP5 transfected cells did 
contain increased p-ERK (Figure 3.27A).  
 
I also used siDUSP5 in conjunction with the 6xDBE luciferase assay (two biological repeats were 
performed). MCF7 wt cells were transfected with siRNA for 24 h, when they were trypsinised and 
reseeded into a 96-well plate. At that time the cells were reverse-transfected with the 6xDBE and Renilla 
constructs. Cells were harvested 24 h later (48 h post siRNA transfection). FOXO activity was non-
significantly reduced in cells transfected with siDUSP5 (Figure 3.28), supporting the siDUSP5 Western 
blotting and RTq-PCR results (Figure 3.27). 
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Figure 3.27 Knockdown of DUSP5 increased ERK phosphorylation. MCF7 wt cells were transfected with 
non-specific siRNA (ns), siDUSP5 or mock control (oligofectamine with buffer). Cells were harvested 24 
and 48 h post-transfection. Protein changes were assessed using Western blotting (A). RTq-PCR was 
used with primers for DUSP5 (B) and FOXO3a (C). Figures show the results of one experiment. Graphed 
data show mean and SEM of three replicates. 
m
o
c
k
n
s
s
iD
U
S
P
5
m
o
c
k
n
s
s
iD
U
S
P
5
0.0
0.5
1.0
1.5
2.0
2.5
24 h 48 h
D
U
S
P
5
/L
1
9
m
o
c
k
n
s
s
iD
U
S
P
5
m
o
c
k
n
s
s
iD
U
S
P
5
0.0
0.5
1.0
1.5
24 h 48 h
F
O
X
O
3
a
/L
1
9
A B 
C 
126 
 
  
m
oc
k ns
si
D
U
S
P
5
0.0
0.5
1.0
1.5
6
x
D
B
E
/R
e
n
il
la
Figure 3.28 Knockdown of DUSP5 reduces 6xDBE reporter activity. MCF7 wt cells were transfected 
with non-specific siRNA (ns), siDUSP5, or mock control (buffer). 24 h after transfection, cells were 
trypsinised, reseeded, and reverse-transfected with 5 ng Renilla and 45 ng 6xDBE plasmids. Cells were 
harvested 24 h later, and results obtained using luciferase assay. Results show mean and SEM of two 
independent experiments, each with six replicates per condition. Results are normalized to mock. 
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3.2.7 Altering DUSP5 or DUSP6 expression does not affect epirubicin sensitivity of 
MCF7 wt 
 
Having confirmed that expression of FLAG-DUSP5 and DUSP6, and knockdown of DUSP5, affects MAPK 
activity in MCF7 wt, my aim was to investigate the effect of those changes on epirubicin sensitivity. Cells 
were seeded into 96 well plates and reverse-transfected with 5 µg FLAG-DUSP5 or DUSP6 constructs 
(Chapter 2.3.1.1), then after 16 h treated with a range of epirubicin concentrations (Figure 3.29). The 
slopes of the fitted curves were different for DUSP overexpressing cells from the control transfected 
cells, resulting in minor differences in EC50. At 48 h, the EC50 for control cells was 0.31 µM with 95% 
confidence intervals 0.22 to 0.45 µM; the same values for FLAG-DUSP5 overexpressing cells were 0.39 
µM with 95% confidence intervals 0.33 to 0.45 µM, while DUSP6 transfected cells had EC50 0.41 µM 
with 95% confidence intervals 0.34 to 0.50 µM. I also investigated the response to epirubicin of cells 
transfected with siDUSP5 siRNA (Figure 3.29). Knockdown of DUSP5 also affected the slope of the fitted 
curve; the EC50 at 48 h was 0.17 µM with 95% confidence intervals 0.12 to 0.26 µM for ns cells, and 0.21 
µM with 95% confidence intervals 0.14 to 0.34 for siDUSP5 cells. These values are lower overall than for 
the overexpression cells. Presumably this reflects the additional stress of the siRNA transfection. 
Knockdown of DUSP5 reduced growth of MCF7 wt cells compared to the control cells (Figure 3.30). 
Conversely, DUSP6 overexpression may have slightly increased growth rate, while FLAG-DUSP5 
expression did not affect growth rate. 
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Figure 3.29 Transfection with FLAG-DUSP5, DUSP6, or siDUSP5 affects the response to epirubicin. 
MCF7 wt cells were reverse-transfected with 5 µg control, FLAG-DUSP5 or DUSP6 plasmid (A), or non-
specific siRNA (ns) or siDUSP5 (B). 16 h after seeding, cells were treated with 0-100 µM epirubicin for 48 
h. Results were obtained using SRB assay. Results show mean and SEM of two independent 
experiments, each with three replicates per condition. EC50 values were obtained after fitting a 
Sigmoidal dose-response curve to the data. 
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Figure 3.30 Transfection with FLAG-DUSP5, DUSP6, or siDUSP5 affects growth rate. MCF7 wt cells 
were reverse-transfected with 5 µg control, FLAG-DUSP5 or DUSP6 plasmid (A), or with non-specific 
siRNA (ns) or siDUSP5 (B). 16 h after seeding, growth medium was replaced with fresh. Cells were 
harvested over a timecourse post-media change. Results were obtained using SRB assay. Results show 
mean and SEM of two independent experiments, each with three replicates per condition. 
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3.3 DISCUSSION 
 
The dual survival-apoptotic roles of the ERK, JNK, and p38 MAPKs have meant that their roles in cancer 
development and drug resistance are not easily determined, and may be cell type/tumour specific 
(Chapter 1.9). I have found that in a doxorubicin/epirubicin-resistant MCF7 cell line, JNK was apparently 
hyperactive. Conversely, ERK activity was downregulated: total ERK1 protein was strongly 
downregulated, while p-ERK2 was proportionately decreased compared to the parental cells. I then 
found that the ERK-specific MKPs DUSP5 and DUSP6 were transcriptionally upregulated in the resistant 
cells. These two genes had also previously been linked to FOXO3a activity. My aims were therefore to 
investigate the potential regulation of DUSP5 and DUSP6 transcription by FOXO3a in MCF7 cells, as well 
as establishing whether DUSP5 and DUSP6 expression contributes to epirubicin resistance in these cells. 
 
I confirmed that DUSP5 and DUSP6 are both transcriptionally upregulated on FOXO3a construct 
activation in a colon cancer-derived FOXO3a inducible system (Delpuech et al., 2007). Unfortunately, my 
results regarding FOXO3a regulation of DUSP5 and DUSP6 in MCF7 wt cells are not conclusive. Firstly, 
the PI3K inhibitor LY294002 unexpectedly caused an increase in Akt activity and inhibition of FOXO3a in 
both breast cancer cell lines tested. It is possible that the mTOR pathway activity increased to 
compensate for PI3K inhibition, which would explain the increase in p-Akt at Ser473 seen. Treatment 
with triciribine in the BT474 cell line did inhibit Akt, but FOXO3a activity was not affected. This suggests 
that non-Akt FOXO regulators are important in this cell line (such as IKKβ). I also knocked down FOXO3a 
using siRNA in MCF7 wt. However, I did not observe changes in mRNA level of the target gene p27 nor 
DUSP5 or DUSP6, despite finding a reduction in p27 protein. I harvested the cells at 48 h post-
transfection, as this has been previously found in my laboratory to provide the best results for FOXO3a 
knockdown. However, it is possible that this timepoint was suboptimal for these MCF7 wt cells. 
Although I confirmed that mRNA of FOXO1 and FOXO4, the other two main FOXOs, were not 
upregulated in response to FOXO3a knockdown, I was unable to assess the effect on FOXO1 and FOXO4 
protein level. These proteins could potentially have been stabilised or activated to compensate for the 
reduction in FOXO3a. This would explain why I did not see cellular effects of siFOXO3a, since FOXOs do 
display functional redundancy. Unfortunately I was not able to try knocking down all FOXOs 
simultaneously. 
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When MCF7 wt were treated with LY294002, a dose dependent decrease in DUSP5 mRNA was seen, 
while DUSP6 mRNA dose dependently increased. Since FOXO3a was inhibited, this supports DUSP5 as a 
FOXO3a target of upregulation, but not DUSP6. Conversely, overexpression of the FOXO3a(A3) mutant 
construct in the same cells resulted in a significant increase in DUSP6 mRNA, but did not affect 
expression of DUSP5 mRNA. This did not seem to have a physiological consequence, as ERK 
phosphorylation was not affected. Without adequate antibodies for endogenous DUSP5 and DUSP6 I 
was unable to investigate whether changes in their mRNA level affects protein availability. Interestingly, 
FOXO3a(A3) expression also increased p-JNK level, in a possible positive feedback loop. Overall, I cannot 
confirm whether DUSP5 and DUSP6 are meaningfully regulated by FOXO3a in MCF7 from the data so 
far. Altogether, it is possible that DUSP5 is transcriptionally upregulated by FOXO3a in MCF7 wt, but 
DUSP6 is more likely to be regulated independently. Both genes are clearly not regulated by FOXO3a in 
the doxR cells, as FOXO3a is inhibited and downregulated. I also found that JNK signalling is upregulated 
in doxR cells. DUSP5 was previously found to be regulated downstream of the JNK target c-Jun in MCF7 
cells (Nunes-Xavier et al., 2010). Therefore it is possible that c-Jun/AP1 mediates the upregulation of 
DUSP5 seen in these cells. 
 
I found that DUSP5 and DUSP6 were transcriptionally upregulated when MCF7 wt cells were treated 
with 1 µM epirubicin over a timecourse. Their mRNA upregulation correlated with a decrease in ERK 
phosphorylation. The doxR cells are grown in and are resistant to at least 17 µM epirubicin, so 
comparable treatment with 1 µM epirubicin in these cells had no effect on cellular signalling (not 
shown). Knockdown of DUSP5 did not have a clear effect on epirubicin response in the sensitive MCF7 
wt cells, though possibly increasing resistance at lower concentrations. From the DUSP5 mRNA 
upregulation seen in doxR cells, I would expect the siDUSP5 transfection in MCF7 wt to sensitise the 
cells. Surprisingly, a decrease in FOXO3a total protein was seen over the epirubicin timecourse in MCF7 
wt. This may reflect global protein degradation as a result of cell death, although my data showed that 
FOXO reporter activity increased over 24 h of 1 µM epirubicin treatment. It may be interesting in future 
to investigate protein levels and activity of the other FOXO proteins in response to drug treatment. The 
upregulation of DUSP5 mRNA follows the kinetics of FOXO reporter activity upon epirubicin treatment, 
so FOXO3a regulation of this MKP in these cells still cannot be ruled out. 
 
As anthracycline treatment is strongly linked to ROS production (Chapter 1.8.1), and MAPKs and MKPs 
are known to be regulated by redox status and ROS level (Chapter 1.9), I also treated the MCF7 wt with 
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H2O2 to assess the effect on DUSP5 and DUSP6 expression and MAPK activity in response to oxidative 
stress. Treatment with 150 µM H2O2 affected activity of JNK and ERK, but not FOXO. Perhaps because 
FOXO was not activated, the cells continued to grow under this treatment, albeit slower. This H2O2 
treatment did not affect mRNA level of DUSP5. However, DUSP6 mRNA level dramatically increased by 4 
h of treatment, before decreasing over the timecourse. The upregulation could explain the decrease in 
p-ERK level seen at 8 h. These data reflect published work from ovarian cancer cells. H2O2 treatment 
resulted in DUSP6 degradation by the proteasome (Chan et al., 2008). 
 
I also overexpressed FLAG-DUSP5 and DUSP6 constructs in MCF7 wt. My hypothesis was that if these 
MKPs were contributing to doxorubicin/epirubicin-resistance in doxR, their overexpression in the 
sensitive cells would also increase resistance. As for the DUSP5 knockdown, I saw a possible increase in 
resistance at low epirubicin concentrations, but the increase in EC50 was slight. Overexpression of both 
constructs in MCF7 followed by Western blotting confirmed that these MKPs are able to 
dephosphorylate ERK in MCF7. I was surprised that FLAG-DUSP5 seemed to be much less efficient at this 
than DUSP6, since DUSP5 is considered to have higher intrinsic activity (Mandl et al., 2005). This may 
reflect interference from the FLAG tag. Importantly, DUSP5 and DUSP6 overexpression was also 
associated with decreased p-JNK level, and to a lesser extent p-p38 level, particularly for DUSP5. DUSP5 
is thought to be ERK-specific, and so should not act against the other MAPKs (Keyse, 2008). DUSP6 on 
the other hand, though mainly specific for ERK, has been reported as being able to partially (removing 
the p-Tyr residue only) dephosphorylate exogenous p38 in HEK293 cells (Zhang et al., 2011 c). However, 
my results did not show a clear downregulation of p-p38 in response to DUSP6 overexpression, 
especially compared to the reduction in p-ERK. I suggest that overexpression of FLAG-DUSP5 and DUSP6 
resulted in upregulation/stabilisation of other MKPs or MAPK-targeting phosphatases. Because of the 
multiple pathways affected by FLAG-DUSP5 or DUSP6 overexpression, these results cannot be 
considered as contributing to my knowledge of ERK’s role in drug resistance in MCF7. 
 
Due to the prevalence of feedback loops in FOXO3a activities (e.g. PI3K signalling; SIRTs and NAD 
metabolism; insulin signalling), I was interested to see whether modulation of ERK activity via DUSP5 
and DUSP6 affected FOXO3a. Knocking down of endogenous DUSP5 appeared to reduce FOXO3a protein 
and mRNA level, and downregulated FOXO reporter activity. These results were in conjunction with an 
increase in p-ERK, and are consistent with published data showing ERK-mediated inhibition and 
degradation of FOXO3a (Yang et al., 2008 b; Brenkman et al., 2008). However, I also observed possible 
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downregulation of FOXO3a and FOXO activity when FLAG-DUSP5 or DUSP6 were overexpressed. This 
may be a response to the loss of JNK activity, as it has been reported to increase FOXO3a stability and 
activity (Shen et al., 2010) (Chapter 1.11.2.2). 
 
Overall, my results represent an investigation into the role of DUSP5 and DUSP6 in drug resistance that 
can be expanded upon in future. Although DUSP6 has previously been linked to drug resistance (Chapter 
3.1), DUSP5 is less well understood in cancer. I have found that it is upregulated at mRNA level in a 
doxorubicin/epirubicin-resistant breast cancer cell line. I also found that JNK is hyperactive in these cells, 
suggesting that it no longer induces apoptosis here, potentially because of the loss of FOXO3a. Further 
research into DUSP5 and DUSP6 in breast cancer may be informative and contribute to better 
understanding of the regulation of MAPKs in drug resistance and advanced cancer. 
 
3.3.1 Future work 
 
To further investigate the roles of DUSP5 and DUSP6 in breast cancer and drug resistance, I would first 
develop working antibodies against the endogenous proteins. This would enable us to study their 
regulation more closely. Regarding possible transcriptional regulation of DUSP5 and DUSP6 by FOXO3a 
in breast cancer cells, I would like to clone proximal promoter regions from both genes for luciferase 
assay. These constructs could also contribute to design of possible ChIP assays to detect FOXO3a binding 
to DUSP5 or DUSP6 promoters. It is also possible that FOXO3a could regulate MKPs indirectly via its 
regulation of miRNAs; bioinformatics methods can initially be used to investigate this possibility. In the 
meantime, my first experiment would be to optimise knocking down of FOXO3a and possible multiple 
simultaneous FOXO knockdowns. Once able to reliably control the expression of endogenous FOXOs, I 
would be able to investigate the effects of loss of FOXO both at basal level and after treatment with 
epirubicin or H2O2. 
 
Considering DUSP6’s various links to tumorigenesis and resistance, I hope to knock down DUSP5 and 
DUSP6 expression in the doxR cells. These cells are not easily transfected so specialised transfection 
reagents may be required. If necessary, viral transduction with shRNA constructs could be tried. I would 
also like to continue the knockdown work in MCF7 wt, repeating the DUSP5 knockdown and also 
transfecting with siDUSP6. 
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4.1 INTRODUCTION 
 
The field of metabonomics has developed following the relatively recent interest in “omics” 
methodologies, including genomics, transcriptomics, lipidomics, proteomics, metabonomics (Roessner 
and Bowne, 2009; Davis et al., 2011). These all aim to analyse entire sets (“global” measurement) of 
certain classes of molecule. For example, metabonomics is used to study the entire set of metabolites in 
a system, called the metabolome (Atherton et al., 2006). Metabonomics is also known as metabolomics: 
although the two names initially described distinct methodologies, they are now used interchangeably 
(Zhang et al., 2011 a). 
 
While traditional metabolite analysis is based around measurement of previously chosen target 
molecules, metabonomics can instead be non-targeted, involving simultaneous measurement then 
identification of as many metabolites as possible within a biological sample (Roessner and Bowne, 
2009). Multivariant and pattern recognition data analysis is used to interpret the results. This is known 
as metabolic profiling. Flux through different metabolic pathways can be studied directly using stable 
isotope labelling (Bennett et al., 2008; Zhang et al., 2011 a). 
 
In cancer, it is hoped that metabolic profiling will lead to new clinical methods for detection, staging and 
treatment (Spratlin et al., 2009), as well as revealing novel drug targets. Metabolic biomarker discovery 
is a major focus of much metabonomic work (Merz and Serkova, 2009). For example, increased urine 
sarcosine has been suggested as a marker for prostate cancer that is not also induced by benign 
prostatic hyperplasia (Sreekumar et al., 2009). Metabonomic analyses of breast cancer cell lines and 
clinical samples have found that compared to non-transformed cells the PPP is upregulated, as is 
glycolysis and levels of choline metabolites (Oakman et al., 2011). 
 
The main physical methods used in metabonomics are mass spectrometry (both gas chromatography 
and liquid chromatography) and nuclear magnetic resonance (NMR) spectrometry (Dunn et al., 2011). 
These are complementary and can be combined to maximise the number of metabolites profiled. NMR 
spectroscopy uses the spin property of certain nuclei, such as 1H or 13C, to obtain information on its 
chemical environment (Mayr, 2008). The sample is held in a magnetic field, and specific radio frequency 
pulses are applied. The recorded signal, a “free induction decay”, is based on nuclei returning to their 
original energy population states, and molecular motion in the sample. Free induction decays, in the 
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time domain, can be Fourier transformed into spectra. Spectral signals are shown as peaks, and are 
separated by chemical shift (δ, ppm), which represents the nuclei’s environment (mostly resulting from 
the electron density experienced by each nucleus). Depending on the other nuclei connected nearby 
within the molecule (usually within three bonds), the peaks will have characteristic “splitting” patterns. 
This can be used to help peak assignment and structural determination. The biggest problem with NMR 
is overlap of peaks arising from different metabolites, although this can be improved on by using 2D 
rather than 1D NMR (Ludwig and Viant, 2010). 
 
FOXO3a is known to regulate the expression of several metabolic enzymes, in different metabolic 
pathways, as well as its supposed involvement in drug resistance. To investigate novel roles for FOXO3a 
in metabolic regulation and drug resistance of breast cancer cells, I wanted to use metabonomics to 
compare the metabolic profiles of MCF7 wt cells and the doxorubicin/epirubicin-resistant doxR cells. I 
hoped that this would contribute to my understanding of the development of drug resistance in these 
cells, and how this could be treated. I decided to use NMR spectroscopy rather than mass spectrometry 
as it is possible to measure metabolites more directly, without separation or derivatisation. 
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4.2 RESULTS 
4.2.1 Comparison of MCF7 wt and doxR extracellular metabolites 
 
To better understand the doxorubicin/epirubicin-resistance of the doxR cells I decided to investigate 
metabolic changes in this cell line. MCF7 wt and doxR cells were seeded into 6 cm dishes with equal 
amounts of fully supplemented DMEM. Cells and media were quenched and harvested at 24 and 48 h 
post-seeding for both cell lines. Unfortunately, was only able to perform this experiment once; three 
replicates were obtained for each condition but from one biological repeat. I consider these results a 
starting point for further investigation. Methanol harvesting was used rather than trypsin as it provides 
a more accurate picture of cellular metabolites; it is quicker and does not cause cells to be stressed 
before quenching (Teng et al., 2008). Scraped cells in methanol were dried using a speedvac. The 
reference compound TSP was added to the media samples. Metabolites from the cell pellets were 
extracted using a chloroform/methanol mixture. The aqueous fraction was freeze dried before 
reconstitution in TSP-containing phosphate buffer. I did not use the organic fraction as most of the small 
metabolites of interest (e.g. amino acids, sugars) are found in the aqueous extract. 
 
I used one dimensional 1H (proton) NMR spectrometry to acquire data from the samples. This nucleus 
does not require prior enrichment of specific isotopes. I chose to use a CPMG pulse sequence for 
acquisition. This sequence is commonly used for metabonomic experiments as it minimises contribution 
from larger molecules such as contaminating proteins or lipids. These give broad signals which can be 
suppressed for cleaner background and baseline when investigating small molecule metabolites 
(Beckonert et al., 2007). Spectra were normalised by median fold change. I first analysed the spectra 
from the media samples (Figure 4.1, Figure 4.2). 
 
Visual inspection of the spectra suggested that many differences between conditions were present. 
Extensive pH-induced shifting of resonances was observed (for example, the glutamine or alanine 
resonances labelled in Figure 4.1). Ethanol resonances were apparent, which were disregarded in 
analysis. I integrated as many separate resonances as possible. Some resonances arose from the 
presence of multiple metabolites, or overlapped so that they could not be resolved. I was able to assign 
resonances arising from 19 separate metabolites in the media spectra (Table 4.1). Note that none of 
these assignments has been confirmed by separate experiments, such as spiking the putative metabolite 
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into the sample. The majority of the assigned metabolites are included in fully supplemented DMEM 
medium (Supplemental Table 7.1). However, acetate, alanine, formate, glutamate and lactate were also 
assigned. I assume that these metabolites were secreted by the cells. 
 
To investigate the metabolites with the biggest changes between conditions/groups, I used Principal 
Component Analysis (PCA), a method of multivariant analysis. The areas of all the peaks that I identified 
were integrated, and this data was used for the analysis, essentially binning the spectra by 
peak/metabolite (Figure 4.3). The scores plot shows the separation between the binned spectra from 
the different media samples. PCA is an unsupervised statistical method; the different groups were 
coloured for clarity. This plot shows that the PCA model separated both cell line and timepoints. To see 
which metabolites were contributing most to the separation, I looked at the loadings plot. It was clear 
that the most important metabolites in the model were glucose and lactate. Other metabolites that 
looked to be driving separation in the model were formate, acetate, and pyruvate. 
 
I then looked more closely at differences in extracellular metabolite levels by plotting the integrated 
peaks as bar charts (Figure 4.4). Glucose in the media significantly decreased from 24 to 48 h, while 
lactate significantly increased for both cell lines (p<0.05). Testing for differences in integrated peak 
values between the cell lines at 24 h using t test (unpaired, 2-tailed) revealed significant differences in 
amount of extracellular lactate (p<0.0001) and glucose (p<0.005). The doxR cells had apparently 
secreted more lactate and taken up more glucose than the MCF7 wt cells. 
 
I found significantly more acetate in the medium from doxR cells at 24 h than MCF7 wt cells (t test, 
p=0.01). Acetate was thought to have been secreted into the medium, and indeed a (non-significant) 
increase was seen from 24 to 48 h for the MCF7 wt media (Figure 4.5). However, no change was seen 
between timepoints for the doxR cells. For pyruvate and formate, I was interested to find that there 
were only small differences (non-significant; ANOVA) between pyruvate or formate levels in media from 
MCF7 wt cells across timepoints (Figure 4.5). However, the media from doxR cells had significantly less 
pyruvate than media from MCF7 wt at 24 h (ANOVA; p<001), suggesting increased uptake, while also 
having significantly more formate (ANOVA; p<001) implying upregulation of secretion in those cells. 
 
Due to the published data suggesting altered glutamine metabolism in cancer, I also investigated 
whether there were differences in extracellular levels of glutamine and its derivative, glutamate. I did 
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not find differences in the amount of glutamine in the media between MCF7 wt and doxR cells, although 
there was a slight (non-significant; ANOVA) decrease at 48 h for both cell lines, suggesting it had been 
taken up by the cells, as expected (Figure 4.6). There were also no significant differences (ANOVA) 
between groups for extracellular glutamate levels, though t testing revealed that the slightly higher 
amount of glutamate at 24 h in media from doxR cells compared to MCF7 wt was significant (p<0.05). 
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Figure 4.1 Annotated spectra from media samples, up to 5 ppm. All the MCF7 wt and doxR full resolution spectra are shown overlaid. Blue = 
MCF7 wt 24h, green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. The largest and best separated peaks are annotated. Branched-chain 
amino acids are isoleucine, leucine and valine. Spectra were normalized to TSP (not shown). 
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Figure 4.2 Annotated spectra from media samples, post water peak. All the MCF7 wt and doxR full resolution spectra are shown overlaid. Blue 
= MCF7 wt 24h, green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. The largest and best separated peaks are annotated. Branched-
chain amino acids are isoleucine, leucine and valine. Spectra were normalized to TSP (not shown). This figure is in the same scale as Figure 4.1. 
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Metabolite 
Acetate 
Alanine 
Arginine 
Choline 
Formate 
Glucose 
Glutamate 
Glutamine 
Histidine 
Isoleucine 
Lactate 
Lysine 
Methionine 
myo-Inositol 
Phenylalanine 
Pyruvate 
Threonine 
Tyrosine 
Valine 
 
 
 
 
 
 
 
 
 
 
Table 4.1 List of metabolites assigned to resonances in media samples. Metabolites listed in 
alphabetical order. Those listed in italics are not part of the DMEM formulation. 
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Figure 4.3 Multivariant analysis of media samples. Spectra were binned by integrated peaks. PCA 
analysis was used to investigate differences between the groups. Top: scores plot. Blue = MCF7 wt 24h, 
green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. Bottom: loadings plot. Component 1 vs 
component 2 is shown. I was not able to assign those labelled with numbers; they are instead labelled 
with their ppm. 
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Figure 4.4 Integrated resonances of glucose and lactate in media samples. Glucose (A) and lactate (B) 
resonances were integrated for all spectra. Bar charts show averaged values for each condition, 
normalized to MCF7 wt 24h. Spectral images are illustrative and not to scale. Statstical analysis was 
performed using ANOVA (p<0.05 *, p<0.001 ***). 
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Figure 4.5 Integrated resonances of acetate, pyruvate and formate in media samples. Acetate (A), 
pyruvate (B) and formate (C) resonances were integrated for all spectra. Bar charts show averaged 
values for each condition, normalized to MCF7 wt 24h. Spectral images are illustrative and not to scale. 
Statistical analysis was performed using ANOVA (p<0.05 *, p<0.01 **, p<0.001 ***). 
A 
B 
C 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Glutamine
w
t (
24
h)
do
xR
 (2
4h
)
w
t (
48
h)
do
xR
 (4
8h
)
0.0
0.5
1.0
1.5
F
o
ld
 d
if
fe
re
n
c
e
Glutamate
w
t (
24
h)
do
xR
 (2
4h
)
w
t (
48
h)
do
xR
 (4
8h
)
0.0
0.5
1.0
1.5
F
o
ld
 d
if
fe
re
n
c
e
Figure 4.6 Integrated resonances of glutamine and glutamate in media samples. Glutamine (A) and 
glutamate (B) resonances were integrated for all spectra. Bar charts show averaged values for each 
condition, normalized to MCF7 wt 24h. Spectral images are illustrative and not to scale. The peaks do 
not overlay due to differences in pH between samples. Statistical analysis was performed using ANOVA 
(p>0.05). 
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4.2.2 Differences between aqueous cell extracts from MCF7 wt and doxR cells 
 
I then looked further into metabolic differences between the cell lines by acquiring spectra from the 
aqueous cell extracts (Figure 4.7, Figure 4.8). These samples were obtained from the same experiment 
as the media samples. The CPMG pulse sequence was used as before. As for the media samples, 
multiple differences between the different groups were seen in the spectra. I was able to assign 
resonances to 24 different metabolites (Table 4.2). The resonances for creatine and phosphocreatine 
overlapped such that I integrated them together. Some resonances could not be differentiated between 
in these spectra, such as those which could have arisen from ATP or ADP, or from histamine or histidine. 
Again, these assignments have not been confirmed with further work. Although I am confident of the 
majority, the assignment of sarcosine is tentative.  
 
To find differences between the MCF7 wt and doxR cell extracts, I binned the spectra by integrated peak 
area and performed PCA analysis as before (Figure 4.9). In the scores plot, clear separation of cell types 
is seen. The model also separated the timepoints, but not as strongly as for the media samples. The 
separation by timepoint also appeared to be driven largely by glucose and lactate. At 48 h, extracts from 
both cell lines appeared to have more lactate and less glucose. The cells were not confluent by 48 h; I 
would not necessarily expect there to be large differences in intracellular metabolites. This could reflect 
alterations in glucose uptake or lactate secretion between the timepoints. Alternatively, it is possible 
that these metabolites are media contaminants in the cell extracts, perhaps bound to cell surface 
proteins at the point of harvesting (the cells were washed twice in PBS, so unbound metabolites should 
have been removed). 
 
I chose the top six assigned metabolites, excluding glucose and lactate, that were contributing most to 
the MCF7 wt and doxR separation in the PCA model for further investigation (I chose the largest/best 
separated resonance for those that appeared more than once in the spectra). The metabolites picked 
were (in ppm order) acetate, glutamate, glutamine, creatine and phosphocreatine (integrated together), 
taurine, and myo-inositol. I took the integrated peak areas for each metabolite and plotted them as bar 
charts. 
 
Comparing intracellular glutamine and glutamate levels between MCF7 wt and doxR (Figure 4.10), I 
found that the doxR cells contained significantly less glutamine than the MCF7 wt cells (ANOVA; p<0.01). 
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Conversely, there was significantly more glutamate in the doxR cell extracts (ANOVA; p<0.001). In the 
media samples, doxR had secreted slightly but significantly more acetate than the MCF7 wt cells by 24 h 
(Figure 4.5). I found that the doxR cell extracts contained significantly (ANOVA; p<0.001) less acetate 
than extracts from MCF7 wt (Figure 4.11). More intracellular taurine was found in MCF7 wt cells than 
doxR (ANOVA; p<0.001) (Figure 4.11). The doxR cells contained significantly more creatine and 
phosphocreatine than the MCF7 wt cells (ANOVA; p<0.001) (Figure 4.12). Finally, I found significant 
differences in myo-inositol levels (Figure 4.12). Extracts from MCF7 wt cells had much less myo-inositol 
(ANOVA; p<0.001); in fact no peak was visible in these spectra. 
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Figure 4.7 Annotated spectra from aqueous cell extracts, up to 5 ppm. All the MCF7 wt and doxR full resolution spectra are shown overlaid. 
Blue = MCF7 wt 24h, green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. The largest and best separated peaks are annotated. 
Branched-chain amino acids are isoleucine, leucine and valine. PC = phosphocholine, GPC = glycerophosphocholine.  
150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Annotated spectra from aqueous cell extracts, post water peak. All the MCF7 wt and doxR full resolution spectra are shown overlaid. 
Blue = MCF7 wt 24h, green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. The largest and best separated peaks are annotated. 
Branched-chain amino acids are isoleucine, leucine and valine. GPC = glycerophosphocholine. This figure is in the same scale as Figure 4.7. 
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Metabolite 
Acetamide 
Acetate 
ADP or ATP 
Alanine 
Aspartate 
Choline 
Creatine and phosphocreatine 
Formate 
Glucose 
Glutamate 
Glutamine 
Glycine 
GPC 
Histidine or histamine 
Isoleucine 
Lactate 
myo-Inositol 
PC 
Phenylalanine 
Sarcosine (tentative) 
Succinate 
Taurine 
Tyrosine 
Valine 
 
 
 
 
 
Table 4.2 List of metabolites assigned to resonances in aqueous cell extract samples. Metabolites 
listed in alphabetical order. Creatine and phosphocreatine could not be resolved. ADP and ATP, and 
histidine and histamine could not be distinguished between as possible metabolites based on these 
spectra. 
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Figure 4.9 Multivariant analysis of aqueous cell extracts. Spectra were binned by integrated 
resonances. PCA analysis was used to investigate differences between the groups. Top: scores plot. Blue 
= MCF7 wt 24h, green = MCF7 wt 48h, red = doxR 24h, magenta = doxR 48h. Bottom: loadings plot. 
Component 1 vs component 2 is shown. Those labelled with numbers I was not able to assign; they are 
instead labelled with their ppm. 
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Figure 4.10 Integrated resonances of glutamine and glutamate in aqueous extracts. Glutamine (A) and 
glutamate (B) resonances were integrated for all spectra. Bar charts show averaged values for each 
condition, normalized to MCF7 wt 24h. Spectral images are illustrative and not to scale. Statistical 
analysis was performed using ANOVA (p<0.01 **, p<0.001 ***). 
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Figure 4.11 Integrated peaks of acetate and taurine in aqueous extracts. Acetate (A) and taurine (B) 
resonances were integrated for all spectra. Bar charts show averaged values for each condition, 
normalized to MCF7 wt 24h. Spectral images are illustrative and not to scale. Statistical analysis was 
performed using ANOVA (p<0.01 **, p<0.001 ***). 
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Figure 4.12 Integrated peaks of creatine and phosphocreatine, and myo-inositol in aqueous extracts. 
Creatine and phosphocreatine (A) and myo-inositol (B) resonances were integrated for all spectra. Bar 
charts show averaged values for each condition, normalized to MCF7 wt 24h. Spectral images are 
illustrative and not to scale. Creatine and phosphocreatine could not be resolved separately and were 
integrated together. Statistical analysis was performed using ANOVA (p<0.001 ***). 
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4.2.3 FOXO3a knockdown did not affect metabolites 
 
My previous experiments have shown that the doxR cells have a low level of FOXO3a protein (Chapter 
3.2.1). I wished to investigate FOXO3a’s contributions to the metabolic differences between the MCF7 
wt and drug resistant doxR cell lines by knocking down FOXO3a. Knockdown was performed as before 
(Chapter 2.3.2). After 48 h of transfection, media samples were taken, and the cells were quenched and 
harvested with methanol as described in Chapter 2.10.1. The experiment was performed three times 
over separate days with one replicate per experiment (n=3). The media samples and dried cell pellets 
were prepared for NMR by C-H Lau, as described in Chapter 2.10.2. As before, I used 1D 1H NMR 
spectroscopy with the CPMG pulse sequence to acquire spectra from media and aqueous cell extract 
samples. These spectra were obtained by C-H Lau. 
  
Visual inspection did not reveal any obvious differences in spectra from siFOXO3a samples compared to 
ns samples (Figure 4.13, Figure 4.15). To look for differences in signals between the ns and siFOXO3a 
groups, I used correlation-covariance plots. These were created in MATLAB from the full resolution (not 
binned) spectra. The covariance of the spectra is shown by the direction and magnitude of the signals. 
The colours projected onto the plot indicates the correlation of the covariance with the group (R2). Dark 
blue indicates that the covariance is not correlated with the group (ns or siFOXO3a), while red shows a 
high correlation. 
 
For the media samples, only half of two resonances were coloured orange-red, at around 1.2 ppm and 
3.6 ppm (Figure 4.13). These signals were assigned to ethanol. This almost certainly reflects usage of 
70% ethanol for sterilization of surfaces during cell culture, and this metabolite was ignored in 
subsequent analysis. Analysis of particular peaks was performed by integration of the appropriate 
resonance. Despite seeding the same number of cells per dish for each experiment, strong differences 
were seen between experiments, suggestive of cell number differences. For example, the pairs of ns and 
siFOXO3a spectra in each experiment had different amounts of extracellular glucose and lactate. 
However, no significant differences were found between groups (ns vs FOXO3a) for these metabolites 
(Figure 4.14). I therefore concluded that there was no difference in extracellular metabolite levels from 
cells transfected with siFOXO3a.  
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Cell culture media represents a cumulative effect of metabolite take up and secretion over the time 
period of the experiment. Cell extracts give more of a snapshot of metabolite levels at the point of 
harvesting/quenching. Using the same correlation-covariance plotting method, I looked for differences 
in resonances between the siFOXO3a and ns groups in aqueous cell extracts (Figure 4.15). I found three 
orange signals that appeared to be higher in siFOXO3a spectra. The singlet peak at 1.92 ppm was 
assigned to acetate, but I was not able to assign the peaks at 2.95 and 3.87 ppm. The peaks were 
integrated and the values compared using the t test (Figure 4.16). No significant differences between 
results from siFOXO3a and ns were found for these signals (n>0.05), although there may have been 
slightly more acetate in the siFOXO3a cells. I also integrated and tested all the other well resolved peaks 
in the cell extract spectra (not shown). No significant differences were found between the two groups. 
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Figure 4.13 Media samples spectra and analysis for siFOXO3a. Full resolution spectra from ns and 
siFOXO3a media samples were plotted together after processing and normalisation (top). Red = ns, blue 
= siFOXO3a. Correlation-covariance plot (bottom). Signal direction and magnitude relates to the 
covariance of the spectra. Projected colours show the correlation of the covariance with the class (R2). 
Dark blue indicates no correlation between the signal size and direction and the group, red shows a 
high correlation. Both top and bottom plots show same ppm range. 
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Figure 4.14 Integrated resonances of glucose and lactate from siFOXO3a media samples. Glucose (A) 
and lactate (B) resonances were integrated, averaged, and normalised to ns. Graphs show mean and 
SEM of three repeats. Statistical analysis was performed using unpaired t test (p>0.05). 
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Figure 4.15 Aqueous cell extracts spectra and analysis for siFOXO3a. Full resolution spectra from ns 
and siFOXO3a aqueous cell extract samples were plotted together after processing and normalisation 
(top). Red = ns, blue = siFOXO3a. Correlation-covariance plot (bottom). Signal direction and magnitude 
relates to the covariance of the spectra. Projected colours show the correlation of the covariance with 
the class (R2). Dark blue indicates no correlation between the signal size and direction and the group, 
red shows a high correlation. Both top and bottom plots show same ppm range. 
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Figure 4.16 Integrated resonances of acetate and two unassigned resonances in siFOXO3a aqueous 
extracts. The resonances were integrated and normalised to ns. Graphs show mean and SEM of three 
repeats. Statistical analysis was performed using unpaired t test (p>0.05). 
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4.3 DISCUSSION 
 
Firstly, I did not find any significant differences in extracellular or intracellular metabolites between cells 
transfected with siFOXO3a or control siRNA. A non-significant increase in acetate was seen in the 
siFOXO3a cells. I expected to see at least increased glycolysis due to a reduction in FOXO-mediated 
inhibition of Myc (Chapter 1.11.3). Most differences seen between spectra in fact related to the three 
experimental repeats. Despite counting cells for seeding, the spectra showed differences in media 
glucose/lactate which generally reflects differences in cell number. It is likely that the number of cells 
seeded for the replicates was not in fact consistent. In previous experiments shown in this work, 
FOXO3a knockdown in MCF7 wt had minimal effects (Figure 3.13, Figure 5.2). The lack of metabolic 
changes seen here may also reflect ineffective knockdown of FOXO. Again, redundancy between FOXO 
members could contribute to this. Unfortunately I was not able to try knocking down all FOXOs 
simultaneously. 
 
A number of publications have reported alterations in metabolism in metastatic or drug resistant cancer 
cells (Griffin and Shockcor, 2004; Merz and Serkova, 2009). I was interested to compare metabolic 
profiles of MCF7 wt and the doxorubicin/epirubicin-resistant derivative line doxR. I hoped to find 
differences in metabolites that would reveal novel metabolic changes in doxorubicin/epirubicin 
resistance, hopefully leading to new drug targets or treatment possibilities. It should be noted that a 
similar study, using 1H and 31P NMR to compare drug-sensitive and doxorubicin-resistant MCF7 cell lines, 
has previously been published (Kaplan et al., 1990). However, the authors only analysed a small subset 
of metabolites. 
 
I analysed both cell culture media and aqueous cell extracts. I was able to assign 19 metabolites in the 
spectra from media samples and 24 metabolites for the aqueous cell extracts, although some 
resonances were not well separated. With the exception of the sarcosine assignment (a singlet with no 
other resonances apparent in the spectra), I am confident of the assignments as these metabolites are 
commonly seen and have been confirmed in similar media/cell extract spectra. If this work was 
continued the metabolites could be formally confirmed by comparison to reference spectra or by spiking 
of reference compounds into the samples. For both data sets I used multivariant analysis to find the 
metabolites with the most significant differences between cell lines. Note that some unassigned 
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resonances also contributed considerably to the PCA models (Figure 4.3, Figure 4.9). I did not look into 
these in this study but future work even with the same samples may be able to investigate further. I 
chose a shortlist of seven assigned metabolites from the media samples and six from the cell extract 
samples. 
 
The extracellular metabolites showing the biggest disparity between the cell lines were glucose and 
lactate. Glucose was taken up and lactate was secreted over the timepoints tested, but the doxR cells 
both consumed significantly more glucose and released significantly more lactate. This change is 
consistent with previously published data using doxorubicin-resistant MCF7 (Kaplan et al., 1990), and 
implies an increase in glycolysis/glycolytic phenotype. Other drug-resistant cancer cells have been 
recorded as being glycolytic. For example, knockdown of the glycolytic enzyme LDH A in taxol resistant 
breast cancer cells, where it was overexpressed, resulted in resensitisation to taxol (Zhou et al., 2010). A 
glycolytic metabolic phenotype has also been proposed as a marker for imatinib resistance in chronic 
myelogenous leukaemia (Kominsky et al., 2009). The doxR cells also took up significantly more pyruvate 
from the media than the parental drug-sensitive cells. Increased uptake of pyruvate is consistent with 
the more glycolytic behaviour of these cells rather than oxidative phosphorylation. Pyruvate can be used 
to generate acetyl-CoA for the TCA cycle. Expression of one enzyme involved in this process, PDK1, has 
been linked to drug resistance in colon cancer cells (Lu et al., 2011). 
 
Significant differences were seen in basal intracellular levels of glutamine and glutamate between the 
MCF7 wt and doxR. The doxR cells contained significantly more glutamate and significantly less 
glutamine. I did not see any difference in glutamine levels between media from each cell line, possibly 
due to the high concentration of glutamine provided. I am unable to infer anything about relative 
glutamine uptake levels from these data alone, as glutamine is also secreted. However, it is clear that 
there is a net uptake of glutamine from 24 to 48 for both cell lines (Figure 4.6). In the media samples, 
the doxR appeared to have secreted more glutamate than the MCF7 wt, though the difference was not 
significant. Glutamate secretion from cancer cells is a known occurrence, including from breast cancer 
cell lines (Sharma et al., 2010). It is thought that glutamate signalling may contribute to cancer cell 
growth by activating pathways such as ERK (DeBerardinis and Cheng, 2010). If this is the case, it would 
make sense that the more transformed doxR cells may upregulate glutamate secretion. It should be 
noted that 1D 1H NMR is not ideal for assaying glutamine and glutamate; the resonances for both 
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metabolites are similar and overlap is seen, especially as the resonances are multiplets. Future work in 
this area would benefit from acquisition of 2D spectra to reduce overlap, or possibly using mass 
spectrometry. 
 
Alterations in the other metabolites chosen for analysis are less quickly interpreted. In future, I would 
like to not only repeat this experiment, including with other cell lines, but also perform metabolic flux 
analysis to better understand the metabolic pathways used. These data are snapshots of net metabolic 
change in the cells. That said, they can provide interesting starting points for further understanding of 
the doxorubicin-resistance phenotype of the doxR and for further investigation. 
 
A notable difference that I uncovered between the two cell lines is that while spectra from the doxR cell 
extracts showed a clear myo-inositol resonance, this peak was essentially not seen in the MCF7 wt 
extract spectra (Figure 4.12). Interestingly, a decrease in myo-inositol concentration in prostatic 
secretion may be a marker for prostate cancer (Serkova et al., 2008). I did not find any differences 
between cell lines for extracellular myo-inositol (note that it is included in the DMEM formulation), 
although unfortunately there was slight overlap by another resonance (Supplemental Figure 7.2). The 
main stereoisomer of inositol, a cyclohexane ring with six hydrogens substituted for –OH groups, myo-
inositol is a key component of PtdIns, and is therefore important in PI3K/Akt signalling. The PtdIns(4,5)P2 
compound (generated in part by PTEN from PtdIns(3,4,5)P3) can also be split into two further signalling 
molecules, 1,2-diacylglycerol and inositol(1,4,5)P3 (IP3) (Monserrate and York, 2010). IP3 can be further 
modified into other inositol polyphosphate and pyrophosphate forms, some of which have also been 
linked to cellular signalling and activity (Chakraborty et al., 2011). For example, IP6 is a known 
antioxidant (Vucenik and Shamsuddin, 2003). Notably, several of these phosphorylated inositol forms 
are able to inhibit PDK1 and Akt (Chakraborty et al., 2011). Inositol can be acquired from food, or 
synthesised de novo in the cell (Monserrate and York, 2010). The first step of de novo synthesis involves 
conversion of the glycolytic intermediate glucose-6-phosphate to inositol-1-phosphate. The enzyme that 
catalyses inositol-1-phosphate synthesis is thought to be a target gene of the transcription factor E2F1 
(Seelan et al., 2004). E2F1 is a cell cycle regulator with both proproliferative and apoptotic roles, but is a 
negative prognostic factor in breast cancer (Vuaroqueaux et al., 2007). In fact, E2F1 is known to be 
expressed at a higher level in the doxR cells (aka MCF7-epiR) compared to the MCF7 wt (Millour et al., 
2011). 
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I found that acetate metabolism was altered in the doxorubicin resistant cell line. Less intracellular 
acetate was found in the doxR cells than the MCF7 wt, while more extracellular acetate was also seen 
for doxR. DMEM media formulation does not contain acetate so I assume that this metabolite was 
secreted by the cells. However, most published work on acetate metabolism has focused on acetate 
uptake. Once in the cells, it is converted to acetyl-CoA that is used mainly for fatty acid synthesis rather 
than the TCA cycle (Plathow and Weber, 2008). Increased acetate uptake is seen in several cancer types, 
such as prostate cancer, which has been linked to expression of acetyl-CoA synthetase and fatty acid 
synthase (Yoshii et al., 2009; Vāvere et al., 2008). Labelled 11C-acetate has been used as a PET (positron 
emission tomography) tracer for cancer detection. Therefore, it is unclear why both MCF7 cell lines 
would secrete acetate into the media. Further investigation is required here. 
 
Creatine and phosphocreatine were found to be significantly elevated in the doxR cells. Unfortunately I 
am not able to resolve these metabolites separately due to resonance overlap, but visual inspection 
suggests a particular increase in phosphocreatine in the resistant cells. These data are consistent with 
previous findings in sensitive and doxorubicin-resistant MCF7 cells (Kaplan et al., 1990). Creatine and 
phosphocreatine are used in the cell for energy storage (Wyss and Kaddurah-Daouk, 2000). Creatine is 
phosphorylated by creatine kinase, which takes the phosphate from ATP. This reaction can be reversed 
when ATP is required. Creatine kinase is found overexpressed in several cancer types, including breast 
(Zarghami et al., 1995; Mooney et al., 2011). My findings suggest that the doxR cells have more energy 
available to them. 
 
Finally, I also found a reduction in intracellular taurine in the resistant cells. This is an amino acid that is 
not incorporated into proteins. This molecule has been linked to various cellular activities, including 
upregulation of antioxidants/direct ROS scavenging, and is thought to be cytoprotective (Schaffer et al., 
2010; Oliveira et al., 2010). Taurine has previously been found increased in breast and other cancers 
(Oakman et al., 2011; Griffin and Shockcor, 2004). Taurine cotreatment has been shown to increase 
doxorubicin retention in ovarian cancer cells, while reducing tumour size (Sadzuka et al., 2009). 
However, consistent with our results, low taurine concentration is thought to be a possible predictor of 
poor response to doxorubicin in breast tumours (Cao et al., 2011). 
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Overall, I have found some changes in metabolism in doxorubicin/epirubicin-resistance that are 
consistent with previously published work, and some that are less well understood. Future work in this 
area may help us to predict ways to resensitise drug resistant breast cancer cells, or suggest other 
inhibitors, drugs or antimetabolites that may be able to take advantage of the metabolic changes seen. 
 
4.3.1 Future work 
 
My first step in continuing this work would be to repeat the comparison experiment with MCF7 wt and 
doxR, as well as ideally including other drug resistant cell lines. As well as cell culture media and cell 
extracts, I would obtain spectra from unused media to confirm the metabolites present. Metabolite 
assignments would also be formally confirmed. To reduce overlap of resonances from different 
molecules, samples could be run using a 2D NMR method rather than just 1D. Again, these results would 
provide a starting point for possible metabolic alterations in the resistant cells. 
 
To observe pathway usage, flux analysis using labelled metabolites would be invaluable. In the case of 
difficult to resolve metabolites, such as glutamine and glutamate, mass spectrometry could also prove 
useful. Considering that I have found altered glutamine metabolism in doxR cells, I would particularly 
like to complement that work with NMR analysis, if not unbiased metabonomics/metabolic profiling. I 
would like to treat MCF7 wt and doxR with labelled glutamine, before harvesting at various timepoints. 
Separate labelling experiments with both carbon and nitrogen labels in glutamine would be informative.  
  
Finally, I would repeat the FOXO knockdown experiment in MCF7 wt to obtain a metabolic profile 
reflecting loss of FOXO, but transfecting with siRNA against all expressed FOXOs. Overexpression of a 
constitutively active FOXO3a could also be used.  
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5.1  INTRODUCTION 
 
Glutamine usage is known to be altered in cancer (Chapter 1.10.4). Glutamine uptake and metabolism is 
increased, where it contributes to protein synthesis, nucleotide synthesis, and the TCA cycle, as well as 
amino acid uptake (Figure 1.3). Glutamine availability has been linked to regulation of growth, 
apoptosis, autophagy, and inflammation. 
 
Glutamine is thought to protect against apoptosis. This is partially due to its use in the production of the 
antioxidant glutathione (Chang et al., 2002; Fuchs and Bode, 2006). In MDA-MB-231 breast cancer cells, 
the unexpected cytostatic effect of tamoxifen treatment was found to be dependent on decreased 
antioxidant capacity, caused by downregulation of glutamine uptake and reduction in glutathione level 
(Todorova et al., 2011). These cells are ER-negative and therefore this represents an ER-independent use 
of tamoxifen. Several glutathione-independent mechanisms of glutamine-mediated protection have also 
been determined. As well as the connections between glutamine, glutathione, ROS and MAPK activity, 
glutamine has been linked to inhibition of JNK/p38 signalling through ASK1. Glutamine was found to 
promote an inhibitory interaction between ASK1 and glutaminyl-tRNA synthetase in HeLa cells (Ko et al., 
2001). Deprivation of glutamine sensitised the cells to FasL-induced apoptosis. Glutamine also inhibits 
these MAPKs by inducing DUSP1 protein (Ko et al., 2009). Glutamine treatment has been shown to 
downregulate the expression of the pro-apoptotic transcription factor Sp3 (Ban and Kozar, 2010). In 
MEFs, glutamine treatment induced HSP70 expression (Peng et al., 2006). HSP70 is a marker for 
hepatocellular carcinoma, and is also overexpressed in other tumour types (Galluzzi et al., 2009; Shin et 
al., 2011). It is a negative prognostic factor, likely due to its anti-apoptotic activities (Jego et al., 2010). 
The presence of glutamine is known to inhibit canonical NFκB activity (Brasse-Lagnel et al., 2009), 
thereby reducing inflammation. Glutamine is also thought to indirectly regulate mTORC1 activity, 
through its use in leucine/amino acid import (Chapter 1.10.4). However, low glutamine availability has 
been linked to both up- and downregulation of autophagy through mTORC1 (Nicklin et al., 2009; 
Sakiyama et al., 2009). 
 
In cancer, glutamine contributes to carbon metabolism via glutaminolysis, where glutamine is converted 
into glutamate then the TCA cycle intermediate α-ketoglutarate, via the enzymes glutaminase and 
glutamate dehydrogenase respectively (DeBerardinis and Cheng, 2010). The concept of glutamine 
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“addiction” has been developed in one laboratory to refer to cancer cells that rely on glutaminolysis for 
growth. For example, removal of glutamine from a glioma cell line resulted in death that was attenuated 
by the provision of α-ketoglutarate (Wise et al., 2008). This is therefore an acquired mechanism by 
which glutamine deprivation can contribute to cell death or growth inhibition by reducing availability of 
TCA cycle intermediates. This process may require Myc activity. Knockdown of Myc rescued glioma cells 
from glutamine-deprivation induced cell death, while activation of a Myc construct in non-transformed 
fibroblasts sensitised the cells to glutamine deprivation and caused apoptosis (Yuneva et al., 2007; Wise 
et al., 2008). Myc also promotes glutaminolysis by upregulation of glutaminase (Dang, 2010). 
 
Glutamine is known as a conditionally non-essential amino acid, because it can be synthesised from 
glutamate by GS (glutamine synthetase). The GS enzyme was first isolated, and the reaction scheme 
(glutamate + ammonia + ATP -> glutamine + ADP + Pi) determined, around the beginning of the 1950s 
(Greenberg and Lichtenstein, 1959). It has since been found to be extremely conserved throughout life 
(Kumada et al., 1993). In mammals, GS forms a homodecameric structure with 10 active sites (Krajewski 
et al., 2008). It is ubiquitously expressed, but its activity is particularly important in neurons, where 
glutamate is a signalling molecule, and in the liver, where it is involved in ammonia homeostasis (Long et 
al., 2010). Treatment with the GS inhibitor methionine sulfoximine is well known to cause seizures 
(Boissonnet et al., 2012). Three human patients with GS deficiency due to point mutations have also 
been reported, all of whom have suffered from seizures; two died as neonates (Häberle et al., 2006, 
2011). 
 
Despite glutamine metabolism consistently changing through tumorigenesis, expression of GS has not 
been extensively studied in cancer. In the liver, GS is usually expressed in only a few hepatocytes, but 
this restricted expression pattern is lost and GS is upregulated in hepatocellular carcinoma (HCC). GS is 
known to be directly upregulated downstream of β-catenin/Wnt signalling in the liver (Cadoret et al., 
2002). β-catenin is oncogenic in HCC (Zeng et al., 2007), and GS overexpression has been linked to β-
catenin activating mutations (Cieply et al., 2009). It has also been proposed as a marker for early HCC 
(Long et al., 2010; Shin et al., 2011). Conversely, in osteoblasts GS may be downregulated in response to 
Wnt signalling (Olkku and Mahonen, 2008). GS expression may also be a useful tool in distinguishing 
between different types of central nervous system tumours (Zhuang et al., 2011). 
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My metabonomic work found that the doxorubicin/epirubicin-resistant doxR cells contained less 
glutamine and more glutamate than the parental MCF7 wt cells (Chapter 4.3). I was therefore interested 
in investigating glutamine metabolism in these cell lines. My collaborator PJ Coffer also suggested to us 
that GS may be a target gene of FOXO3a (van der Vos, 2010). This would be a novel role for FOXO in 
glutamine metabolism. I wished to establish whether GS was regulated by FOXO3a in MCF7 breast 
cancer cells, as well as determining the effect of glutamine deprivation on these cells. I hoped to 
determine whether the apparently altered glutamine metabolism of the doxR cell line is relevant to 
cancer treatment. 
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5.2 RESULTS 
5.2.1 GS expression is regulated by FOXO3a 
 
Experiments performed by my collaborator, PJ Coffer, suggested that GS is a novel FOXO3a target gene 
(van der Vos, 2010). My first step was to confirm their finding in the DL23 cells, which were used by PJ 
Coffer’s group. Cells were treated with 200 nM OHT over a timecourse. An increase in GS protein level 
was seen at the 16 and 24 h timepoints (Figure 5.1). Analysis of mRNA level by RTq-PCR also showed a 
~25x increase in GS mRNA by 24 h of OHT exposure. 
 
To investigate regulation of GS in MCF7, I first knocked down FOXO3a using siRNA as before (Chapter 
3.2.3). I did not see a decrease in GS protein level by Western blotting (Figure 5.2), nor was there a 
definite decrease in mRNA level. Conversely, 24 h overexpression of FOXO3a(A3) in MCF7 wt did result 
in an increase of both GS protein and mRNA (Figure 5.3). To investigate more directly whether GS is a 
direct transcriptional target of FOXO3a, I wished to use luciferase reporter assays. The GS reporter was a 
kind gift from PJ Coffer, as were the mutated reporters (Gaunitz et al., 2001; van der Vos, 2010). The 
parental reporter spans the region -2530 to +150 of the rat GS proximal reporter. Cells were transfected 
with the GS reporter and increasing amounts of either the FOXO3a wt or FOXO3a(A3) constructs (or 
control plasmid), as described in Chapter 2.7. Unfortunately, I was unable to detect any light output 
using the GS reporter in MCF7 cells. I then tried HEK293 cells, known for their high transfection 
efficiency. A FOXO3a dose-dependent increase in GS reporter activity was observed, for the wt FOXO3a 
construct as well as for the constitutively active mutant (Figure 5.4). 
  
I was also given access to five mutated versions of the GS reporter. Each has a disruption in one of the 
five predicted FOXO binding sites within that sequence. Cells were transfected with 5 ng Renilla, 20 ng of 
one of the GS reporters, and 20 ng of control, FOXO3a wt or FOXO3a(A3) construct. Before 
normalization to the control transfection cells, the reporter activity for all versions of the GS reporter in 
response to the A3 FOXO3a mutant were similar (Figure 5.5A). However, cells transfected with the 
mut1, mut3, mut4 and mut5 reporters emitted noticeably more light from the FOXO3a control 
transfected cells (empty vector) than those cells transfected with the parental GS reporter or mut2. This 
may be due to recruitment of proteins directly to the mutated site, or overall changes in recruitment 
once FOXO3a is not able to bind. I therefore normalized the results for each reporter to the FOXO3a 
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control result (Figure 5.5B). It was then clear that aside from mut2, loss of any of the other four 
potential FOXO binding sites was sufficient to abrogate the reporter’s response to FOXO3a activity. This 
result suggests that FOXO3a is binding to the GS promoter region, and that the transcriptional 
upregulation seen is direct. 
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Figure 5.1 Treatment of DL23 cells with OHT upregulates GS mRNA and protein. DL23 cells were 
treated with 200 nM OHT over a timecourse. Western blotting was used to assess protein levels (A). 
RTq-PCR was performed using primers specific for GS (B). Graph shows mean and SEM of two 
independent experiments. Results are normalized to 0 h 
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Figure 5.2 Knockdown of FOXO3a does not affect GS expression. MCF7 wt cells were transfected with 
non-specific siRNA (ns), siFOXO3a of mock control (buffer). Cells were harvested 48 h post-transfection. 
Western blotting was used to determine protein levels (A). RTq-PCR was performed with primers 
specific for GS (B). Graph shows mean and SEM of three independent experiments. Results are 
normalized to mock. Statistical analysis using ANOVA did not find any significant differences (p>0.05). 
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Figure 5.3 Overexpression of FOXO3a(A3) upregulates GS. MCF7 wt cells were transfected with 5 µg 
control or FOXO3a(A3) construct. Cells were harvested for Western blotting 24 h post-transfection (A). 
RTq-PCR was also performed, using primers for GS (B). Graph shows mean and SEM of three 
independent experiments. Results are normalized to control transfection. Significance testing using 
two-tailed t test found no difference between control and FOXO3a(A3) groups (p>0.05). 
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Figure 5.4 Overexpression of FOXO3a increases GS reporter activity. 293 cells were co-transfected 
with 20 ng GS reporter, 5 ng Renilla and 0-20 ng FOXO3a wt or FOXO3a(A3). Cells were harvested 24 h 
post-transfection and reporter activity was determined using luciferase assay. Results shown are mean 
and SEM of three independent experiments, each with six replicates per condition. Significance testing 
was performed using ANOVA with Bonferroni’s post-test (p<0.05 *, p<0.001 ***). Results were tested 
for significance against the 0 ng condition for each FOXO3a plasmid, and are expressed as fold change 
compared to that condition. 
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Figure 5.5 Mutation of potential FOXO binding sites in the GS reporter affects response to FOXO3a 
overexpression. 293 cells were co-transfected with 20 ng parental or mutated GS reporter, 5 ng Renilla 
and 20 ng FOXO3a wt, FOXO3a(A3), or control plasmid. Cells were harvested 24 h post-transfection and 
reporter activity was determined using luciferase assay. Results shown are mean and SEM of two 
independent experiments, each with five replicates per condition. Results were normalized to Renilla 
only (A), and to Renilla then control (B). 
A 
B 
178 
 
 
5.2.2 Removal of extracellular glutamine increases GS activity and affects cell 
growth 
 
I then wanted to investigate the response of MCF7 wt cells to glutamine deprivation, based on the links 
between glutamine status and apoptosis. Cells were seeded, and the medium was replaced 24 h after 
seeding with either full DMEM or DMEM which had not been supplemented with glutamine. GS protein 
level increased gradually over time in cells grown in full DMEM (Figure 5.6A). However, in the glutamine-
free medium, there was a dramatic increase in GS protein. The increase in GS in the cells in full medium 
did not occur until 48 h. I also assessed in vitro GS activity, following the protocol in Chapter 2.8, in 
response to glutamine removal over a shorter timecourse (Figure 5.6B). Although the increase in GS 
protein level was consistent over the timecourse for both conditions, the GS activity fluctuated in cells 
treated with full DMEM. All cells were asynchronous. These fluctuations were not seen for cells treated 
with non-supplemented medium, where a consistent increase of GS activity was seen. 
 
As some published data have shown affected growth or death upon glutamine starvation, I performed 
SRB assays to assess cell growth. Cells deprived of extracellular glutamine grew slower than cells in full 
medium, but did not stop growing (Figure 5.7A). Because of the possible links between glutamine and 
FOXO3a regulation via JNK/p38 and NFκB signalling, I also used the 6xDBE reporter assay to investigate 
FOXO activity in glutamine-deprived cells. FOXO activity was apparently reduced over the timecourse, 
albeit not significantly (Figure 5.7B). The upregulation of GS protein seen on glutamine deprivation is 
unlikely to involve FOXO3a. 
 
As a counterpoint to the removal of glutamine, I also treated cells with additional glutamine for 24 h 
(Figure 5.8). This did not have any effect on GS protein level or cell growth. There was also no effect on 
total FOXO3a protein or total or phosphorylated Akt level. Note that the SRB assay was unfortunately 
not repeated. However, as no changes were seen using Western blotting, I am confident that the SRB 
result is likely to be reliable. 
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Figure 5.6 GS activity increases when glutamine availability is low. MCF7 wt cells were treated with 
fully supplemented medium or medium without added glutamine over 0-96 h. Western blotting was 
used to assess protein levels (A). MCF7 wt cells were treated as before for 0-48 h. GS activity assay was 
used to determine GS activity (B). Graphed data show mean and SEM of two independent experiments. 
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Figure 5.7 Lack of glutamine reduces growth rate and FOXO activity of MCF7 wt. MCF7 wt cells were 
treated with fully supplemented medium (complete) or medium without added glutamine from 0-96 h. 
Results were obtained using SRB assay (A). MCF7 wt cells were transfected with 45 ng 6xDBE and 5 ng 
Renilla. 16 h post-transfection, cells were treated with glutamine-unsupplemented medium. Cells were 
harvested together and reporter activity was determined using luciferase assay (B). Results shown are 
mean and SEM of three independent experiments, with three replicates per condition for (A) and six 
replicates per condition for (B). Significance testing for (B) was performed using ANOVA with 
Bonferroni’s post-test; no significant differences between groups was found. Results in (B) were 
normalized first to Renilla then to untreated cells for each timepoint. 
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Figure 5.8 Addition of excess glutamine does not affect MCF7 wt cells. MCF7 wt cells were treated 
with 0-25 mM glutamine for 24 h, in addition to the 4 mM in the complete medium. Western blotting 
was performed (A). Cells were treated with 0-25 mM glutamine for 0-72 h. Results were obtained using 
SRB assay (B). This graph shows mean and SEM of three replicates; from one experiment only. 
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5.2.3 Overexpression of GS does not restore growth rate in glutamine-deprived 
medium 
 
Reduction in growth due to reduced glutamine availability could reflect alterations in several pathways. I 
saw that GS protein was upregulated in this condition; perhaps the endogenous GS was not able to 
synthesise enough glutamine to meet demand. I generated a construct to overexpress FLAG-GS 
(described in Chapter 2.2.1.1) and transfected it into MCF7 wt (Figure 5.9). The FLAG-GS construct 
appeared as a double band at the expected 42 kDa. I am not sure of the identity of the second band, but 
it may demonstrate some kind of post-translational modification. GS activity assay was performed to 
confirm that the construct was functional (Figure 5.9B). A dose-dependent increase in activity was seen. 
Although no change in total FOXO3a was seen on FLAG-GS overexpression, there was a possible if very 
weak dose-dependent decrease in protein level of the FOXO3a target p27. 
 
I then transfected FLAG-GS into MCF7 wt, reseeded the cells and replaced the media with full DMEM or 
DMEM that had not been supplemented with glutamine. SRB assays showed that GS overexpressing 
cells still grew slower when deprived of glutamine (Figure 5.10). However, because the reduction in 
growth requires several days’ observation, transient transfection is not ideal. I therefore created a 
pooled cell line stably overexpressing GS, as described in Chapter 2.1.2. MCF7 wt cells were transfected 
with 5 µg GS or control plasmid (empty pCMV-14-FLAG vector) and selected using G418. After 4 weeks, 
the cells were pooled as the new cell lines wt-vector and wt-GS, for control and FLAG-GS transfected 
respectively. These cells were maintained in 0.5 mg/ml G418. Western blotting was used to confirm the 
GS overexpression (Figure 5.11). The level of GS mRNA was increased, as was in vitro GS activity. No 
change was seen in FOXO3a or p27 protein level. Cells were then seeded for SRB assay and treated with 
glutamine-supplemented or non-supplemented media (Figure 5.12). Again, the GS overexpressing cells 
grew slower when glutamine was not included in the culture medium. I also tested the stably GS 
overexpressing cell line to see if the extra GS affected epirubicin sensitivity, on the basis that glutamine 
has been shown to protect cells from apoptosis. These cells were as sensitive as the control cell line 
(Figure 5.13). 
 
The growth reduction seen for glutamine-deprived cells is therefore not due to lack of GS. I wondered if 
GS was not able to meet the required supply of glutamine due to limiting concentrations of glutamate 
183 
 
 
and/or ammonia. Addition of glutamate to MCF7 wt cells for 24 h did not affect protein levels of GS 
(Figure 5.14). However, cell growth was reduced just by exposure to glutamate (Figure 5.14B). Similar 
results were seen for ammonium hydroxide (NH4OH), although it did not affect cell growth as strongly 
(Figure 5.15).  
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Figure 5.9 FLAG-GS construct is active in cells. MCF7 wt cells were transfected with 0, 2, 4, 8, 10 µg 
FLAG-GS plasmid. Cells were harvested 48 h post-transfection. Western blotting was performed to 
confirm expression (A). GS activity assay was used to determine GS activity (B). Results shown are mean 
and SEM of two independent experiments, each with four replicates. 
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Figure 5.10 Transient overexpression of FLAG-GS does not prevent reduced growth rate on glutamine 
removal. MCF7 wt cells were reverse-transfected with 5 µg FLAG-GS or control plasmid. 16 h post-
seeding, cells were treated with fully supplemented medium (complete) or medium without added 
glutamine (without gln). Results were obtained using SRB assay. Results show mean and SEM of two 
independent experiments. 
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Figure 5.11 MCF7 wt cells stably overexpressing FLAG-GS. MCF7 wt cells were transfected with 5 µg 
FLAG-GS or control plasmid. Transfected cells were selected for using 1 mg/ml G418 treatment for 
three weeks. Cells were pooled to make wt-vector (control) and wt-GS cell lines, and maintained in 0.5 
mg/ml G418. Western blotting (A) and RTq-PCR (B) were used to confirm FLAG-GS expression. GS 
activity assay was also performed (C).  
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Figure 5.12 Stable overexpression of FLAG-GS does not restore growth rate after glutamine 
deprivation. MCF7 wt-derived stable cell lines wt-vector and wt-GS (stably expressing FLAG-GS) were 
treated with fully supplemented medium (complete) or medium without added glutamine (without 
gln). Results were obtained using SRB assay. Results show mean and SEM of three independent 
experiments. 
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Figure 5.13 Stable overexpression of FLAG-GS does not affect sensitivity to epirubicin. MCF7 wt-
derived stable cell lines wt-vector and wt-GS (stably expressing FLAG-GS) were treated with 0-100 µM 
epirubicin for 48 h. Results were obtained using SRB assay. Results show mean and SEM of three 
independent experiments. 
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Figure 5.14 Glutamate reduces growth rate of MCF7 wt cells. MCF7 wt cells were treated with 0-10 
mM glutamate for 24 h. Western blotting was used to assess protein changes (A). Cells were treated 
with 0-10 mM glutamate for 0-72 h. Results were obtained using SRB assay (B). Results show mean and 
SEM of two independent experiments. 
 
A 
B 
190 
 
 
 
  
0 20 40 60 80
0
100
200
300
400
500
0 mM
5 mM
10 mM
25 mM
Time (h)
G
ro
w
th
 (
%
 o
f 
0
h
)
Figure 5.15 NH4OH reduces growth rate of MCF7 wt cells. MCF7 wt cells were treated with 0-10 mM 
NH4OH for 24 h. Western blotting was used to assess protein changes (A). Cells were treated with 0-25 
mM NH4OH for 0-72 h. Results were obtained using SRB assay (B). Results show mean and SEM of two 
independent experiments. 
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5.2.4 Knockdown of GS reduces growth of MCF7 by limiting glutamine availability 
 
As overexpression of FLAG-GS did not affect cells, I decided to knock down endogenous GS by siRNA.  
Western blotting showed that the knockdown was successful (Figure 5.16). No change in total FOXO3a 
was seen. However, an increase in p27 protein was observed at the later timepoints. I investigated the 
72 h siGS timepoint further (Figure 5.17). RTq-PCR and Western blotting confirmed the GS knockdown. 
Again, no alteration in p-FOXO3a or total FOXO3a protein was seen. However, p27 was found to be 
upregulated at protein and mRNA level. SRB assays demonstrated that MCF7 wt cells transfected with 
siGS grew slower than cells transfected with control siRNA (Figure 5.18A). This reduction in cell growth 
was the same as the reduction seen for cells in glutamine-free medium (Figure 5.18B). Cells both 
knocked down for GS and deprived of extracellular glutamine grew slower again.   
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Figure 5.16 Knockdown of GS in MCF7 wt cells. MCF7 wt cells were transfected with non-specific siRNA 
(ns) or siGS. The mock control was cells treated with oligofectamine without siRNA. Cells were 
harvested at the indicated times post-transfection, and Western blotting performed. 
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Figure 5.17 Knockdown of GS for 72 h upregulates p27. MCF7 wt cells were transfected with non-
specific siRNA (ns) or siGS. The mock control was cells treated with oligofectamine without siRNA. Cells 
were harvested 72 h post-transfection. Western blotting was performed to assess protein levels (A). 
RTq-PCR was used with primers specific for GS (B) and p27 (C). Results show mean and SEM of two 
independent experiments. 
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Figure 5.18 GS knockdown reduces growth of MCF7 wt cells. MCF7 wt cells were transfected with non-
specific siRNA (ns) or siGS. The mock control was cells treated with oligofectamine without siRNA. 16 h 
post-transfection, cells were seeded into 96 well plates. 8 h later, cells had their media replaced with 
fresh fully supplemented medium (A), or treated with fully supplemented medium (complete) or 
medium without glutamine (without gln) (B). Results were obtained using SRB assay, and each shows 
mean and SEM of two independent experiments. 
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5.2.5 GS expression or glutamine availability does not affect autophagy in MCF7 wt 
cells 
 
Previous publications have linked glutamine availability to both increased and downregulated autophagy 
(Nicklin et al., 2009; Sakiyama et al., 2009). I therefore tested whether lack of glutamine affected 
autophagy in my MCF7 wt cells. I did not see any changes in LC3B protein (either form) in cells treated 
with DMEM not supplemented with glutamine (Figure 5.19A), or when GS was knocked down (Figure 
5.19B). Therefore glutamine availability is unlikely to be linked to autophagy in these cells. 
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Figure 5.19 Autophagy is not upregulated in MCF7 wt by glutamine deprivation. MCF7 wt cells were 
treated with fully supplemented medium (complete) or medium without added glutamine for 0-48 h, 
and harvested for Western blotting (A). Cells were transfected with non-specific (ns) siRNA, siGS, or 
mock control (buffer) and harvested 72 h post-transfection for Western blotting (B).  
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5.2.6 GS activity is inhibited by epirubicin and H2O2 
 
Glutamine has been associated with protection from various apoptosis-inducing conditions via a number 
of mechanisms. I found that GS expression is linked to glutamine availability in MCF7 wt cells. I therefore 
wondered about the effect of stressors on GS activity. I treated cells with 1 µM epirubicin or 150 µM 
H2O2 (Figure 5.20). Control cells were left untreated. Western blotting showed a steady increase in GS 
protein for the untreated and H2O2-treated cells, which was not seen with epirubicin treatment. The 
Western blot results were quantified using densitometry (labelled “density”) for comparison with the GS 
activity results Figure 5.20B-D). Again, I saw fluctuation in GS activity between timepoints. These 
changes in activity were most apparent in untreated cells. Lysates from untreated cells also had higher 
GS activity than epirubicin or H2O2-treated cell lysates. For H2O2, although the amount of total GS 
protein had more than doubled by 48 h, across the timecourse the GS activity was the same as 0 h, or 
had decreased (Figure 5.20D). 
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Figure 5.20 GS activity is reduced by treatment with epirubicin or H2O2. MCF7 wt cells were treated 
with 1 µM epirubicin, 150 µM H2O2, or left untreated. Cells were harvested at timepoints 0-48 h. 
Western blotting was performed to investigate total GS protein level (A). Blots were quantified with 
densitometry: untreated (B), 1 µM epirubicin (C) and 150 µM H2O2 (D). Data were normalized to 
tubulin, then to 0 h. Results shown are mean and SEM of two independent experiments. To determine 
GS activity, GS activity assay was used with 5 ug whole cell extract: untreated (B), 1 µM epirubicin (C) 
and 150 µM H2O2 (D). Results shown are mean and SEM of two independent experiments, each with 
four replicates. Data were normalized to 0 h. 
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5.2.7 GS is not expressed in doxR cells 
 
I have shown that MCF7 wt cells require GS activity for full growth, and that GS is partially inactivated by 
epirubicin treatment. I also confirmed that GS is upregulated by FOXO3a. I therefore investigated GS 
expression in doxR cells, which lack FOXO3a (Chapter 3.2.1) as well as containing less intracellular 
glutamine (Chapter 4.3). The doxR cells contained very low GS protein and mRNA levels (Figure 5.21). I 
then transfected the cells with the FOXO3a wt or FOXO3a(A3) construct (Figure 5.22). These results 
were not clearly defined. No increase in FOXO3a protein was seen, but more FOXO3a mRNA was found 
in cells transfected with the FOXO3a(A3) construct. The FOXO3a target gene p27 was strongly 
downregulated at mRNA level and also reduced at protein level. I did not observe any changes in GS 
protein level, but an increase in GS mRNA was seen for doxR cells transfected with the FOXO3a wt 
construct. It is not clear why the A3 mutant form of FOXO3a did not also cause an increase in GS mRNA. 
 
Since the doxR cells have low basal GS expression, I tested their response to glutamine deprivation. 
These cells did not upregulate or stabilise GS when treated with medium not supplemented with 
glutamine (Figure 5.23). SRB assays showed that prolonged exposure (beyond 72 h) to medium without 
added glutamine resulted in growth arrest (Figure 5.23B). It is possible that before 72 h, residual 
intracellular glutamine and/or trace glutamine from the serum enabled growth. 
 
I then transfected doxR cells with the FLAG-GS construct. Western blotting and GS activity assay 
confirmed that GS was overexpressed and was active (Figure 5.24). Cells expressing FLAG-GS had lower 
p27 protein level. SRB assay was used to investigate whether transient FLAG-GS overexpression in doxR 
could restore the growth defect caused by glutamine deprivation. I did not find any differences in 
growth between cells transfected with FLAG-GS or a control plasmid (Figure 5.24C). 
 
As the doxR cells were apparently unable to synthesise glutamine, I wondered if they were using 
autophagy to obtain this amino acid. Transfection with FLAG-GS did not affect LC3B modification in doxR  
(Figure 5.24A). The problems of reliably detecting autophagic activity have been much discussed 
(Klionsky et al., 2007). Western blotting for LC3B conversion is the simplest method, but I was concerned 
that the low transfection efficiency of the doxR cells may affect results if only a few cells actually 
contained FLAG-GS. I therefore used the GFP-LC3 transfection system. This plasmid was previously used 
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in this laboratory. It consists of LC3 fused to EGFP. Cells expressing GFP-LC3, when visualized with 
fluorescence microscopy, show GFP-positive puncta when undergoing autophagy. The doxR cells were 
seeded into chamber slides and 6 well plates, then co-transfected with GFP-LC3 and FLAG-GS. I hoped to 
score cells for autophagy that were expressing only GFP-LC3 versus cells that were expressing both 
proteins. Cells were harvested after 24 h for Western blotting to confirm that the transfection had 
worked (Figure 5.25). Cells in the chambers were fixed 24 h post-transfection, and stained with anti-
FLAG antibody (previously optimised) and DAPI. However, fluorescence microscopy looking at GFP-LC3 
showed that the transfection efficiency was extremely low, even lower than expected (Figure 5.26). The 
GFP transfected cells have been marked with circles on the Merged image. I did not find any cells 
positive for FLAG. This could be because of the low transfection efficiency or problems with the 
antibody, although it had been previously optimised. All the GFP-LC3 expressing cells that I found 
contained GFP puncta, although it is possible that if there were cells not undergoing autophagy, the 
diffuse expression may have been overlooked. Staining from two independent experiments was scored 
to quantify the GFP-LC3 transfection efficiency. I found that it was around 1%. 
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Figure 5.21 doxR cells have low basal GS expression. MCF7 wt and doxR cells were seeded then 
harvested after 24 h. Western blotting (A) and RTq-PCR with GS specific primers (B) were performed. 
Graphed data show mean and SEM of three independent experiments. Statistical analysis was 
performed using unpaired t test (p<0.05 *). 
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Figure 5.22 Overexpression of FOXO3a in doxR may upregulate GS mRNA. doxR cells were transfected 
with 5 µg control, FOXO3a wt or FOXO3a(A3) plasmids. Cells were harvested after 24 h. Western 
blotting (A) and RTq-PCR with FOXO3a (B), p27 (C) and GS specific primers (D) were performed. 
Graphed data show mean and SEM of two independent experiments. 
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Figure 5.23 GS is not upregulated in doxR when glutamine is not provided. doxR cells were treated 
with medium without supplemented glutamine for 0-96 h. Cells were harvested for Western blotting 
(A). doxR cells were treated with fully supplemented medium (complete) or medium without glutamine 
(without gln) (B). Results were obtained using SRB assay, and show mean and SEM of three 
independent experiments. 
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Figure 5.24 Expression of FLAG-GS in doxR doesn’t rescue growth in glutamine-free medium. doxR 
cells were transfected with FLAG-GS or control plasmid. Cells were harvested after 24 h. Western 
blotting (A) and GS activity assay (B) were used to confirm expression (A). doxR cells were reverse-
transfected with FLAG-GS or control, and treated with fully supplemented medium (complete) or 
medium without glutamine (without gln). Results were obtained using SRB assay (C). Graphed data 
show mean and SEM of two independent experiments. 
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Figure 5.25 Co-transfection of doxR with GFP-LC3 and FLAG-GS. doxR cells were transfected with GFP-
LC3, FLAG-GS, control, or both GFP-LC3 and FLAG-GS together. Cells were harvested 24 h post-
transfection for Western blotting. 
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Figure 5.26 GFP-LC3 expression in doxR cells. doxR cells were seeded into chamber slides and co-
transfected with GFP-LC3 and FLAG-GS as before (Figure 5.25). Cells were washed, fixed and stained 
with anti-FLAG and then anti-mouse secondary antibody, 24 h post-transfection. The mounting medium 
contained DAPI. Fluorescence microscopy was used to obtain results, using 10x and 40x objective 
lenses. No FLAG-positive cells were seen. For 10x images, circles in Merge show GFP-positive cells. 
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5.3 DISCUSSION 
 
I confirmed that GS is a target gene of FOXO3a. This may be mediated through one or more of the 
putative FOXO3a regulatory elements in the proximal promoter, ~2000 bp upstream of the GS start 
codon (van der Vos, 2010). Overexpression of the mutant FOXO3a(A3) construct in MCF7 wt resulted in 
GS upregulation. Future work may be able to determine the physiological conditions in which FOXO3a 
regulates GS in breast cancer. Regardless, this regulation is a novel role for FOXO in glutamine 
metabolism. Interestingly, upregulation of GS again pits FOXO against Myc, with its role in promoting 
glutaminolysis. FOXO is known to inhibit Myc by competing for promoters, and upregulating Myc 
inhibitors (Delpuech et al., 2007; Chandramohan et al., 2008; Jensen et al., 2011; Ferber et al., 2011; 
Amente et al., 2011). Although it is presumed that GS activity downregulates production of glutathione 
by depleting the glutamate pool, several non-glutathione mechanisms have been discovered in which 
glutamine attenuates cell death (Chapter 5.1). If it is true that SIRT-mediated deacetylation of FOXO 
promotes transcriptional upregulation of a subset of pro-survival target genes, it would be interesting to 
see if GS was upregulated here. I investigated FOXO activity and phosphorylation status in response to 
glutamine deprivation, because of the published data showing glutamine-mediated regulation of JNK 
and p38 (Chapter 3.1). I did not find any link between glutamine supplementation/GS expression and 
FOXO3a Akt-mediated phosphorylation. However, glutamine deprivation was associated with slightly 
lower (though non-significant) FOXO reporter activity. I would like to directly assess JNK and p38 activity 
in response to glutamine in future. 
 
My results showed that GS activity was attenuated by epirubicin and H2O2 in MCF7 wt. GS is known to 
be inactivated by oxidative stress as well as by reactive nitrogen species (Görg et al., 2007; Fernandes et 
al., 2011). My results demonstrate that epirubicin treatment also reduces GS activity, presumably 
through the generation of ROS by epirubicin (Chapter 1.8.1). It is not clear whether this inhibition 
contributes to survival or death, and whether it would be clinically relevant. 
 
I also demonstrate that MCF7 wt endogenously express GS, and that GS is required for maximal growth 
rate. I believe that GS is required for synthesis of glutamine in these cells, rather than removal of 
glutamate or ammonia. Although treatment with glutamate or ammonia proved to reduce growth, 
relatively high concentrations were used to treat the cells, and no upregulation of GS protein was seen, 
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unlike when glutamine was not added to the media. Also, knockdown of GS sensitised cells to glutamine 
deprivation, as well as reducing growth of cells in fully supplemented medium. In full DMEM, glutamine 
was provided at the relatively high concentration of 4 mM. The plasma glutamine concentration in 
humans may be around 0.5 mM (Graham et al., 2000; Hiscock and Pedersen, 2002), while glutamine 
concentration in unsupplemented medium including 10% serum is likely to be ~0.1 mM (Turowski et al., 
1994). External glutamine concentration apparently is not limiting, as addition of extra glutamine did not 
affect growth. 
 
Why do these cells require glutamine synthesis? This glutamine is presumably not used in production of 
glutathione, glutaminolysis (TCA cycle), or amino acid synthesis, as these require glutamate i.e. the 
reverse reaction (Figure 1.3) (DeBerardinis and Cheng, 2010; Wise and Thompson, 2010; Anastasiou and 
Cantley, 2012). Glutamine itself has multiple cellular uses, including nucleotide synthesis, protein 
synthesis (as an amino acid directly), synthesis of asparagine, and import of other essential amino acids 
such as leucine (Tong et al., 2009; Wise and Thompson, 2010). It is clear that both glutamine and 
glutamate are required for important pathways that contribute to cell proliferation. I hypothesise that 
the glutamine import transporters in MCF7 wt were not able to take up sufficient glutamine for maximal 
growth rate. The next question is why, despite GS protein and activity upregulation on glutamine 
depletion, proliferation was slowed in this condition. The substrates glutamate and ammonia were, at 
least individually, not limiting. I suggest that limited ATP availability may have prevented GS synthesising 
all the glutamine required. The growth inhibitory effect of the glutamate treatment was surprising, 
considering its many cellular uses, and more work is required to investigate whether glutamate toxicity 
is important in cancer cells or drug resistance. 
 
Although published work using other cell types had shown induction of apoptosis or cell cycle arrest on 
glutamine deprivation (Chapter 5.1), my finding that MCF7 wt cells do not respond strongly to this 
condition is consistent with published data (Kung et al., 2011). In my cells, glutamine availability did not 
affect levels of autophagy. Glutamine treatment in MCF7 has previously been associated with activation 
of S6K1, a marker of mTORC1 activity (Nicklin et al., 2009). The authors assumed that this would result in 
a reduction in autophagy. However, the published work used treatment of starved cells, unlike mine, 
and they did not assess autophagy directly in MCF7. 
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GS expression level, but not glutamine supplementation status, was also linked to p27 expression in my 
data, although I am not sure of the mechanism behind this. Knockdown of GS in MCF7 wt cells caused an 
increase in p27 mRNA and protein, while a reduction in p27 protein was seen in doxR cells transfected 
with FLAG-GS. Note that p27 was also downregulated when doxR were transfected with FOXO3a 
constructs, so this may reflect some consistent response to overexpression. I found that the doxR were 
extremely resistant to transfection by Fugene, despite my attempts to optimise (Chapter 2.3.1.2). 
 
Importantly, I discovered a differential response to glutamine deprivation in doxR cells compared to the 
parental cells. While MCF7 wt cells showed slower growth in non-supplemented media, the doxR cells 
apparently entered growth arrest. Considering MCF7 wt required GS expression for full growth rate, this 
difference was likely due to the loss of GS expression in doxR cells. The small amount of glutamine 
available from the serum clearly did not sustain growth for longer than 48 h. The loss of GS in these cells 
is interesting in the light of my findings that GS is upregulated by FOXO3a, and that it is inactivated by 
epirubicin treatment. Prolonged exposure to epirubicin or doxorubicin, as in the creation of the doxR 
cell line, could reduce GS activity and force cells to compensate by e.g. increasing glutamine uptake, and 
so loss of GS expression may not further disadvantage the cells. At the same time, downregulation of 
FOXO3a to suppress apoptosis may result in transcriptional downregulation of GS expression. 
Interestingly, a recent comparison of several breast cancer cell lines suggested that cells derived from 
basal-like tumours were more dependent on glutamine provision for growth, and had lower expression 
of GS than luminal cells (Kung et al., 2011). MCF7 are luminal-derived, but basal-like breast cancers are 
similar to some drug resistant cells in that they have a worse prognosis and are more aggressive than 
luminal tumours (Eroles et al., 2011). Together, these data suggest that loss or low expression of GS, as 
well as loss of FOXO3a, may be a marker for aggressive or drug-resistant breast cancer cells. 
 
5.3.1 Future work 
 
I would like to build on my GS reporter work using ChIP to investigate FOXO3a promoter occupancy in 
response to different conditions, as well as looking at GS mRNA and protein levels. This would help 
enable us to determine the physiological role of FOXO3a regulation of GS. I would also like to look into 
regulation of JNK and p38 by glutamine in MCF7, and whether glutamine is protective in these cells. I 
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would also clarify, regarding published work (Nicklin et al., 2009), whether glutamine treatment of MCF7 
results in downregulation of autophagy via activation of mTORC1. 
 
I would also like to analyse GS expression and activity (as I have seen that the two are not necessarily 
connected) in a panel of breast cancer cells as well as clinical samples, to see whether its expression 
correlates with drug resistance, poor prognosis, or invasiveness. To further support FOXO3a’s 
involvement with GS, FOXO3a expression could be concurrently determined. Metabolic flux analysis 
combined with metabonomics could also contribute to establishing the importance of GS expression and 
intracellular glutamine/glutamate levels in chemotherapeutic drug resistance. 
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6.1 CHALLENGES ENCOUNTERED DURING THIS STUDY 
 
I was able to obtain positive and novel results from my research, which are discussed fully below 
(Chapter 6.2). However, many challenges were encountered during this work. For example, the inability 
of the DUSP5 and DUSP6 antibodies to detect endogenous proteins was disappointing. I discuss two of 
the most persistent challenges in my work here. 
 
6.1.1 Variation in FOXO3a Western blots 
 
To investigate protein activity, it can be crucial to have a specific antibody to recognise the protein, 
especially if the protein is regulated post-translationally by covalent modifications or modulation of 
stability, as in FOXO3a’s case. In this work I used the Millipore 07-702 FOXO3a antibody, which was 
raised against the C-terminal of human FOXO3a. Although previous experiments in the laboratory had 
suggested that this antibody is better than the other main alternative, FKHRL1 (H-144) from Santa Cruz 
Biotechnology, I experienced a great deal of heterogeneity in my Western blot results. 
 
Comparing the FOXO3a blots presented throughout this thesis, it is apparent that the antibody is not 
specific for FOXO3a. Several apparently non-specific bands are seen in each blot. However, the pattern 
of non-specific binding, particularly the intensity of these bands, is varied: for example, compare Figure 
3.4 to Figure 3.13. This made identification of the correct band problematic in some cases. The FOXO3a 
band was assigned according to its size relative to the Western blot protein ladder, and in comparison 
with Western blots obtained from FOXO3a knockdown lysates. 
 
Overexpression of a FOXO3a construct (for example in Figure 3.15) resulted in a large, thick band 
extending between the 80 kDa and 110 kDa standard bands of the ladder. The expected FOXO3a size is 
around 90 kDa. It is not clear whether some of the “non-specific” bands usually seen represent 
therefore modified FOXO3a proteins, or whether this just demonstrates huge overexpression of the 
protein. In Figure 3.13, FOXO3a knockdown is seen to reduce the intensity of two larger bands as well as 
the one at the expected size. However, this is not the case in another equivalent experiment, seen in 
Figure 5.2. 
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Overall, caution is required for interpreting results based on this antibody. In future, FOXO3a research 
would greatly benefit from generation of a more specific antibody, made in-house if no suitable 
commercial antibodies are yet available. 
 
6.1.2 p27Kip1 as a FOXO3a target in breast cancer cells 
 
The cell cycle regulator p27 has long been considered a target of transcriptional upregulation by FOXO 
(Dijkers et al., 2000; Stahl et al., 2002). Expression of p27 increased with activation of the 
FOXO3a(A3):ERα construct or inhibition of PI3K in various cell types. A FOXO recognition element was 
also found in the p27 proximal promoter (Lynch et al., 2005), and overexpression of FOXO3a wt or 
FOXO3a(A3) significantly increased activity of a p27 reporter construct in muscle precursor cells 
(Rathbone et al., 2008). Since the first papers were published, p27 has been considered an important 
downstream target of FOXO, and has often been used as a marker of FOXO transcription factor activity 
(e.g. Martínez-gac et al., 2004; van Gorp et al., 2006; Fang et al., 2011; Jensen et al., 2011). Following 
this precedent, I also used p27 as a standard FOXO3a target gene. 
 
However, my results have not been consistent with FOXO3a mediating p27 transcriptional upregulation 
in MCF7 cells. Overexpression of FOXO3a(A3) in MCF7 wt cells also transcriptionally downregulated p27. 
I also used a p27 reporter construct, previously generated in the laboratory, to test responsiveness to 
FOXO3a constructs in HEK293 cells, as I was not able to detect a signal from the reporter in MCF7 wt 
cells (Supplemental Figure 7.4). A significant dose-dependent increase in reporter activity was observed 
when the non-Akt responsive construct was transfected, but not the FOXO3a wt construct. These data 
may reflect the fact that the cells were not stressed by e.g. drug treatment, requiring cell cycle arrest or 
apoptosis, but does not explain the disparity between my and similar results from other cell lines or 
laboratories. Overall p27 may not be the ideal choice for a canonical FOXO3a target gene in breast 
cancer cells at least; my results suggest that GS expression may better reflect expected FOXO3a activity. 
More direct methods for estimating FOXO3a transcriptional activity, such as the 6XDBE reporter 
construct are recommended for future work. 
 
Interestingly, although the p27 protein or mRNA level in MCF7 did not seem to correlate well with 
FOXO3a activity, I found an apparent correlation between GS expression and p27. Knockdown of GS in 
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MCF7 wt increased p27 expression, while transfection of FLAG-GS into doxR cells further reduced the 
p27 protein level. However, lack of glutamine supplementation in MCF7 wt did not affect p27 protein. 
This could be connected to the reduction in growth seen when GS was knocked down. 
 
6.2 KEY FINDINGS OF THIS WORK 
 
Several important results are presented in this thesis. I will discuss in more detail the most striking and 
unequivocal findings, listed here in bullet point form: 
 
 mRNA of DUSP5 and DUSP6 are upregulated in doxR cells 
 MCF7 wt and doxR show metabolic differences 
 GS is downregulated in doxR cells 
 doxR cells require exogenous glutamine for growth 
 
These are discussed in depth below. All of these discoveries form a strong basis for further research in 
this area. The data demonstrating the loss of GS expression and glutamine-dependence in the doxR cells 
are particularly interesting, as they suggest that development of a novel clinical regime may be 
beneficial in treatment of advanced/drug-resistant breast cancer. However, the upregulation seen of the 
two ERK-specific DUSPs in doxR also aids understanding of ERK MAPK in cancer and drug-resistance, 
further supporting the idea that ERK is not always pro-proliferation/pro-tumourigenesis in cancer. 
Finally, I hope that future work will investigate the possibility of using myo-inositol as a marker for drug 
resistance in breast cancer. 
 
6.2.1 Upregulation of DUSP5 and DUSP6 in doxR 
 
A substantial body of evidence links the MAPKs ERK, JNK and p38 to tumorigenesis and cancer 
progression (Chapter 1.9). Because of the complexity of MAPK signalling and regulation, it is important 
to gain a better understanding of how their expression and activity changes in cancer and drug 
resistance. I investigated expression of DUSP5 and DUSP6 in MCF7 cells to investigate their role in 
doxorubicin/epirubicin-resistance, as well as their potential as FOXO3a target genes. 
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As MAPKs are activated by dual phosphorylation, they are inhibited by dual-specificity phosphatases, 
particularly of the MKP family. As with the MAPKs they regulate, their roles in cancer are not always 
clearly defined. DUSP1 has been most studied in cancer out of all of the MKPs. It is regulated by p53, 
and has been reported to contribute to oxidative stress-induced cell death (Liu et al., 2008 b). Unlike 
DUSP5, this protein is able to act on all three MAPKs, although functionally its dephosphorylation of JNK 
may be most important in cancer (Keyse, 2008). Interestingly, DUSP1 is directly transcriptionally 
upregulated by c-Jun, causing a negative feedback loop in JNK signalling (Kristiansen et al., 2010). DUSP1 
has been found overexpressed in several cancer types, including breast cancer. This was linked to lower 
JNK activity and increased aggressiveness of the tumour cells. In fact, overexpression of DUSP1 resulted 
in cisplatin resistance in several cell types (Keyse, 2008), as well as resistance to other chemotherapeutic 
drugs such as doxorubicin and tamoxifen in breast cancer cells, and a low response rate to the EGFR 
targeted therapy cexitumab in colorectal cancer (Montagut et al., 2010; Haagenson and Wu, 2010). I 
found that my doxorubicin/epirubicin-resistant MCF7 doxR cells had upregulated JNK signalling. 
Although I did not test it, this implies that DUSP1 expression has been downregulated in these cells, and 
is consistent with other studies showing that even prolonged JNK signalling can become prosurvival in 
cancer. Indeed, loss of DUSP1 has been found in later stage or metastatic prostate, colon and bladder 
cancer (Keyse, 2008). 
 
I discovered that mRNA of two ERK-specific MKPs, DUSP5 and DUSP6, were upregulated in the doxR cell 
line. I also found that epirubicin treatment of the sensitive MCF7 wt cells resulted in transcriptional 
upregulation of DUSP5 and DUSP6. Do these genes have a pro-survival role in breast cancer? Various 
studies have looked at possible DUSP6 activity in drug resistance (Chapter 3.1). Conversely, little is 
currently known about DUSP5 in cancer. It is transcriptionally regulated by p53, suggesting that DUSP5 
could be lost in cancer, allowing upregulation of ERK activity (Ueda et al., 2003). DUSP5 expression has 
also been linked to oncogenic Ras activity, in a MEK-dependent manner (Zuber et al., 2000; Kim et al., 
2004). My own results found that DUSP5 knockdown or overexpression did not significantly affect the 
response to epirubicin in MCF7 wt cells. However, knocking down of DUSP5 in the doxR cells, where the 
mRNA is upregulated, may provide more insight in future. 
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Both DUSP5 and DUSP6 may be transcriptionally regulated by FOXO. My findings could not confirm 
whether this is the case in MCF7 cells, but my data do support potential FOXO3a regulation of DUSP5 
particularly. These are important results that suggest a role for DUSP5 in cancer drug resistance, as well 
as a novel involvement for FOXO in MAPK pathway regulation. Upregulation of ERK-specific MKPs by 
FOXO reveals a positive feedback loop. It would be interesting to investigate whether any other 
DUSP/MKPs, such as ones targeting JNK or p38, are transcriptionally regulated by FOXO. 
 
Understanding of MAPK activity and regulation is important as targeted therapies that affect them are 
developed. Drugs such as gefitinib inhibit ERK (and Akt) signalling by inhibiting upstream growth factor 
receptor activity (Takeuchi and Ito, 2010). However, I have found downregulation of ERK as well as total 
Akt in the doxR cells, which may translate to a modest response to such drugs. Inhibition of Akt may also 
affect FOXO activity. Other inhibitors have been developed against the upstream ERK activators MEK 
and Raf that are being tested in clinical trials, such as the Raf antagonist sorafenib and the MEK inhibitor 
AZD6244 (Pratilas and Solit, 2010). Considering the multiple feedback mechanisms involved in MAPK-
FOXO-MKP regulation, research in this area is essential for personalised medicine and prediction of drug 
response in the future, as well as understanding of de novo and intrinsic resistance to chemotherapeutic 
drugs. 
 
6.2.2 Metabolic differences between MCF7 wt and doxR 
 
Metabolic changes in cancer are considered important markers of tumourigenesis, and are being 
extensively investigated to develop novel drug targets and cancer detection methods. To investigate 
metabolic alterations associated with anthracycline resistance, I used metabonomics to compare MCF7 
wt and doxR cells. I found several significant differences in metabolite levels between the cell lines, 
suggesting that broad changes across many cellular metabolic pathways had occurred during the 
development of doxorubicin/epirubicin resistance. The doxR cells were considered more glycolytic, as 
they took up more glucose and secreted more lactate into the culture medium. Other energy-related 
changes were increased pyruvate uptake and creatine/phosphocreatine levels. Increased glycolysis has 
been previously seen to contribute to drug resistance in other cell types. Overexpression of 
mitochondrial uncoupling protein 2 (UCP2) in colon cancer cells increased aerobic glycolysis, reduced 
ROS levels, and protected against doxorubicin and etoposide-induced apoptosis (Derdak et al., 2008). In 
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taxol-resistant breast cancer cells, knockdown or inhibition of LDH A increased cellular response to taxol 
(Zhou et al., 2010).  
 
There has been interest in developing inhibitors against glycolytic enzymes for clinical usage to target 
cancer cells (Pelicano et al., 2006; Scatena et al., 2008). One such treatment that has previously been 
tested in clinical trials is the antimetabolite 2-deoxy-D-glucose (2-DG). The radiolabelled version of this 
compound is used for tumour imaging by PET (Plathow and Weber, 2008). It is a glucose analogue that 
competes with glucose thus blocking glycolysis and the PPP (Sottnik et al., 2011; Xi et al., 2011). In some 
cells, 2-DG treatment alone is enough to inhibit growth or induce apoptosis (Aft et al., 2002). Other 
studies have found that 2-DG sensitises cells to treatment with chemotherapeutic drugs including 
doxorubicin and cisplatin (Maschek et al., 2004; Giammarioli et al., 2011). Unfortunately, 2-DG 
treatment has also been linked to upregulation of Akt and ERK activity in some cancer cell lines (Zhong 
et al., 2009). Another glycolysis inhibiting drug, 3-bromopyruvate, was shown to inhibit growth of 
leukemia cells, reduce intracellular ATP levels, and sensitise multidrug resistant cells to 
chemotherapeutic drugs (Xu et al., 2005). The authors hypothesised that the reduction in available ATP 
may have reduced the ability of the cells to excrete the drugs via transporters such as MDR1. Similar 
data were obtained using doxorubicin-resistant colon cancer cell lines treated with lonidamine (Fanciulli 
et al., 2000). This mechanism could partially explain the links between energy metabolism and drug 
resistance seen in other cells. 
 
I have shown metabonomic results which revealed possible novel differences to distinguish sensitive 
and drug resistant breast cancer cells. Future work may be able to build on these findings, increasing 
understanding of the drug-resistant phenotype and how metabolism contributes to resistance. 
Knowledge of cancer metabolic pathways and how they affect each other is particularly relevant if the 
novel therapeutic possibilities discovered using new omics techniques, notably metabonomics, are to be 
successfully targeted, as well as optimising use of currently existing antimetabolites and other drugs 
against metabolic pathways. Ideally, I hope that alterations in levels of extracellular metabolites can be 
translated into biomarkers of cancer or drug resistance in biofluids, allowing minimally-invasive 
detection. My results suggest that as well as glutamine levels, myo-inositol may be a marker of drug 
resistance in breast cancer that is worth investigating further. 
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6.2.3 Altered glutamine metabolism in doxR cells 
 
The metabolic change that I chose to look further into in this study was the altered glutamine 
metabolism observed in the doxR cells. These cells contained less glutamine and more glutamate than 
the parental MCF7 wt.  
 
Increased glutamine usage in cancer (Chapter 1.10.4) can result in cell death or growth inhibition being 
caused by glutamine withdrawal, despite it being ostensibly a non-essential amino acid. I found that the 
doxR cell line stops proliferating when the culture medium is not supplemented with glutamine. This is 
likely due to the loss of GS expression that I found in these cells. Importantly, the parental MCF7 wt still 
proliferated in non-supplemented medium. The reason for the glutamine sensitivity of the doxR cells is 
not yet known: are they “glutamine addicted” and require glutamine for energy production in the TCA 
cycle; does glutamine removal result in essential amino acid deprivation (e.g. leucine); does loss of 
glutamine inhibit growth via inhibition of nucleotide synthesis, or amino acid synthesis? Or is it a 
combination of all of the above? More work is required to clarify this, although I believe there is some 
involvement of glutaminolysis. 
 
Glutamine metabolism in cancer has been linked to the Warburg effect. Glutamine-dependent 
glioblastoma cells upregulated usage of glutamine in the TCA cycle when glucose was unavailable, in a 
glutamate dehydrogenase-dependent manner (Yang et al., 2009). Glutamate dehydrogenase allows 
glutamate entry into the TCA cycle, by converting it to α-ketoglutarate. Glutamine catabolism was also 
required for survival of glucose deprivation in a MEF cell line (Choo et al., 2010). In my MCF7 cells, 
growth was inhibited and cells presumably died without supplemented glucose, regardless of glutamine 
availability (Supplemental Figure 7.3). However, the doxR cells, that require glutamine provision for 
growth, were equally affected by removal of glutamine or glucose. This suggests that the doxR cells do 
use glutamine in the TCA cycle. 
 
Glutamine is used in the synthesis of the non-essential amino acid asparagine (Figure 1.3). The 
mammalian asparagine synthetase enzyme converts aspartate to asparagine via addition of an NH3 
group; glutamine is thought to be the main donor in vivo, making asparagine synthetase functionally a 
glutaminase (Richards and Kilberg, 2006). Conversely, asparagine can be degraded into aspartate and 
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ammonia by an asparaginase enzyme. Despite being considered a non-essential amino acid, certain cell 
types, including acute lymphoblastic leukaemia cells, have low expression of asparagine synthetase, and 
rely on uptake of asparagine from the extracellular environment for growth. Treatment with a bacterial 
asparaginase is the main treatment for acute lymphoblastic leukaemia, as well as certain other cancers 
(Schrey et al., 2011). Asparaginase treatment depletes plasma asparagine levels, depriving cells of this 
amino acid (van den Berg, 2011). Unsurprisingly, cells develop resistance by upregulating expression of 
asparagine synthetase (Richards and Kilberg, 2006).  
 
The clinically used asparaginases, from E. coli and Erwinia, in fact also have intrinsic glutaminase activity; 
the activity varies relative to their asparaginase activity but is generally lower (van den Berg, 2011). 
Reduction of plasma glutamine levels by asparaginase is thought to contribute to the efficacy of the 
treatment, by suppressing asparagine synthesis, as well as inhibiting mTOR. Plasma glutamine deficiency 
has however been linked to treatment side effects (Reinert et al., 2006; Offman et al., 2011). GS has 
been shown to contribute to asparaginase resistance. Inhibition of GS by MSO sensitised sarcoma cells 
to asparaginase and reduced proliferation (Tardito et al., 2007), while GS activity (but not mRNA) is 
increased in asparaginase resistant cells (Aslanian and Kilberg, 2001; Rotoli et al., 2005). 
 
The loss of GS expression and requirement for extracellular glutamine provision in the 
doxorubicin/epirubicin-resistant MCF7 doxR suggests that they may be sensitive to asparaginase 
treatment. I also confirmed that GS is transcriptionally upregulated by FOXO3a. This could be a silver 
lining to loss of FOXO activity or expression in advanced or drug-resistant breast cancers. This treatment 
works on plasma amino acid levels and the protein does not need to enter the cell, and so is not 
affected by upregulation of multidrug resistance transporters. Recent findings that cell lines derived 
from basal-like breast cancers also have low GS expression and are dependent on glutamine for growth 
(Kung et al., 2011) also suggest that asparaginase could have clinical value in treatment of certain breast 
cancers. Early trials of asparaginase treatment for breast cancer patients were not impressive (Wilson et 
al., 1975; Yap et al., 1979; Hortobagyi et al., 1980). My and published data suggest that it may be worth 
revisiting this drug for use in drug-resistant breast cancer, now based on prior identification of 
susceptible tumours via biomarkers such as asparagine synthetase or GS expression.  
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Figure 7.1 Optimising transfection of doxR cells. Cells were seeded into 6-well plates and transfected 
with 1 µg FLAG-GS DNA and varying amounts of FuGENE 6 (A). Following (A), doxR cells were seeded 
into 6-well plates as before and transfected with increasing amounts of FLAG-GS DNA at a fixed 6:1 
FuGENE µl:DNA µg ratio (B). 
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Molecule 
Glucose 
Glutamine 
Pyruvate 
Lysine 
Valine 
Isoleucine 
Leucine 
Threonine 
Tyrosine 
Cysteine 
Arginine 
Serine 
Glycine 
Phenylalanine 
Histidine 
Methionine 
Tryptophan 
Phenol red 
myo-Inositol 
Niacinamide 
Choline 
Pyridoxine 
Pantothenic acid 
Thiamine 
Folic acid 
Riboflavin 
 
 
Table 7.1 List of organic compounds found in DMEM medium including 4 mM glutamine 
supplementation. Compounds listed in order of quantity (in mM). Glucose concentration is 5.6 mM. 
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Figure 7.2 Integrated resonance of myo-inositol from media samples. The myo-inositol resonance was 
integrated for all spectra. Samples were cell culture media from MCF7 wt and doxR cells. Results show 
mean and SEM values from one experiment with three replicates, normalised to MCF7 wt 24h. 
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Figure 7.3 Lack of glucose or glutamine reduces growth rate of MCF7 wt and doxR. MCF7 wt (A) and 
doxR (B) cells were treated with fully supplemented DMEM medium, medium without glucose (but with 
glutamine), medium without glutamine (but without glucose) or medium without added glucose or 
glutamine. Cells were harvested at the indicated timepoints and results were obtained using SRB assay. 
Results show mean and SEM of three independent experiments. 
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Figure 7.4 Overexpression of FOXO3a(A3) increases p27 reporter activity. HEK293 cells were co-
transfected with 20 ng p27 reporter, 5 ng Renilla and 0-20 ng FOXO3a wt or FOXO3a(A3). Cells were 
harvested 24 h post-transfection and reporter activity was determined using luciferase assay. Results 
shown are mean and SEM of four independent experiments, each with six replicates per condition. 
Significance testing was performed using ANOVA with Bonferroni’s post-test (p<0.001 ***). Results 
were tested for significance against the 0 ng condition for each FOXO3a plasmid, and are expressed as 
fold change compared to that condition. 
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